We-PL3 Plenary Session 3 NOVEL APPROACHES TO … fileWe-PL3 Plenary Session 3 NOVEL APPROACHES TO...

We-PL3 Plenary Session 3

NOVEL APPROACHES TO TREATMENTChairs: O. Faergeman (Åarhus, Denmark);

A.M. Gotto, Jr. (New York, NY, USA); M. Averna (Palermo, Italy)

8.30 - 9.00 ADIPOCYTOKINES: EMERGING THERAPEUTIC TARGET FOR METABOLIC 301SYNDROMEY. Matsuzawa (Osaka, Japan)

9.00 - 9.30 HDL THERAPY FOR CARDIOVASCULAR DISEASES 301G. Franceschini (Milan, Italy)

9.30 - 10.00 CAN CANDIDATE GENE GENOTYPES IMPROVE ESTIMATION OF CHD RISK 301OVER-AND ABOVE CONVENTIONAL RISK FACTORS IN HEALTHY UK MEN?S.E. Humphries, J.A. Cooper, P.J. Talmud, G.J. Miller (London, UK)

10.00 - 10.30 STEM CELLS: ROLE IN CARDIOVASCULAR DISEASE PROGRESSION AND 302THERAPYS. Dimmeler (Frankfurt, Germany)

10.30 End of the Session

10.30 - 11.00 BREAK - POSTERS - EXHIBITS

We-S12 Sponsored Symposium 12

PHYTOSTEROL-BASED FUNCTIONAL FOODS: NEW TOOLS IN CARDIOVASCULAR PREVENTION

Chairs: E. Bruckert (Paris, France); R. Paoletti (Milan, Italy)

11.00 - 11.05 OPENING REMARKS –R. Paoletti (Milan, Italy)

11.05 - 11.30 PHYTOSTEROLS: PHYSIOLOGY AND MECHANISM OF ACTION 337P.J. Jones (Winnipeg, MB, Canada)

11.30 - 11.55 PHYTOSTEROLS AND CHOLESTEROL-LOWERING EFFICACY IN 337DIFFERENT FOOD FORMATSE.A. Trautwein (Vlaardingen, The Netherlands)

11.55 - 12.20 PHYTOSTEROL INTAKE AND DIETARY RECOMMENDATIONS 337L. Ose (Oslo, Norway)

12.20 - 12.45 PLANT STEROL INTAKE TO REDUCE RISK FOR CORONARY HEART DISEASE 338E. Windler (Hamburg, Germany)

12.45 - 12.55 GENERAL DISCUSSION –12.55 - 13.00 CLOSING REMARKS –

E. Bruckert (Paris, France) 13.00 End of the Session

Supported in part by an unrestricted educational grant provided by: Unilever

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

8.30 - 13.00 WEDNESDAY, June 21 ROOM 1

abstract bk.page ref.:

hour:

WEDNESDAY

103

WEDNESDAY

104

We-W30 Workshop 30

FAMILIAL HYPER- AND HYPOLIPIDEMIASChairs: P. Pajukanta (Los Angeles, CA, USA); S. Calandra (Modena, Italy)

11.00 - 11.20 GENETIC DETERMINANTS OF PLASMA LIPOPROTEINS 305J.C. Cohen, A. Pertsemlidis, H.H. Hobbs (Dallas, TX, USA)

11.20 - 11.40 LECITHIN: CHOLESTEROL ACYLTRANSFERASE DEFICIENCY SYNDROMES 305L. Calabresi, G. Franceschini (Milan, Italy)

11.40 - 12.00 FROM MAPPING TOWARDS FUNCTION: SUSCEPTIBILITY GENES OF 305FAMILIAL COMBINED HYPERLIPIDEMIAP. Pajukanta (Los Angeles, CA, USA)

12.00 - 12.15 GENOME-WIDE EXPRESSION ANALYSIS OF CELLS EXPRESSING WILD-TYPE 306OR GAIN OF FUNCTION MUTANT (D374Y) PCSK9A. Chester, X.M. Sun, A.K. Soutar (London, UK)

12.15 - 12.30 EPISTATIC EFFECT OF FREQUENT APOLIPOPROTEIN E AND LIPOPROTEIN LIPASE 306GENE VARIANTS ON HYPERTRIGLYCERIDEMIA-HYPERAPOBETALIPOPROTEINEMIA EXPRESSIONP. Perron, D. Brisson, M. Santure, P. Blackburn, J.P. Despres, D. Gaudet(Quebec, QC, Canada)

12.30 - 12.45 THE APOAV GENE IS ASSOCIATED WITH FAMILIAL COMBINED HYPERLIPIDEMIA 306AND DYSLIPIDEMIAG.M. van der Vleuten, A. Isaacs, W. Zeng, P.H. Talmud, C.M. van Duijn, A.F.H. Stalenhoef, J. de Graaf (Nijmegen, Rotterdam, The Netherlands and London, UK)

12.45 - 13.00 FASTING INDUCES HYPERLIPIDEMIA IN MICE OVEREXPRESSING PCSK9 306G. Lambert, T. Pineau, M. Krempf, P. Costet (Nantes and Toulouse, France)




INHIBITION OF SQUALENE SYNTHASEChairs: R. Laaksonen (Helsinki, Finland); A. Corsini (Milan, Italy)

13.00 - 13.20 INHIBITION OF CHOLESTEROL BIOSYNTHESIS BEYOND HMG-CoA 338REDUCTASE: PERSPECTIVES AND ADVANTAGESA. Corsini (Milan, Italy)

13.20 - 13.40 SQUALENE SYNTHASE INHIBITOR IN THE SCENARIO OF LIPID –LOWERING THERAPYD. Harats (Tel Aviv, Israel)

13.40 - 14.00 A NOVEL SQUALENE SYNTHASE INHIBITOR: LIPID LOWERING PROPERTIES 339IN ANIMAL MODELST. Nishimoto, Y. Amano, R. Tozawa (Osaka, Japan)

14.00 - 14.20 STABILIZATION OF CORONARY ATHEROSCLEROSIS BY A SQUALENE 339SYNTHASE INHIBITORM. Shiomi, S. Yamada, Y. Amano, T. Nishimoto, T. Ito (Kobe and Osaka, Japan)

14.20 - 14.30 QUESTION AND ANSWER SESSION –14.30 End of the session

Supported in part by an unrestricted educational grant provided by: Takeda Pharmaceuticals North America, Inc.



hour:

We-W31 Workshop 31

DIAGNOSTIC TECHNOLOGIES FOR ARTERIAL DISEASES (1st part)

Chairs: D.H. O'Leary (Boston, MA, USA); G. Vaudo (Perugia, Italy)

11.00 - 11.05 XX ANNIVERSARY OF THE CAROTID INTIMA MEDIA THICKNESS DETERMINATION –AWARD PRESENTED BY:Sirtori C.R. (Milan, Italy)

11.05 - 11.35 ASSESSMENT OF STRUCTURAL MARKERS AS SURROGATE ENDPOINTS 307FOR ARTERIAL DISEASED.H. O'Leary (Boston, MA, USA)

11.35 - 11.55 INTIMA-MEDIA THICKNESS AS AN ADDITIVE MARKER OF CARDIOVASCULAR 307RISKD. Baldassarre (Milan, Italy)

11.55 - 12.10 VASA VASORUM NEOVASCULARIZATION VISUALIZED WITHIN THE HUMAN 308CAROTID ATHEROSCLEROTIC PLAQUE: CONTRAST-ENHANCED ULTRASOUNDIMAGING AND HISTO-PATHOLOGIC CORRELATESS. Feinstein, M. Davidson, M. Feinstein, R. Neems, M. Goldin, P. Balan, F. Shah, P. Espinosa (Chicago, IL, and Princeton, NJ, USA)

12.10 - 12.25 ULTRASOUND PHENOTYPES OF CAROTID ATHEROSCLEROSIS ARE BIOLOGICALLY 308AND GENETICALLY DISTINCTJ.D. Spence, A.A. House, A. Fenster, R.A. Hegele (London, ON, Canada)

12.25 - 12.40 HOMOCYSTEINE AND FOLIC ACID LEVELS AND RELATION TO CAROTID 308ATHEROSCLEROSIS IN HIGH-RISK INDIVIDUALSC. Held, G. Sumner, P. Sheridan, M. McQueen, S. Smith, S. Yusuf, E. Lonn (Stockholm, Sweden and Hamilton, ON, Canada)

12.40 - 12.55 CAROTID INTIMA-MEDIA THICKNESS BY B-MODE ULTRASOUND AS A NEW 308TOOL TO RECOGNIZE CAD IN PATIENTS WITH NO EVICENCES OF ANGIOGRAPHIC NARROWINGSM. Amato, P. Montorsi, A. Ravani, E. Oldani, S. Galli, E. Tremoli, D. Baldassarre (Milan, Italy)



We-ML6 Master Lecture 6

LIFESTYLE MODULATION OF INFLAMMATORYPROCESSES

Chair: F. Crea (Rome, Italy)

13.00 - 13.30 LIFESTYLE MODULATION OF INFLAMMATORY PROCESSES 303E.B. Rimm (Boston, MA, USA)

13.30 - 13.45 GENERAL DISCUSSION –13.45 End of the Session

Supported in part by an unrestricted educational grant provided by: Nutrition Foundation of Italy



hour:

WEDNESDAY

105

WEDNESDAY

106

We-W32 Workshop 32

INFLAMMATION (2nd part)Chairs: H.N. Ginsberg (New York, NY, USA); P. Pintus (Cagliari, Italy)

11.00 - 11.20 ROLE OF INFLAMMATION IN ATHEROGENESIS AND IN PLAQUE INSTABILITY 309F. Crea (Rome, Italy)

11.20 - 11.35 A STANDARIZED STIMULUS AUGMENTS CRP SIMILARLY IN PATIENTS WITH 309A HISTORY OF STABLE OR UNSTABLE CHDJ.P. Werba, P.G. Massironi, M. Frigerio, C. Biancardi, M. Amato, D. Baldassarre,F. Veglia, E. Tremoli, M. Camera (Milan, Italy)

11.35 - 11.50 INFUSION OF C-REACTIVE PROTEIN MEDIATES ACTIVATION OF CIRCULATING 309LEUKOCYTES IN HUMANSR. Bisoendial, R. Birjmohun, F. Akdim, C. van 't Veer, C. Spek, D. Hartman, E. de Groot, D. Bankaitis-Davis, J. Kastelein, E. Stroes (Amsterdam, The Netherlands, Reykjavik, Iceland and Boulder, CO, USA)

11.50 - 12.05 INFLUENZA VIRUS DIRECTLY INFECTS ATHEROSCLEROTIC PLAQUES OF NORMAL 309AND ATHEROSCLEROTIC MICE AND EXACERBATES INFLAMMATION IN THE ATHEROSCLEROTIC PLAQUEM. Madjid, M. Haidari, D. Vela, S. Litovsky, P. Wyde, W. Casscells (Houston, TX, USA)

12.05 - 12.20 RESISTIN CORRELATES WITH LOW GRADE INFLAMMATION, BUT NOT WITH 310PREATHEROSCLEROSIS AND INSULIN RESISTANCE IN OBESE JUVENILESH. Mangge, S. Pilz, K. Sargsyan, R. Horejsi, R. Moeller, R. Dimitrova, G. Weihrauch,W. März (Graz, Austria)

12.20 - 12.35 HIGHER SYSTEMIC INFLAMMATORY RESPONSE IN UNSTABLE ANGINA AND 310CORONARY ACCELERATED ATHEROSCLEROSIS. OSTEOPONTIN, A MARKER OF PERSISTENT INFLAMMATIONA. Mazzone, M.S. Parri, D. Giannessi, M. Ravani, P. Altieri, L. Casalino, M.S. Maltinti, A. Biagini, S. Berti, A. Barsotti (Massa, Pisa and Genoa, Italy)

12.35 - 12.50 APOLIPOPROTEIN A-I MIMETIC PEPTIDE L-4F, PREVENTS 310LIPOPOLYSACCHARIDE-INDUCED CHANGES IN VASCULAR FUNCTIONH. Gupta, Z. Zhang, L. Dai, J. Honavar, G.M. Anantharamaiah, C.R. White(Birmingham, AL, USA)

12.50 - 13.05 TARGETING OF SCAVENGER RECEPTOR CLASS B TYPE I BY SYNTHETIC 310AMPHIPATHIC HELICAL CONTAINING PEPTIDES BLOCKS LPS UPTAKE ANDLPS-INDUCED PROINFLAMMATORA. Bocharov, T. Eggerman (Bethesda, MD, USA)




THE METABOLIC SYNDROME IN AN ELDERLYITALIAN COHORT: THE ILSA STUDY

Chair: J. Davignon (Montreal, QC, Canada)

13.00 - 13.30 THE METABOLIC SYNDROME IN AN ELDERLY ITALIAN COHORT: THE 303ILSA STUDYG. Crepaldi (Padua, Italy)




hour:

We-W33 Workshop 33

OBESITY AND WEIGHT REDUCTION (1st part)Chairs: J.W. Anderson (Lexington, KY, USA); G. Paolisso (Naples, Italy)

11.00 - 11.20 THE GENETICS OF HUMAN OBESITY 310P. Froguel (London, UK and Lille, France)

11.20 - 11.40 EFFECTS OF OBESITY TREATMENT ON PLASMA LIPOPROTEINS 311J.W. Anderson (Lexington, KY, USA)

11.40 - 11.55 ADIPOSITY IS AN IMPORTANT DETERMINANT OF CHRONIC LOW-GRADE 311INFLAMMATION AND IS ASSOCIATED WITH CAROTID ARTERY INTIMA-MEDIATHICKNESSA. Passaro, E. Dalla Nora, E. Mari, C. Marcello, R. Fellin (Ferrara, Italy)

11.55 - 12.10 INABILITY OF HDL FROM OBESE SUBJECTS IN COUNTERACTING THE INHIBITORY 311EFFECT OF OXIDIZED LDL ON ENDOTHELIUM-DEPENDENT VASORELAXATIONL. Perségol, B. Vergès, P. Gambert, L. Duvillard (Dijon, France)

12.10 - 12.25 AN INTERLEUKIN-18 (IL-18) HAPLOTYPE IS ASSOCIATED WITH HIGHER BMI AND 312INFLAMMATORY MARKERS IN SUBJECTS WITH DIABETES AND CORONARY HEART DISEASES.R. Thompson, J. Sanders, J.W. Stephens, G.D. Lowe, S.E. Humphries (London, Swansea and Glasgow, UK)

12.25 - 12.40 VARIATION IN THE UCP2-UCP3 GENE CLUSTER PREDICTS THE DEVELOPMENT 312OF TYPE 2 DIABETES IN HEALTHY MIDDLE-AGED MEND. Gable, J. Stephens, J. Cooper, G. Miller, S. Humphries (London and Swansea, UK)

12.40 - 12.55 TACE+/- MICE ARE PROTECTED FROM OBESITY AND INSULIN RESISTANCE 312M. Serino, M. Hribal, R. Menghini, D. Lauro, P. Sbraccia, R. Lauro, M. Federici(Rome, Italy)




POSCH TRIAL AND THE INITIAL PROOF OF THECHOLESTEROL HYPOTHESIS: IMPLICATIONS FOR TODAY

Chairs: C.J. Packard (Glasgow, UK); C.R. Sirtori (Milan, Italy)

13.00 - 13.30 POSCH TRIAL AND THE INITIAL PROOF OF THE CHOLESTEROL HYPOTHESIS: 304IMPLICATIONS FOR TODAYH. Buchwald (Minneapolis, MN, USA)




hour:

WEDNESDAY

107

WEDNESDAY

108

We-W34 Workshop 34

DIAGNOSTIC TECHNOLOGIES FOR ARTERIAL DISEASES: ARTERIAL PHYSIOLOGY

Chairs: J.A. Vita (Boston, MA, USA); M. Montagnani (Siena, Italy)

11.00 - 11.20 REGULATION OF ARTERIAL INTIMAL HYPERPLASIA BY ANGIOGENESIS 312RELATED AND UNRELATED MECHANISMSJ.F. Martin (London, UK)

11.20 - 11.40 WHAT IS THE CLINICAL SIGNIFICANCE OF ENDOTHELIAL DYSFUNCTION? 313J.A. Vita (Boston, MA, USA)

11.40 - 11.55 THE FAMILIALITY OF THE COMMON DYSLIPIDEMIAS IN CHILDHOOD AFFECTS 313THE SUBSEQUENT ARTERY FLOW MEDIATED DILATATION. THE STRIP-STUDYJ. Lapinleimu, I.O. Nuotio, O. Raitakari, J.S.A. Viikari (Turku, Finland)

11.55 - 12.10 ENDOTHELIAL DYSFUNCTION PREDICTS TYPE 2 DIABETES IN ESSENTIAL 313HYPERTENSIONR. Maio, M. Vatrano, G. Iemma, A. Sciacqua, F. Borrello, R.D. Grembiale, G. Sesti, F. Perticone (Catanzaro, Italy)

12.10 - 12.25 FRACTALKINE INDUCES VASCULAR DYSFUNCTION AND REDUCES NITRIC OXIDE 313BIOAVAILABILITY BY INCREASED GENERATION OF SUPEROXIDE ANIONSA. Schäfer, C. Schulz, D. Fraccarollo, M. Leutke, G. Ertl, J. Bauersachs(Würzburg and Munich, Germany)

12.25 - 12.40 LIPOPOLYSACCHARIDE-INDUCED CORONARY AND PERIPHERAL VASCULAR 314DYSFUNCTION IS REDUCED IN MICE LACKING THE 5-LIPOOXYGENASE GENEJ. Wikström, J. Grönros, U. Brandt-Eliasson, D. Carlsson, R. Fritsche-Danielson,L.-M. Gan (Göteborg and Mölndal, Sweden)

12.40 - 12.55 HETEROGENEITY OF CONCORDANCE BETWEEN CORONARY PLAQUE BURDEN AND 314ENDOTHELIAL DYSFUNCTION IN THE SAME CORONARY ARTERYJ.W. Kim, H.S. Seo, B.W. Cheon, H.W. Kim, H.H. Kim, S.K. Moon, S.Y. Suh, S.W. Rha, C.G. Park, D.J. Oh (Seoul, South Korea)



We-S14 Joint ISA2006 - International Chair on Cardiometabolic RiskSymposium 14

INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK Chairs: H.B. Brewer, Jr. (Washington, DC, USA); P.J. Barter (Sydney, NSW, Australia)

13.00 - 13.05 OPENING REMARKS –H.B. Brewer, Jr. (Washington, DC, USA)

13.05 - 13.30 IDENTIFYING INDIVIDUALS AT HIGH RISK OF CARDIOVASCULAR DISEASE: 340IS THERE A ROLE FOR THE METABOLIC SYNDROME?M. Stern (San Antonio, TX, USA)

13.30 - 13.55 SCIENTIFIC RATIONALE FOR THE 2005 AHA/NHLBI UPDATE OF THE 340NCEP-ATPIII METABOLIC SYNDROMES.M. Grundy (Dallas, TX, USA)

13.55 - 14.20 FROM CVD RISK TO CARDIOMETABOLIC RISK 340 J.P. Després (Sainte-Foy, QC, Canada)

14.20 - 14.30 CLOSING REMARKS: FROM METABOLIC SYNDROME TO CARDIOMETABOLIC 341RISK: THE COMMON GROUNDP.J. Barter (Sydney, NSW, Australia)


Symposium organized in collaboration with the International Chair on Cardiometabolic Risk



hour:

We-W35 Workshop 35

GENETICS (2nd part)Chairs: B. Dahlbäck (Malmö, Sweden); P. Alessandrini (Venice, Italy)

11.00 - 11.20 GENETIC MECHANISMS OF THROMBOPHILIA 314B. Dahlbäck (Malmö, Sweden)

11.20 - 11.40 INHERITED AND ACQUIRED RISK FACTORS FOR JUVENILE MYOCARDIAL 315INFARCTION IN AN EUROPEAN COHORTG. Di Minno, M. Margaglione, S. Pezzullo, V. Palmieri, P. Migliaresi, A. Celentano, S.E. Humphries, P. Morange, I. Juhan-Vague, A. Hamsten, E. Tremoli, HIFMECH Study Group (Naples, Italy)

11.40 - 11.55 A VARIANT IN THE THROMBOMODULIN PROMOTER LEADS TO IMPAIRED 315EXPRESSION IN RESPONSE TO INFLAMMATORY CYTOKINES; PREVIOUS CHD-RISK ASSOCIATION EXPLAINEDC.J. Konstantoulas, J. Cooper, J. Grizenkova, G.J. Miller, S.E. Humphries, H. Ireland (London, UK)

11.55 - 12.10 COMPLEMENT FACTOR H Y402H POLYMORPHISM DECREASES CARDIOVASCULAR 315DISEASE RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIAK.C.M.C. Koeijvoets, G.M. Dallinga-Thie, E.J.G. Sijbrands (Rotterdam, The Netherlands)

12.10 - 12.25 ADAM17: A NEW CANDIDATE GENE OF ATHEROSCLEROSIS SUSCEPTIBILITY 316IDENTIFIED BY QUANTITATIVE TRAIT LOCUS MAPPING IN LDL-RECEPTORDEFICIENT MICEL.M. Holdt, D. Teupser, J.L. Breslow, J. Thiery (Leipzig, Germany and New York, NY, USA)

12.25 - 12.40 MATRIX METALLOPROTEINASE-1 GENE HAPLOTYPE INFLUENCES RISK OF 316MYOCARDIAL INFARCTIONE. Pearce, D. Tregouet, A. Samnergard, A. Morgan, C. Cox, A. Hamsten, P. Eriksson,S. Ye (Southampton, UK, Paris, France and Stockholm, Sweden)





hour:

WEDNESDAY

109

WEDNESDAY

110


We-W36 Workshop 36

INTERVENTION AT THE POPULATION LEVELChairs: A.P. Simopoulos (Washington, DC, USA); S. Muntoni (Cagliari, Italy)

11.00 - 11.20 RECENT DATA ON OMEGA-3 FATTY ACIDS IN PREVENTION OF 316CARDIAC DEATHM. de Lorgeril, P. Salen (Grenoble, France)

11.20 - 11.40 HEALTH EFFECTS OF A MEDITERRANEAN DIET: WHAT IS SO SPECIAL 316ABOUT THE DIET OF GREECE? THE SCIENTIFIC EVIDENCEA.P. Simopoulos (Washington, DC, USA)

11.40 - 11.55 VITAMIN B12 IS A BETTER INVERSE CORRELATE FOR HOMOCYSTEINE THAN 317FOLATE IN AN ELDERLY POPULATION SAMPLEB. Blades, N. Naumovski, P.D. Roach, M. Lucock, C. Travers, P. Lewis, J. Sturm, M. Veysey (Ourimbah and Gosford, Australia)

11.55 - 12.10 LOW ATHEROSCLEROSIS RISKS OF FISH AND SOY EATERS IN THE WORLD 317Y. Yamori, M. Sagara, M. Mori, H. Mori (Nishinomiya and Kyoto, Japan)

12.10 - 12.25 ALCOHOL CONSUMPTION, MORTALITY AND CARDIAC EVENTS: EFFECT OF 317INFLAMMATION. THE HEALTH, AGING, AND BODY COMPOSITION STUDYC. Maraldi, S. Volpato, S. Kritchevsky, E. Andresen, T. Harris, A. Newman, A. Kanaya, K. Johnson, R. Fellin, M. Pahor (Ferrara, Italy, Gainesville, FL,Winston-Salem, NC, Bethesda, MD, Pittsburgh, PA, San Francisco, CA,and Memphis, TN, USA)

12.25 - 12.40 PLASMA LEVELS OF PLANT STEROLS AND THE RISK OF FUTURE CORONARY 318ARTERY DISEASE IN HEALTHY MEN AND WOMEN; THE PROSPECTIVE EPIC-NORFOLK POPULATION STUDYM.N. Vissers, S. Pinedo, S.M. Boekholdt, K. von Bergmann, K. Elharchaoui, S.A. Bingham, N.J. Wareham, D. Lütjohann, J.J.P. Kastelein, K.T. Khaw (Amsterdam, The Netherlands, Bonn, Germany and Cambridge, UK)

12.40 - 12.55 DECREASE OF INTIMA-MEDIA THICKNESS IN PATIENTS AT RISK TO CEREBRAL 318ISCHEMIA AFTER SUPPLEMENTATION WITH FOLIC ACID, VITAMINS B6 AND B12U. Till, A. Jentsch, K. Bellstedt, A. Müller, R. Vollandt, H.S. Fink (Jena, Germany)




hour:


hour:

WEDNESDAY

111

We-W37 Workshop 37

ANIMAL MODELS (1st part)Chairs: L. Havekes (Leiden, The Netherlands); P. Pauletto (Treviso, Italy)

11.00 - 11.20 THE METABOLIC SYNDROME: IT'S IN THE MOVEMENT OF FATTY ACIDS, 318AS LEARNT FROM STUDIES IN TRANSGENIC MICEL. Havekes, P. Voshol, P. Rensen, K. Willems van Dijk, F. Kuipers, J.A. Romijn (Leiden and Groningen, The Netherlands)

11.20 - 11.40 UNSTABLE PLAQUE IN LABORATORY ANIMALS: THE APOLIPOPROTEIN E 319KNOCKOUT MOUSE FED A HIGH-FAT DIETJ.L. Johnson (Bristol, UK)

11.40 - 11.55 AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH) KNOCKOUT 319MOUSE HAS DELAYED CATABOLISM OF LDL IN VIVO BUT NORMAL INTERNALIZATION OF LDL IN VITROM. Harada-Shiba, A. Takagi, K. Marutsuka, S. Moriguchi, H. Yagyu, S. Ishibashi,Y. Asada, S. Yokoyama (Suita, Osaka, Miyazaki, Miyazaki, Kawachi-gun, Tochigi,and Nagoya, Aichi, Japan)

11.55 - 12.10 INCREASED ACTIVITY OF ABCA1 PROTECTS AGAINST ATHEROSCLEROSIS 319R.R. Singaraja, C. Fievet, M.R. Hayden (Vancouver, BC, Canada and Lille, France)

12.10 - 12.25 MACROPHAGE ABCB4 DEFICENCY PROMOTES ATHEROSCLEROTIC LESION 319DEVELOPMENT IN LDLR DEFICIENT MICEM. Pennings, R.B. Hildebrand, Th.J.C. van Berkel, A.K. Groen, M. van Eck(Leiden and Amsterdam, The Netherlands)

12.25 - 12.40 DEFICIENCY OF MACROPHAGE PHOSPHOLIPID TRANSFER PROTEIN PROTECTS 320AGAINST ATHEROSCLEROTIC LESION DEVELOPMENTR. Vikstedt, J. Metso, D. Ye, R.B. Hildebrand, Th.J.C. van Berkel, C. Ehnholm, M. Jauhiainen, M. van Eck (Helsinki, Finland and Leiden, The Netherlands)

12.40 - 12.55 METABOLIC CHARACTERIZATION OF A DOMINANT NEGATIVE PPAR-GAMMA 320MOUSE LINEE. Dalla Nora, S.L. Gray, J. Grosse, S. O'Rahilly, P.J. Voshol, S. Cinti, A. Vidal Puig (Cambridge, UK, Martinsried, Germany, Leiden, The Netherlands, Ferrara and Ancona, Italy)




WEDNESDAY

112


KEY QUESTIONS IN THE MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES: NEW FINDINGS

FROM THE FIELD TRIALChairs: S.M. Grundy (Dallas, TX, USA); C.R. Sirtori (Milan, Italy)

14.30 - 14.50 PATIENT WITH TYPE 2 DIABETES: MAIN CHALLENGES TO FACE THE 342GLOBAL BURDEN OF THE DISEASEG. Steiner (Toronto, ON, Canada)

14.50 - 15.20 EFFECTS OF LONG-TERM FENOFIBRATE THERAPY ON CARDIOVASCULAR 342EVENTS AMONG 9795 PEOPLE WITH TYPE 2 DIABETES MELLITUS: THE FIELD STUDY, A RANDOMISED CONTROLLED TRIALA.C. Keech, on behalf of the FIELD Study Investigators (Sydney, NSW, Australia)

15.20 - 15.40 THE FIELD TRIAL: CLINICAL IMPLICATIONS 342A. Zambon (Padua, Italy)

15.40 - 16.00 COMBINATION THERAPY WITH FIBRATE PLUS STATINS: WHERE DO WE 343STAND IN 2006?P.H. Jones (Houston, TX, USA)


Supported in part by an unrestricted educational grant provided by: Fournier Pharma, member of the Solvay Group & Abbott

16.00 - 16.30 BREAK - POSTERS - EXHIBITS


DIETARY APPROACHES FOR ATHEROSCLEROSISPREVENTION: VEGETABLE PROTEIN

Chairs: K. Widhalm (Vienna, Austria); C.R. Sirtori (Milan, Italy)

16.30 - 16.35 OPENING REMARKS –C.R. Sirtori (Milan, Italy)

16.35 - 16.55 HEALTHY FOOD CHOICES RECOMMENDED IN THE EUROPEAN GUIDELINES 343ON CVD PREVENTION: HOW ABOUT THE IMPLEMENTATION IN CLINICALPRACTICE?G.G. De Backer (Ghent, Belgium)

16.55 - 17.15 VEGETABLE PROTEINS: MECHANISM FOR CHOLESTEROL REDUCTION 343M.R. Lovati, C. Manzoni, S. Castiglioni (Milan, Italy)

17.15 - 17.35 SOY AND IMPACT ON PEROXISOME PROLIFERATOR ACTIVATED 344RECEPTORS (PPARs)S. Kersten (Wageningen, The Netherlands)

17.35 - 17.55 SOY AND PHYTOESTROGENS: BEYOND LIPID LOWERING, ANTI-OXIDANT, 344ANTI-INFLAMMATORY EFFECTST.A.B. Sanders (London, UK)

17.55 - 18.15 SAFETY AND EFFICACY OF SOY IN PREVENTION OF ATHEROSCLEROSIS IN 344CHILDRENK. Widhalm, D. Weghuber (Vienna, Austria)


Supported in part by an unrestricted educational grant provided by: Alpro Foundation



hour:

We-W38 Workshop 38

PHARMACOLOGY OF ARTERIAL DISEASE:HDL-TARGETED THERAPIES (2nd part)

Chairs: M.J. Chapman (Paris, France); R. Fellin (Ferrara, Italy)

16.30 - 16.50 THE ROLE OF VARIOUS STRUCTURAL MOTIFS OF HDL-MIMETIC 320PEPTIDES IN CHOLESTEROL EFFLUX BY THE ABCA1 TRANSPORTERA.T. Remaley, J. Stonik, T. Fairwell, S. Demosky, E.B. Neufeld, H.B. Brewer (Bethesda, MD and Washington, DC, USA)

16.50 - 17.10 PHARMACOLOGICAL MODULATION OF CELLULAR CHOLESTEROL EFFLUX 320F. Bernini (Parma, Italy)

17.10 - 17.30 HOW DOES NICOTINIC ACID MODIFY THE ATHEROGENIC LIPID PROFILE? 321M.J. Chapman, W. Le Goff, M. Guerin, A. Kontush (Paris, France)

17.30 - 17.50 PHARMACOLOGIC COMBINATION THERAPY FOR REGRESSION OF 321ATHEROSCLEROSISB.G. Brown (Seattle, WA, USA)

17.50 - 18.05 EFFECT OF INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ON THE 322KINETICS OF HDL CHOLESTERYL ESTER TRANSPORT IN PLASMA: IN VIVOSTUDIES IN RABBITSP.H.R. Barrett, P. Kee, D. Caiazza, K.A. Rye, L.A. Morehouse, P.J. Barter (Perth, WA, Sydney, NSW, Australia and Groton, CT, USA)

18.05 - 18.20 ANTIOXIDANT EFFECTS OF αα-HELIX APOLIPOPROTEIN A-I PEPTIDE MODELS 322IN RELATION TO THEIR STRUCTUREM. Petraki, K. Harilogis, C. Sakarellos, M. Sakarellos-Daitsiotis, A.D. Tselepis(Ioannina, Greece)

18.20 - 18.35 NO-1886 SUPPRESSING ATHEROSCLEROSIS IN HIGH-FAT/ HIGH-SUCROSE/ 322HIGH-CHOLESTEROL FED BAMA MINIPIGS IS RELATED TO UPREGULATINGABCA1C. Zhang, W.D. Yin, D.F. Liao, L. Huang, Z.B. Wang, K. Tsutsumi, C.K. Tang, Y. Liu, Q.K. Li, M.B. Cai (Hengyang, China and Tokushima, Japan)




hour:

WEDNESDAY

113

WEDNESDAY

114

We-W39 Workshop 39

DIAGNOSTIC TECHNOLOGIES FORARTERIAL DISEASES (2nd part)

Chairs: A.M. Zeiher (Frankfurt, Germany); A. Capurso (Bari, Italy)

16.30 - 16.50 ENDOTHELIAL FUNCTION AS A SURROGATE ENDPOINT TO ASSESS 322ARTERIAL DISEASEA.M. Zeiher (Frankfurt, Germany)

16.50 - 17.10 EARLY DIAGNOSIS OF ATHEROSCLEROSIS BY NON-INVASIVE 323ULTRASOUND TO IMPROVE CARDIOVASCULAR EVENT PREDICTIONP. Rubba (Naples, Italy)

17.10 - 17.30 INFLAMMATORY ACTIVITY AS A MARKER AND TARGET OF THERAPY OF 323CORONARY DISEASEL. Jonasson (Linköping, Sweden)

17.30 - 17.45 CLINICAL SIGNIFICANCE AND UNDERLYING MECHANISMS REGULATING 323VASCULAR CALCIFICATIONC.M. Giachelli (Seattle, WA, USA)

17.45 - 18.00 FLOW-MEDIATED VASODILATION PREDICTS OCCULT CORONARY ARTERY 324DISEASE DETECTED BY POSITRON EMISSION TOMOGRAPHYV. Vaccarino, J. Goldberg, F.A. Cheema, U. Reddy, C. Maisano, L. Jones, N.V. Murrah, A.Q. Quyyumi, J.D. Bremner (Atlanta, GA and Seattle, WA, USA)

18.00 - 18.15 EFFECT OF SMOKING HABITS ON THE RELATIONSHIPS BETWEEN 324ATHEROSCLEROSIS RISK FACTORS AND CAROTID IMTS. Castelnuovo, B. Frigerio, G. De Giosa, M. Amato, E. Tremoli, C.R. Sirtori, D. Baldassarre (Milan, Italy)

18.15 - 18.30 CAROTID INTIMA-MEDIA THICKNESS TESTING IDENTIFIES AT RISK PATIENTS 324MISSED BY FRAMINGHAM 10-YEAR RISK SCORINGA.L. Doneen, B.F. Bale, S.L. Charland, T.F. Smith (Spokane, WA, Cranbury, NJ and Austin, TX, USA)




hour:

We-W40 Workshop 40

ANTITHROMBOTIC THERAPYChairs: J.I. Weitz (Hamilton, ON, Canada); P.M. Mannucci (Milan, Italy)

16.30 - 16.50 NEW ANTICOAGULANTS FOR ATHEROTHROMBOSIS 324J.I. Weitz (Hamilton, ON, Canada)

16.50 - 17.10 DETERMINANTS OF THE INTERINDIVIDUAL VARIABILITY IN THE 325ANTIPLATELET EFFECTS OF LOW-DOSE ASPIRINB. Rocca (Chieti, Italy)

17.10 - 17.25 PLATELET FUNCTION IS AN INDEPENDENT PREDICTOR OF MYOCARDIAL 325DAMAGE IN PATIENTS WITH ACUTE MI TREATED BY PCIR. Marcucci, R. Paniccia, E. Antonucci, S. Poli, G. Ciuti, A.M. Gori, D. Poli, D. Prisco, R. Abbate, G.F. Gensini (Florence, Italy)

17.25 - 17.40 PLATELET ADP RECEPTORS AND PHOSPHOINOSITIDE 3-KINASES ARE ESSENTIAL 325IN PREVENTING THROMBOEMBOLISM ON COLLAGEN AND FIBROUSATHEROSCLEROTIC LESIONSJ. Cosemans, I. Munnix, R. Wetzker, R. Heller, S.P. Jackson, J.W.M. Heemskerk(Maastricht, The Netherlands, Jena, Germany and Melbourne, VIC, Australia)

17.40 - 17.55 S18886, A SELECTIVE ANTAGONIST OF TP-RECEPTORS, ENHANCES 325ATHEROSCLEROTIC PLAQUE STABILITYK. Tailford, S. Jhanke, P. Stickler, S.-J. Le, Z. Cong, G.R. Campbell, J.H. Campbell (Brisbane, QLD, Australia)

17.55 - 18.10 PLATELET ASSOCIATED TISSUE FACTOR EXPRESSION: MODULATION BY 326NITRIC OXIDEM. Camera, M. Frigerio, E. Tremoli (Milan, Italy)

18.10 - 18.25 GLYCOPROTEIN VI INHIBITION IS MORE POTENT THAN ADP-RECEPTOR 326ANTAGONISM OR ASPIRIN IN REDUCING PLAQUE-INDUCED PLATELET THROMBUS FORMATIONS. Penz, A.J. Reininger, R. Brandl, R. Farndale, W. Siess (Munich, Germany and Cambridge, UK)




hour:

WEDNESDAY

115

WEDNESDAY

116

We-W41 Workshop 41

IMMUNE SYSTEMChairs: S.C. Whitman (Ottawa, ON, Canada); M. Federici (Rome, Italy)

16.30 - 16.50 THE IMMUNE SYSTEM AND ATHEROSCLEROSIS: DEFINING THE ROLE 326OF INNATE IMMUNITY USING MOUSE MODELS OF THE DISEASES.C. Whitman (Ottawa, ON, Canada)

16.50 - 17.10 PATHOGENIC AND REGULATORY IMMUNE PATHWAYS IN 326 ATHEROSCLEROSIS. IMPLICATIONS FOR RISK DETERMINATIONZ. Mallat (Paris, France)

17.10 - 17.25 INCREASED LEVELS OF IGG1 AGAINST AN ALDEHYDE-MODIFIED PEPTIDE 327SEQUENCE IN APOB-100 IS ASSOCIATED WITH DECREASED SEVERITY OFCAROTID STENOSISG.N. Fredrikson, A. Schiopu, G. Berglund, R. Alm, J.Å. Nilsson, P.K. Shah, J. Nilsson (Malmö, Sweden and Los Angeles, CA, USA)

17.25 - 17.40 CD4+ NATURAL KILLER T CELLS AUGMENT ATHEROSCLEROSIS IN 327APOLIPOPROTEIN-E DEFICIENT MICEK.Y.Y. To, B.H. Toh, D. Godfrey, A. Bobik (Melbourne, VIC, Australia)

17.40 - 17.55 PRO-ATHEROGENIC EFFECT OF CD1D-RESTRICTED NKT CELLS IN FORMATION 327OF EARLY PLAQUEE. Tupin, H.E. Agardh, N. Gerdes, I. Bodin, A. Nicoletti, G.K. Hansson,G. Paulsson-Berne (Stockholm, Sweden, Paris, France and San Diego, CA, USA)

17.55 - 18.10 IMPACT OF DENDRITIC CELL LIFESPAN AND IMMUNOGENICITY ON 328ATHEROSCLEROSIS PROGRESSIONE. Gautier, T. Huby, B. Ouzilleau, J. Chapman, P. Lesnik (Paris, France)

18.10 - 18.25 THE EFFECTS OF 7BETA-HYDROXYCHOLESTEROL ON NK CELLS IN PATIENTS 328WITH CORONARY ARTERY DISEASEW. Li, X.-M. Yuan, L. Jonasson (Linköping, Sweden)




hour:

We-W42 Workshop 42

OBESITY AND WEIGHT REDUCTION (2nd part)Chairs: F.F. Samaha (Philadelphia, PA, USA); A. Angeli (Turin, Italy)

16.30 - 16.50 DIET AND INFLAMMATION 328D. Giugliano, K. Esposito (Naples, Italy)

16.50 - 17.10 POPULAR DIETS AND PREVENTION OF CARDIOVASCULAR DISEASE 328F.F. Samaha (Philadelphia, PA, USA)

17.10 - 17.25 RIMONABANT IMPROVES CARDIOMETABOLIC RISK FACTORS IN 329OVERWEIGHT/OBESE PATIENTS IRRESPECTIVE OF TREATMENT WITH STATINS: POOLED DATA FROM THE RIO PROGRAMJ.-P. Després, L. Van Gaal, A. Scheen, F.X. Pi-Sunyer (Sainte-Foy, QC, Canada, Edegem-Antwerp, Liège, Belgium and New York, NY, USA)

17.25 - 17.40 WEIGHT LOSS RESTORES PLATELET SENSITIVITY TO ANTI-AGGREGATING 329EFFECTS OF NITRIC OXIDE, PROSTACYCLIN, cGMP AND cAMP IN SUBJECTSWITH CENTRAL OBESITYI. Russo, M. Traversa, L. Mattiello, K. Bonomo, A. De Salve, G. Doronzo, P. Del Mese, M. Trovati, G. Anfossi (Orbassano, Italy)

17.40 - 17.55 COMPARISON OF EFFECTS OF ATORVASTATIN AND FISH OILS ON APOC3 329METABOLISM IN OBESITYM.N. Nguyen, D.C. Chan, G.F. Watts, P.H.R. Barrett (Perth, WA, Australia)

17.55 - 18.10 PIOGLITAZONE, BUT NOT GLICLAZIDE OR METFORMIN, IMPROVES THE ADIPOKINE 330PROFILE OF OVERWEIGHT TYPE 2 DIABETES PATIENTS INDEPENDENT OF GLYCAEMIC CONTROLJ. Reid, J.M. Lawrence, G.J. Taylor, C.A. Stirling, J.P.D. Reckless (Bath and Salisbury, UK)

18.10 - 18.25 OBESITY AND ADIPOKINES AS RISK FACTORS FOR MAJOR CORONARY HEART 330DISEASE EVENTS IN PATIENTS WITH CHD: RESULTS FROM THE LIPID TRIALD. Colquhoun, S. Soderberg, A. Kirby, A. Keech, J. Simes, W. Hague, I. Hamilton-Craig, A. Tonkin (Brisbane, QLD, Sydney, NSW, Adelaide, SA, Melbourne, VIC, Australia and Umea, Sweden)




hour:

WEDNESDAY

117

WEDNESDAY

118

We-W43 Workshop 43

LIPOPROTEIN RECEPTORSChairs: M. Krieger (Cambridge, MA, USA); A. Pontiroli (Milan, Italy)

16.30 - 16.50 THE HDL RECEPTOR SR-BI AND MURINE MODELS OF FATAL CORONARY 330HEART DISEASEM. Krieger (Cambridge, MA, USA)

16.50 - 17.10 ADAPTOR PROTEINS A NOVEL MECHANISM FOR THE REGULATION OF 330LIPOPROTEIN RECEPTORS: THE CASE OF AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH) PROTEIN AND LDLRM. Arca, I. Sirinian, F. Campagna, F. Belleudi, T. Garofano, M. Sorice, M.R. Torrisi (Rome, Italy)

17.10 - 17.25 ACTIVATION OF PPAR INDUCES HEPATIC LDL RECEPTOR EXPRESSION 331J. Han, Z. Huang, W. He, X. Zhou, A.C. Nicholson, A.M. Gotto, Jr., D.P. Hajjar(New York, NY, USA)

17.25 - 17.40 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IS REGULATED BY 331INSULIN, SREBP-1C AND PPARALPHAP.H. Costet, B. Cariou, T. Pineau, B. Staels, M. Krempf (Nantes, Lille, and Toulouse, France)

17.40 - 17.55 STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 NEGATIVELY 331REGULATES LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP1)TRANSCRIPTIONV. Llorente Cortes, P. Costales, J. Bernues, S. Camino Lopez, L. Badimon(Barcelona, Spain)

17.55 - 18.10 MACROPHAGE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 331DEFICIENCY ENHANCES ATHEROSCLEROSISL. Hu, L.S.M. Boesten, P. May, J. Herz, N. Bovenschen, M.V. Huisman, J.F.P. Berbee,L.M. Havekes, B.J.M. van Vlijmen, J.T. Tamsma (Freiburg, Germany, Dallas, TX, USA, Leiden and Utrecht, The Netherlands)

18.10 - 18.25 EXTRA-HEPATIC EXPRESSION OF HUMAN-SR-BI (CLA-1) ENHANCED THE 332ATHEROSCLEROTIC LESION FORMATION IN CLA-1 TRANSGENIC MOUSEY. Ueda, H. Komori, T. Kita (Kyoto, Japan)




hour:

We-W44 Workshop 44

GENETICS (3rd part)Chairs: R.W. James (Geneva, Switzerland); A.V. Gaddi (Bologna, Italy)

16.30 - 16.50 GENETIC ASSOCIATION ANALYSIS OF CANDIDATE GENES FOR 332CARDIOVASCULAR DISEASEH.A. Erlich, S. Cheng, B.K. Rhees, V.H. Brophy (Alameda, CA, USA)

16.50 - 17.10 PHARMACOGENETICS OF ANTI-ATHEROSCLEROTIC DRUGS FROM THE 332PERSPECTIVE OF LIPOPROTEIN OXIDATION AND ASSOCIATED INFLAMMATIONR.W. James, S. Deakin (Geneva, Switzerland)

17.10 - 17.25 LECTIN-LIKE OXIDIZED-LDL RECEPTOR-1 (LOX-1) POLYMORPHISM IS 333ASSOCIATED WITH INCREASED RATE OF CARDIOVASCULAR EVENTS DURINGSTATIN TREATMENTG. Todiere, F. Bruni, A.L. Pasqui, M. Pastorelli, F. Ciani, A. Palazzuoli, A. Auteri,L. Puccetti (Siena and Florence, Italy)

17.25 - 17.40 ARYLESTERASE ACTIVITY AND HDL-CHOLESTEROL LEVELS ARE DEPENDENT 333ON THE PON 55M AND PON 192R POLYMORPHISMSM. Nus, F. Frances, J.M. Sánchez-Montero, D. Corella, F.J. Sánchez-Muniz(Madrid and Valencia, Spain)

17.40 - 17.55 A TWO STEP STRATEGY TO LOCALIZE GENE(S) INFLUENCING LOW HIGH-DENSITY 333LIPOPROTEIN CHOLESTEROL LEVEL ON CHROMOSOME 16Q23-24J.L. Lee, B. Aouizerat, J. Genest, M.-R. Taskinen, P. Pajukanta (Los Angeles, San Francisco, CA, USA, Montreal, QC, Canada and Helsinki, Finland)

17.55 - 18.10 DEVELOPMENT OF A MULTIPLEX ASSAY FOR DIAGNOSIS OF FAMILIAL 333HYPERCHOLESTEROLEMIA IN GREECE BY USE OF NANOCHIP® MICROELECTRONIC ARRAY TECHNOLOGYE. Laios, E. Drogari (Athens, Greece)

18.10 - 18.25 CXCL5 GENE POLYMORPHISM AND MAJOR CARDIOVASCULAR EVENTS IN THE 334INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)I. Zineh, A.L. Beitelshees, T.Y. Langaee, R.M. Cooper-DeHoff, C.J. Pepine, J.A. Johnson (Gainesville, FL and St. Louis, MO, USA)




hour:

WEDNESDAY

119

WEDNESDAY

120

We-W45 Workshop 45

EPIDEMIOLOGY OF CARDIOVASCULARDISEASE: PREVENTION

Chairs: H. Arnesen (Oslo, Norway); E. Agabiti Rosei (Brescia, Italy)

16.30 - 16.50 THE VENTIMIGLIA DI SICILIA HEART PROJECT: A PROSPECTIVE STUDY 334IN A MEDITERRANEAN POPULATIONA. Notarbartolo (Palermo, Italy)

16.50 - 17.10 DIETARY COUNSELING FOR CORONARY PREVENTION IN MEN WITH 334LONG STANDING HYPERLIPIDEMIAH. Arnesen (Oslo, Norway)

17.10 - 17.25 MORTALITY AND RISK FACTORS IN THE AUSTRALIAN ELDERLY: THE DUBBO 335STUDYL.A. Simons, J. Simons, J. McCallum, Y. Friedlander (Sydney, NSW, Melbourne, VIC, Australia and Jerusalem, Israel)

17.25 - 17.40 INFLUENCE OF THE LOCATION AND THE EXTENT OF ATHEROSCLEROTIC 335VASCULAR DISEASE ON NEW CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETESP.M. Gorter, F.L.J. Visseren, A. Algra, Y. Van der Graaf (Utrecht, The Netherlands)

17.40 - 17.55 HUMAN LIPOXYGENASE GENE VARIATION IN SUBCLINICAL ATHEROSCLEROSIS: 335THE DIABETES HEART STUDYS.S. Rich, K.P. Burdon, C.D. Langefeld, Y. Liu, B.I. Freedman, J.J. Carr, C.C. Hedrick, D.W. Bowden (Winston-Salem, NC and Charlottesville, VA, USA)

17.55 - 18.10 APOLIPOPROTEIN AV, TRIGLYCERIDES AND RISK OF FUTURE CORONARY ARTERY 335DISEASE IN APPARENTLY HEALTHY MEN AND WOMEN; THE EPIC-NORFOLK POPULATION STUDYS.F.C. Vaessen, F.G. Schaap, J.A. Kuivenhoven, A.K. Groen, B.A. Hutten, S.M. Boekholdt, M.S. Sandhu, S.E. Humphries, P.J. Talmud, K.T. Khaw (Amsterdam, The Netherlands, Cambridge and London, UK)

18.10 - 18.25 GENE POLYMORPHISMS IN PLATELET RECEPTORS, FIBRINOLYTIC SYSTEM AND 336COAGULATION FACTORS OF THE MYOCARDIAL RISK INFARCTION IN YOUNG SARDINIANR. Rossi, L. Musino, A. Partenza, G. Mureddu, I. Maoddi, C. Carru, G. Baggio,L. Deiana (Sassari, Nuoro and Padua, Italy)




hour:

POSTER DISPLAY: for the duration of one day (Wednesday, June 21 from 8.30 am to 6.30 pm). Participants mayview the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows:Wednesday, June 21: from 10.30 am to 11.00 amWednesday, June 21: from 1.00 pm to 2.30 pmWednesday, June 21: from 4.00 pm to 4.30 pm

We-P11 Poster Session 11

OPTIMAL ATHEROSCLEROSIS MANAGEMENT (1st part)

1 REDUCING THE CARDIOVASCULAR RISK AT PATIENTS WITH TYPE 2 DIABETES BY 346CONTROLLING THE RISK FACTORSC. Tudor, R.A. Jeberean, R. Buzas, A. Popescu, M. Ionita (Timisoara, Romania)

2 PERIPHERAL ARTERIAL DISEASE AND PREDICTOR RELATED FACTORS IN DIABETIC 346ELDERLY PATIENTST. Kuswardhani, I. Aryana, P.K. Wirajaya, N. Astika, K. Suastika (Denpasar, Bali, Indonesia)

3 PULSE PRESSURE, AN IMPORTANT RISK FACTOR FOR ATHEROSCLEROSIS, IS 346SIGNIFICANTLY INCREASED IN DIABETES TYPE IIL. Salvanos (Pireaus and Vyronas, Greece)

4 NORMAL GLUCOSE DISPOSAL AND DECREASED INSULIN SENSITIVITY IN YOUNG 346NORMAL WEIGHT MEN WITH NON-TREATED HYPERTENSIONL. Salvanos (Pireaus and Vyronas, Greece)

5 POSTPRANDIAL LIPEMIA AND INSULIN RESISTANCE IN INDIVIDUALS WITH AND 347WITHOUT TYPE 2 DIABETESJ. Rioja, F. Escalona, M.J. Ariza, M.T. Gonzalez-Alegre, E. Ulzurrun, P. Valdivielso, P. Gonzalez-Santos (Malaga, Spain)

6 ANTI-ELASTIN IGG SUBCLASSES AND MICROVASCULAR COMPLICATIONS 347A. Nikolov, G. Nicoloff (Pleven, Bulgaria)

7 SERUM FIBRILLIN-ANTIFIBRILLIN IMMUNE COMPLEXES AMONG DIABETIC CHILDREN 347A. Nikolov, G. Nicoloff (Peven, Bulgaria)

8 ABILITY OF HDL TO RECEIVE LIPIDS FROM AN ARTIFICIAL LIPOPROTEIN MODEL IN 347DIABETIC PATIENTS WITH OR WITHOUT CORONARY ARTERY DISEASEC.H. Dina, R.F. Amâncio, W. Hueb, N.H. Lopes, M.R. Rodrigues, M.C.M. Latrilha, R.C. Maranhão (São Paulo, Brazil)

9 BLOOD PRESSURE VARIATION AND ANTIHYPERTENSIVE TREATMENT 347MODIFICATION IN TYPE 2 DIABETES MELLITUSI. Lentzas, A. Alevizos, P. Daskalakis, M. Papathanasiou, L. Salvanos, E. Konstantinou,A. Kamaratos, A. Katsanaki, G. Belos, A. Melidonis (Pireaus and Vyronas, Greece)

10 MANAGEMENT OF HYPERTENSIVE PATIENTS WITH AND WITHOUT DIABETES IN 348PIRAEUSI. Lentzas, P. Daskalakis, A. Alevizos, M. Papathanasiou, L. Salvanos, B. Gizlis, A. Kamaratos, A. Katsanaki, G. Belos, A. Mariolis (Pireaus and Vyronas, Greece)

11 RELATIONSHIP BETWEEN CIRCULATING THROMBOMODULIN LEVELS AND LATENT 348PROGRESSION OF ATHEROSCLEROSIS IN TYPE 2 DIABETIC PATIENTSI. Korzh, I. Fedotova, V. Nemtsova (Kharkov, Ukraine)

12 RELATIONSHIP OF CORONARY HEART DISEASE MORTALITY TO CASUAL BLOOD 348GLUCOSE LEVEL AND SELF-REPORTED PAST HISTORY OF DIABETES MELLITUSS. Kadowaki, T. Hayakawa, T. Okamura, K. Nakamura, Y. Murakami, Y. Nakamura, T. Kadowaki, S. Saito, A. Okayama, H. Ueshima (Otsu, Izumo, Kyoto, Sapporo and Suita, Japan)

13 GENETICS AND OUTCOMES ON LIPIDS IN TYPE 2 DIABETES-BASELINE 348CHARACTERISTICS OF A PROSPECTIVE STUDY OF MYOCARDIAL INFARCTION INDIABETICSM.C.O. Izar, W.G.M. Relvas, R.M.S. Povoa, N. Kasinski, L. Pinto, S.S.M. Ihara, T. Helfenstein, A.O. Santos, A.C.C. Carvalho, F.A.H. Fonseca (São Paulo, Brazil)

POSTER AREA “B” WEDNESDAY, June 21 1-277


posterboard no.:

WEDNESDAY

121

WEDNESDAY

122

14 THE ASSESMENT OF PULSE WAVE VELOCITY AND ANKLE-BRACHIAL INDEX IN 348PATIENTS WITH TYPE2 DIABETESM. Iiyama, Y. Go, H. Kitaoka (Sakai, Japan)

15 THE D9N POLYMORPHISM IS A MARKER OF MYOCARDIAL INFARCTION AMONG 349DIABETICSM. Izar, T. Helfenstein, W. Relvas, S. Ihara, M. Fonseca, L. Pinto, S. Fischer, A. Santos,A. Carvalho, F. Fonseca (Sao Paulo, Brazil)

16 DIABETES MELLITUS HAVE IMMUNE SYSTEM ALTERATIONS SIMILAR TO THAT OF 349UNSTABLE ANGINA: A CLUE TO EXPLAIN HIGH CARDIOVASCULAR RISK OF DIABETESS. Brugaletta, S. Giubilato, D. Pitocco, M. Narducci, V. Colafrancesco, G. Ghirlanda,L. Biasucci, G. Liuzzo, M. Conte, F. Crea (Rome, Italy)

17 DURATION OF TYPE 2 DIABETES AND THE OCCURRENCE OF SUBCLINICAL 349ATHEROSCLEROSIS IN 64-YEAR-OLD WOMENG. Brohall, C.J. Behre, J. Wikstrand, J. Hulthe, B. Fagerberg (Gothenburg, Sweden)

18 THE EFFECTS OF APOE POLYMORPHISM ON THE RELATIONSHIPS BETWEEN CETP 349ACTIVITY AND LIPID PROFILE IN TUNISIAN PATIENTS WITH TYPE 2 DIABETES MELLITUSM. Smaoui, N. Attia, S. Hammami, R. Chaaba, N. Koubaa, A. Nakbi, A.S. Masmoudi, M. Hammami (Monastir, Tunisia)

19 ASSESSMENT OF VON WILLEBRAND FACTOR (VWF) AND ITS CORRELATION WITH 350CARDIOVASCULAR RISK FACTORS IN TYPE 2 DIABETES AND NON DIABETIC POPULATIONR. Kapoor, A. Kapoor, K.S. Gill (Amritsar, India)

20 IMPACT OF AORTIC VALVE CALCIFICATION IN CARDIAC DEATH FOR JAPANESE 350TYPE 2 DIABETIC PATIENTS DURING END-STAGE RENAL DISEASE THERAPYA. Sato, T. Nakagami, T. Babazono, Y. Iwamoto (Tokyo, Japan)

21 INSULIN THERAPY REDUCE PROGRESSION OF CAROTID STENOSIS IN TYPE 2 350DIABETIC PATIENTS: A RETROSPECTIVE LONGITUDINAL STUDYF. Piarulli, S. Viaggi, G. Bax, B. Laverda, G. Sartore, D. Fedele (Padua, Italy)

22 CAROTID ATHEROSCLEROTIC PLAQUES IN TYPE 2 DIABETIC PATIENTS: ROLE OF 350GLYCOXIDATIONF. Piarulli, A. Lapolla, G. Sartore, B. Laverda, R. Reitano, R. Marin, E. Manzato, D. Fedele (Padua, Italy)

23 ACE AND PAI-1 INSERTION/DELETION POLYMORPHISMS AND AGE-RELATED 350CHANGES IN PULSE PRESSURE IN SUBJECTS WITH TYPE 2 DIABETESG. Penno, D. Lucchesi, L. Pucci, C. Fotino, S. Triscornia, F. Caricato, S. Del Prato, R. Miccoli (Pisa, Italy)

24 ATHEROGENIC EFFECTS OF UPPER RESPIRATORY INFECTIONS AND PASSIVE 351SMOKING IN CHILDREN WITH TYPE 1 DIABETES MELLITUSM. Odermarsky, S. Willers, P. Liuba (Lund, Sweden)

25 CORONARY ARTERY DISEASE IN TYPE 2 DIABETES: EFFECTS OF WEIGHT LOSS ON 351LIPID PEROXIDE LEVELS, ANTIOXIDANT ENZYME ACTIVITY AND INSULIN SENSITIVITYN.M. Lalic, M. Ostojic, K. Lalic, A. Jotic, M. Zamaklar, L.J. Lukic, T. Milicic, N. Rajkovic(Belgrade, Serbia-Montenegro)

26 CORONARY ARTERY DISEASE IN TYPE 2 DIABETES: RELATIONSHIP BETWEEN CHANGES 351IN LDL PARTICLE SIZE, LIPOPROTEIN SUBFRACTION LEVELS AND INSULIN RESISTANCEK. Lalic, M. Zamaklar, N.M. Lalic, M. Ostojic, V. Kalimanovska, A. Topic, N. Rajkovic, A. Jotic, J. Vekic (Belgrade, Serbia-Montenegro)

27 INSULIN RESISTANCE AND HYPOFIBRINOLYSIS FACILITATE GRAFT STENOSIS 351AFTER CORONARY ARTERY BYPASS GRAFTING IN TYPE 2 DIABETIC PATIENTSV. Kanjuh, N.M. Lalic, M. Ostojic, K. Lalic, S. Kanjuh, A. Jotic, L.J. Lukic, T. Milicic (Belgrade, Serbia-Montenegro)

28 LOWER ANTIOXIDANT ENZYME ACTIVITY IS ASSOCIATED WITH INSULIN 352RESISTANCE IN TYPE 2 DIABETICS WITH DIFFERENT SUBTYPES OF ISCHEMIC STROKEA. Jotic, N.M. Lalic, VS. Kostic, N. Sternic, T. Milicic, L.J. Lukic, M. Mijailovic, M. Macesic(Belgrade, Serbia-Montenegro)

29 RAS ASSOCIATED WITH DIABETES (RAD) MODULATES INDUCIBLE NITRIC OXIDE 352SYNTHASE (INOS) ACTIVITY IN VASCULAR SMOOTH MUSCLE CELLS (VSMC) FROMDIABETIC RATSP. Di Tomo, A. Giardinelli, S. Di Silvestre, N. Di Pietro, G. Formoso, P. Di Fulvio, F. Capani, A. Consoli, A. Pandolfi (Chieti-Pescara, Italy)

30 MARBURG HYPOTHESIS OF CORONARY ARTERY DISEASE: A NEW CONCEPT OF 352ATHEROSCLEROSIS IN PATIENTS WITH DIABETES MELLITUSJ.R. Schaefer, S. Klumpp, B. Hufnagel, B. Maisch, J. Krieglstein (Marburg and Muenster,Germany)

31 DIABETES MELLITUS AND ARTHEROSCLEROSIS 352L. Vasilje, M. Galjak (Novi Pazar, Serbia-Montenegro)

32 UNCOUPLED ENDOTHELIAL NITRIC OXIDE SYNTHASE IN DIABETIC BONE 353MARROW-IMPACT ON ENDOTHELIAL PROGENITOR CELLST. Thum, D. Fraccarollo, P. Galuppo, M. Schultheiss, G. Ertl, J. Bauersachs(Würzburg, Germany)

33 PARAOXONASE GENE POLYMORPHISM (PON1 192) IS ASSOCIATED WITH 353ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETESC. Irace, C. Cortese, F. Dell'Aquila, L. Liberatoscioli, L. Mannucci, G. Federici, A. Gnasso(Catanzaro and Rome, Italy)

34 DYSLIPIDAEMIAS IN NON-OBESE TYPE II DIABETIC PATIENTS WITH 353ATHEROSCLEROSIS (HORMONAL PATTERNS)V. Anestiadi, V. Anestiadi, Z. Anestiadi, I. Tsiple, I. Cosciug (Chisinau, Moldova)

35 METFORMIN IMPROVES OXIDATIVE STRESS AND DECREASES PLATELET 353ACTIVATION IN NEWLY DIAGNOSED TYPE 2 DIABETIC SUBJECTSG. Formoso, E.A. De Filippis, N. Michetti, G. Ciabattoni, P. Di Fulvio, A. Pandolfi, F. Capani, G. Davì, A. Consoli (Chieti-Pescara, Italy)

36 IMPAIRED GLUCOSE METABOLISM IN PATIENTS WITH NEWLY DIAGNOSED 353CORONARY ARTERY DISEASEA. Gotsis, P. Bozia, S. Dourtsiou, A. Labrou, L. Papadopoulou, A. Savvopoulou, L. Borghi, D. Theodoridis, S. Karras, A. Panagiotidou (Komotini, Greece)

37 HUMAN SERUM PARAOXONASE (PON1) CONCENTRATION PREDICTS 354CARDIOVASCULAR DISEASE IN DIABETIC PATIENTSM. Inoue, Y. Ikeda, T. Suehiro, H. Takata, S. Inada, N. Ogami, F. Osaki, K. Arii, K. Hashimoto (Nankoku, Japan)

38 NEWLY DIAGNOSED ABNORMAL GLUCOSE TOLERANCE IN PATIENTS WITH ACUTE 354CORONARY SYNDROMES. Denchev, R. Ivanova, S. Dimitrov, L. Terzieva (Sofia, Bulgaria)

39 OXIDATIVE STRESS DURING DIABETES AND HEART FAILURE 354Z. Lankin, E. Arzamastseva, K. Tikhaze, T. Ageev, Yu. Mareev, N. Belenkov (Moscow, Russia)

40 IS ELEVATED BLOOD GLUCOSE ESSENTIAL FOR ENHANCED VASCULAR DISEASE 354IN DIABETES?R.G. Gerrity, J.L. Nadler (Augusta, GA, and Charlottesville, VA, USA)

41 HIGH GLUCOSE STIMULATES FRACTALKINE AND MCP-1 EXPRESSION IN HUMAN 355AORTIC SMOOTH MUSCLE CELLSE. Dragomir, M. Voinea, I. Manduteanu, M. Tircol, M. Simionescu (Bucharest, Romania)

42 DIABETES INDUCES A SPECIFIC FORM OF ATHEROSCLEROSIS AT THE 355MOLECULAR, CELLULAR AND FUNCTIONAL LEVELA.C. Calkin, T.J. Allen, E.E. Jones, J.P. Chin-Dusting, K.A. Jandeleit-Dahm, P. Kantharidis, M.E. Cooper (Prahran, VIC, Australia)

43 DECREASED LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END 355PRODUCTS IN TYPE 2 DIABETES: ASSOCIATION WITH OXIDATIVE STRESS ANDMETABOLIC CONTROLF. Santilli, E. Devangelio, G. Formoso, P. Ferroni, L. Bucciarelli, N. Mchetti, C. Clissa, G. Ciabattoni, A. Consoli, G. Davì (Chieti, Rome and Milan, Italy)

44 REGULATION OF IRAP AND GLUT4 MRNA EXPRESSION BY ANGIOTENSIN II, 355ANGIOTENSIN IV AND INSULIN IN VASCULAR SMOOTH MUSCLE CELLS: ALTEREDRESPONSE IN PATIENTS WITH TYPE 2 DIABETESW. Hodroj, J. Randon, N. Foudi, L. Legedz, M.-C. Bourdillon, P. Feugier, C. Cerutti, G. Bricca (Lyon, France)

45 ROLE OF COAGULATION PARAMETERS IN THE DEVELOPMENT OF DIABETIC 356VASCULAR COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS TYPE 2A. Severina, L. Chirkova, M. Shestakova (Moscow, Russia)

46 DIABETES MELLITUS AS A RISK FACTOR IN OCCURRENCE OF ATHEROSCLEROTICAL 356CHANGES OF THE BRAINS. Makrevska, E. Manasievska, Z. Krstevska (Kumanovo, Macedonia)

47 THE EFFECT OF BLOOD GLUCOSE LEVELS ON HEMORHEOLOGICAL PARAMETERS, 356PLATELET ACTIVATION AND AGGREGATION IN ORAL GLUCOSE TOLERANCE TESTSK. Koltai, G. Feher, G. Kesmarky, Z. Keszthelyi, L. Czopf, K. Toth (Pécs, Hungary)

48 PREVALENCE OF RENAL ARTERY STENOSIS IN TYPE 2 DIABETES 356I. Klefortova, M. Shamkhalova, N. Smirnova, M. Shestakova, V. Alpenidze, E. Tugeeva, U. Buziashvili (Moscow, Russia)

WEDNESDAY

123

WEDNESDAY

124

49 SAFETY AND EFFICACY OF LONG-TERM (UP TO 24 MONTHS) EZETIMIBE (EZE) 356THERAPY IN HYPERCHOLESTEROLEMIC PATIENTSE. Veltri, R. Suresh, J. Strony (Kenilworth, NJ, USA)

50 THE STOCKHOLM ATHEROSCLEROSIS GENE EXPRESSION (STAGE) STUDY - 357MULTIORGAN EXPRESSION PROFILING IN WELL-CHARACTERIZED CORONARYARTERY DISEASE PATIENTSS. Hägg, J. Lundström, J. Skogsberg, R. Nilsson, K. Hallén, P. Noori, T. Ivert, A. Hamsten, J. Tegnér, J. Björkegren (Stockholm and Linköping, Sweden)

51 A RANDOMIZED CONTROLLED TRIAL FOR RISK FACTOR REDUCTION IN PATIENTS WITH 357SYMPTOMATIC VASCULAR DISEASE: THE VASCULAR PREVENTION BY NURSES STUDYB.M.B. Goessens, F.L.J. Visseren, B.G.M. Sol, J.M. de Man- van Ginkel, Y. van der Graaf (Utrecht, The Netherlands)

52 DECREASED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) DURING ACUTE 357HYPERINSULINEMIAH.M.A. Eid, H. Reims, H. Arnesen, S.E. Kjeldsen, T. Lyberg, I. Seljeflot (Oslo, Norway)

53 SCREENING FOR SILENT MYOCARDIAL ISCHEMIA IN TYPE 2 DIABETIC PATIENTS? 357D. Dvorscak, D. Trsinski, K. Koscak, D. Slunjski, K. Kukolja, J. Dumicic, M. Jeric(Varazdin, Croatia)

54 EFFECT OF LOSARTAN, COMPARED TO ATENOLOL, ON ENDOTHELIAL FUNCTION 358AND OXIDATIVE STRESS IN PATIENTS WITH DIABETES TYPE 2 AND HYPERTENSIONA.J. Flammer, F. Hermann, P. Wiesli, B. Schwegler, F. Ruschitzka, T.F. Luescher, I. Sudano, W. Riesen, G. Noll, R. Lehmann (Zurich and St. Gallen, Switzerland)

55 PIOGLITAZONE AND METFORMIN HAVE FAVOURABLE EFFECTS ON PAI-1 IN 358OVERWEIGHT PATIENTS WITH TYPE 2 DIABETESJ.M. Lawrence, J. Reid, G.J. Taylor, C.A. Stirling, J.P.D. Reckless (Salisbury and Bath, UK)

56 NEWLY DIAGNOSED ABNORMAL GLUCOSE TOLERANCE - IMPORTANT FACTOR 358AFFECTING OUTCOME OF PRIMARY PERCUTANEOUS INTERVENTIONM. Roik, G. Horszczaruk, J. Kochman, Z. Huczek, G. Opolski (Warsaw, Poland)

57 DIABETES MELLITUS AND ITS INFLUENCE ON QUALITY OF LIFE FIVE YEARS AFTER 358MYOCARDIAL REVASCULARIZATIONM. Zdravkovic, M. Ristic, N. Milic, S.U. Pavlovic, M. Krotin, D. Trifunovic-Zamaklar,D. Zdravkovic, D. Gostiljac, R. Zivkovic, N. Milinic (Belgrade, Serbia-Montenegro)

58 INCREASE OF HDL LEVEL BY FIBRATE THERAPY WAS ASSOCIATED WITH DECREASED 358ARTERIAL STIFFNESS IN DIABETIC PATIENTS WITH HYPERTRIGLYCERIDEMIAS.H. Kim, J.H. Zo, M.A. Kim (Seoul, South Korea)

59 THE CONTRIBUTION OF NIACIN FOR THE TREATMENT OF DYSLIPIDEMIA IN PATIENTS 359WITH TYPE 2 DIABETES RECEIVING COMBINATION THERAPY WITH STATINSA. Bozinovska, L. Balalovska, D. Bozinovski (Bitola, Macedonia)

60 THE IMPACT OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION AND CHOLESTEROL 359TURNOVER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASEV. Blaha, C. Andrys, A. Smahelova, R. Hyspler, D. Solichova, A. Ticha, D. Cernohorsky, F. Musil, Z. Zadak (Hradec Kralove, Czech Republic)

61 CONCOMITANT REDUCTION OF LDL-CHOLESTEROL AND BIOMARKERS OF INFLAMMATION 359 WITH LOW DOSE SIMVASTATIN THERAPY IN PATIENTS WITH TYPE 1 DIABETESI. Jialal, E. Miguelino, S. Griffen, N. Glaser, S. Devaraj (Sacramento, CA, USA)

62 REDUCTION OF LARGE VLDL PARTICLES BY FENOFIBRATE IS ASSOCIATED WITH 359REDUCTION OF SMALL DENSE LDL IN TYPE 2 DIABETES: FIELD HELSINKI SUBSTUDYA. Hiukka, E. Leinonen, H. Hilden, H. Perttunen-Nio, A. Keech, M.R. Taskinen (Helsinki, Finlandand Sydney, NSW, Australia)

63 POSTER WITHDRAWN –64 REDUCTION IN PRO-INFLAMMATORY MARKERS BY STATINS AND RAS-INHIBITORS 360

AFFECTS THE DEVELOPMENT OF VASCULAR DISEASES. Ljubic, M. Vucic Lovrencic, J. Bozikov, Z. Metelko (Zagreb, Croatia)

65 ROSIGLITAZONE THERAPY IMPROVES INSULIN RESISTANCE PARAMETERS IN 360OVERWEIGHT AND OBESE DIABETIC PATIENTS INTOLERANT TO METFORMING. Derosa, S.A.T. Salvadeo, A. D'Angelo, I. Ferrari, L. Ciccarelli, M.N. Piccinni, F. Pricolo, M. Ghelfi, A. Gravina, P.D. Ragonesi (Pavia and Milan, Italy)

66 FEATURES OF INSULIN MEDIATE GLUCOSE UTILIZATION IN WOMEN WITH 360POLYCYSTIC OVARIES SYNDROME (PCO) AND CORONARY HEART DISEASE (CHD)IN ANAMNESIST. Zykova, A. Strelkova, K. Balandina, O. Batrakova (Arkhangelsk, Russia)

67 UNDIAGNOSED DIABETES AND IMPAIRED FASTING GLYCAEMIA AMONGST PATIENTS 360PRESENTING FOR SURGERY, AND THEIR IMPACT ON POST-OPERATIVE OUTCOMESD. Mullhi, A. Barnett, A. Jones, F. Gao (Birmingham, UK)

68 INSULIN SENSITIVITY IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM 361BEFORE AND AFTER SURGICAL TREATMENTD. Micic, G. Cvijovic, A. Kendereski, M. Sumarac-Dumanovic, S. Zoric, D. Pejkovic, K. Cubrilo, M. Georgiev (Belgrade, Serbia-Montenegro)

69 GLUCOSE INTOLERANCE AND INSULIN SENSITIVITY IN PATIENTS WITH 361OBSTRUCTIVE SLEEP APNEA SYNDROMEE. Vlachogiannis, Z. Koukoulidou, C.H. Liavas, E. Gouridou, E. Daskalopoulou, A. Dougalis (Thessaloniki, Greece)

70 INSULIN SENSITIVITY AND LIPID LEVELS IN OBESE PATIENTS WITH POLYCYSTIC 361OVARY SYNDROMEA. Kendereski, D. Micic, G. Cvijovic, M. Sumarac-Dumanovic, S. Zoric, D. Pejkovic, K. Cubrilo, M. Georgiev (Belgrade, Serbia-Montenegro)

71 INSULIN RESISTANCE BEFORE AND AFTER TRANSSFENOIDAL SURGERY IN 361PATIENTS WITH ACROMEGALYT. Isailovic, M. Petakov, S. Ognjanovic, D.J. Macut, B. Popovic, I. Bozic, S. Damjanovic (Belgrade, Serbia-Montenegro)

72 HIGH-SENSITIVITY C-REACTIVE PROTEIN AND SERUM AMYLOID A REFLECT 361INSULIN RESISTANCE IN SMOKERSO. Hanyu, T. Miida, A. Takahashi, K. Obayashi, K. Kosuge, Y. Aizawa (Niigata and Oita, Japan)

73 CARDIOVASCULAR RISK: ENDOTHELIAL DYSFUNCTION, INSULIN RESISTANCE AND 362ASSOCIATED FACTORSD.M. Duda-Seiman, C.A. Sarau, S. Iurciuc, M. Iurciuc, L. Barbu, G. Ciorica, B. Petcov, S. Mancas (Timisoara, Romania)

74 FIRST PHASE INSULIN RESPONSE AND INSULIN SENSITIVITY IN OBESE AND LEAN 362WOMEN WITH POLYCYSTIC OVARY DISEASEG. Cvijovic, D. Micic, A. Kendereski, M. Sumarac-Dumanovic, S. Zoric, D. Pejkovic, K. Cubrilo, M. Georgiev (Belgrade, Serbia-Montenegro)

75 INSULIN SENSITIVITY AND LIPID LEVELS IN LEAN PATIENTS WITH POLYCYSTIC 362OVARY SYNDROMEK. Cubrilo, D. Micic, A. Kendereski, G. Cvijovic, M. Sumarac-Dumanovic, S. Zoric, D. Stamenkovic-Pejkovic, M. Georgiev (Belgrade, Serbia-Montenegro)

76 RAPID INTRAVENOUS INSULIN INFUSION REDUCES PLASMA ADIPONECTIN LEVELS 362K. Ashidate, M. Kawamura, R. Chin, E. Yano, Y. Yamazaki, S. Miyazaki, T. Teramoto, Y. Hirata (Tokyo, Japan)

77 ARGATROBAN, A SYNTHETIC THROMBIN ANTAGONIST, CAN REDUCE INSULIN 362RESISTANCE THROUGH THROMBIN INACTIVATION IN THE DB/DB MOUSE MODEL OF TYPE 2 DIABETESK. Aihara, M. Mihara, H. Azuma, M. Akaike, Y. Ikeda, S. Yagi, T. Iwase, S. Hashizume, M. Fujimura, T. Matsumoto (Tokushima, Japan)

78 INSULIN RESISTANCE AS A DETERMINANT OF PLATELET ACTIVATION IN OBESE WOMEN 363S. Basili, F. Santilli, G. Pacini, M.T. Guagnano, M.R. Manigrasso, L. Pescara, G. Ciabattoni, C. Patrono, G. Davì (Rome, Chieti and Padua, Italy)

79 ASSOCIATION BETWEEN MILD CHANGES IN THYROID STATUS AND INSULIN 363RESISTANCE IN EUTHYROID SUBJECTSO. Mayer, Jr., Z. Hess, H. Rosolová, J. Vrzalová, O. Topolcan (Plzen, Czech Republic)

80 HYPERINSULINISM AND INSULIN RESISTANCE: TWO ENEMIES TO DEFEAT 363L.M. Pérez-Pérez, R.M. González, G. Pereira, A. Seuc, C. Valenti, O. Mateo de Acosta (Havana, Cuba)

81 ASSOCIATION OF INSULIN RESISTANCE WITH INCREASED PLASMA 363TRANSAMINASES LEVELS IN A SWISS POPULATION / THE COLAUS STUDYM. Firmann, V. Mayor, K. Song, F. Paccaud, D. Waterworth, V. Mooser, G. Waeber, P. Vollenweider (Lausanne, Switzerland and Collegeville, PA, USA)

82 PREVALENCE OF DIABETES AND IMPAIRED GLUCOSE REGULATION IN A SWISS 364POPULATION / THE COLAUS STUDYM. Firmann, V. Mayor, V. Mooser, F. Paccaud, G. Waeber, P. Vollenweider (Lausanne, Switzerland and Collegeville, PA, USA)

83 DIFFERENTIAL CORRELATION OF ORAL AND INTRAVENOUS GLUCOSE INTAKE. INSULIN 364SENSITIVITY TAKEN AS A RISK FACTOR FOR CAROTID INTIMA MEDIA THICKNESS IN ATHEROSCLEROSIS PATIENTSS. Deo, S.R. Mahadik, A.R. Chogle, S.L. Sonoji, C.P. Lulla (Mumbai, India)

WEDNESDAY

125

WEDNESDAY

126

84 THE INFUSION OF C-REACTIVE PROTEIN ADVERSELY AFFECTS GLUCOSE 364METABOLISM IN HUMANSR. Birjmohun, R. Bisoendial, M. Ackermans, A. Zwinderman, D. Hartman, J. Kastelein,E. Stroes, H. Sauerwein (Amsterdam, The Netherlands and Reykjavik, Iceland)

85 INSULIN RESISTANCE AND CARDIOVASCULAR RISK IN OBESE CHILDREN 364S. Hijano, J.A. Bermúdez, P. Fernandez-Riejos, R. de la Iglesia, P. Lopez-Campos, A. Barco, J. Gentil, E. Martínez, F. Fabiani (Seville, Spain)

86 FACTOR ANALYSIS OF PULSE WAVE VELOCITY INCREASE IN ASYMPTOMATIC 365SUBJECTSS. Mancas, D.M. Duda-Seiman, S. Iurciuc, L. Barbu, M. Rada, L. David, G. Ciorica, E. Nistor (Timisoara, Romania)

87 INSULIN RESISTANCE, PULSE WAVE VELOCITY AND CARDIOVASCULAR RISK 365S. Mancas, C.A. Sarau, D. Velimirovici, M. Dumitrasciuc, L. Barbu, D.M. Duda-Seiman, S. Urseanu, B. Petcov (Timisoara, Romania)

88 TERM NEONATES WHOSE MOTHERS SHOW AN O´SULLIVAN POSITIVE TEST 365PRESENT HIGH INSULIN LEVELS AND LOWER INSULIN SENSITIVITY AT BIRTHE. Gesteiro, A. Fernández de los Ríos, S. Bastida, F.J. Sánchez-Muniz (Badajoz and Madrid, Spain)

89 POSTER WITHDRAWN –90 METABOLIC SYNDROME: CONNECTION WITH SOME GENE POLYMORPHISMS, 365

FATTY ACID COMPOSITION AND OXIDATIVE STRESSL. Janíková, B. Stanková, M. Vecka, M. Jáchymová, E. Tvrzická, A. Zak (Prague, Czech Republic)

91 REDUCED SENSITIVITY OF ISLET INSULIN SECRETION AND GLUCOSE 365INTOLERANCE IN HYPERCHOLESTEROLEMIC LDL RECEPTOR KNOCKOUT MICEM.L. Bonfleur, P.R. Patricio, G.G. Dorighello, E.M. Carneiro, A.C. Boschero, H.C.F. Oliveira (Campinas, Brazil)

92 ACTIVITY OF INDUCIBLE NO-SYNTHASE AND SERUM LEVEL OF FIBRONECTIN IN 366METABOLIC SYNDROME PATIENTS WITH AND WITHOUT DIABETESL. Mogylnytska, B.N. Mankovsky (Khmelnitsky and Kiev, Ukraine)

93 COMBINING NATURAL TREATMENTS TO REACH LIPID TARGET IN METABOLIC 366SYNDROME PATIENTS: A RANDOMIZED CLINICAL TRIALA. Lucicesare, A.F.G. Cicero, G. Derosa, A.V. Gaddi (Bologna and Pavia, Italy)

94 METABOLIC SYNDROME AND HDL LEVEL ARE HIGHLY ASSOCIATED WITH 366ARTERIAL STIFFNESS IN DIABETIC PATIENTSS. Kim, J.-H. Zo, M.-A. Kim (Seoul, South Korea)

95 METABOLIC SYNDROME IN A POPULATION OF 259,014 SPANISH WORKERS. 366IBERMUTUAMUR CARDIOVASCULAR RISK PREVENTION STUDY GROUPM.A. Sánchez Chaparro, J. Román García, E. Calvo Bonacho, A. Fernández Meseguer, M. Cabrera Sierra, J.C. Sainz Gutiérrez, A. García García, J. Rueda Vicente, A. Gálvez Moraleda, A. González Quintela (Madrid, Spain)

96 SERUM ADIPONECTIN CONCENTRATION AND METABOLIC SYNDROME 366F. Okajima, Y. Nakajima, T. Kyoko, H. Sugihara, S. Ohtani, H. Kotake, S. Oikawa(Tokyo and Sendai, Japan)

97 CLUSTERING OF BORDERLINE RISK FACTORS INCORPORATED IN METABOLIC 367SYNDROME DEFINITION IS SIMILAR TO AN ESTABLISHED ONE REGARDINGINFLAMMATORY CONDITIONK. Matsushita, H. Yatsuya, K. Tamakoshi, T. Kondo, T. Murohara, H. Toyoshima (Nagoya, Japan)

98 PLASMA INTERLEUKIN-6 LEVELS ARE INCREASED IN SUBJECTS WITH IMPAIRED 367GLUCOSE TOLERANCE BUT NOT IN THOSE WITH IMPAIRED FASTING GLUCOSE IN A COHORT OF ITALIAN CAUCASIANM. Cardellini, F. Andreozzi, M.A. Marini, E. Laratta, M. Perticone, M.R. Mancuso, E. Succurro, A. Sciacqua, M.L. Hribal, G. Sesti (Rome and Catanzaro, Italy)

99 HISPANICS WITH THE METABOLIC SYNDROME SHOWED HIGHER INCIDENCE OF 367ATRIAL FIBRILLATIONP.I. Altieri, H.L. Banchs, M. Crespo, N. Escobales, Y. Figueroa, J.C. Lopez, J. Hernandez, H. Mundo, P. Casillas (San Juan, Puerto Rico)

100 FATTY LIVER CONTRIBUTES SIGNIFICANTLY TO THE PROGRESSION OF 367CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROMEK. Takata, Y. Toyota, A. Hiraoka, N. Mitauba, I. Takahashi, T. Ohta(Hiroshima and Okinawa, Japan)

101 THE PREVALENCE OF METABOLIC SYNDROME AMONGST PATIENTS PRESENTING 368FOR ELECTIVE SURGERY, AND ITS ASSOCIATION WITH POST-OPERATIVECOMPLICATIONSD. Mullhi, J. Wu, T. Melody, A. Barnett, A. Jones, F. Gao (Birmingham, UK)

102 ASSOCIATION OF THE TNF-ALFA -308 G/A PROMOTER POLYMORPHISM WITH 368DYSLIPIDEMIA, INSULIN RESISTANCE AND METABOLIC SYNDROMEN. Kondratova, G. Roytberg, T. Ushakova (Moscow, Russia)

103 IDENTIFIED VARIANTS IN THE ADIPONECTIN GENE ACT AS MARKERS FOR THE 368METABOLIC SYNDROME IN SOUTHERN EUROPE BUT NOT THE NORTHD. Gable, R. Whitall, L.I. Ka Wah, H. Cakmak, J. Cooper, S. Humphries (London, UK)

104 LDL SUBFRACTIONS IN PATIENTS WITH METABOLIC SYNDROME 368I. Gazi, T. Filippatos, E. Bairaktari, C. Kostara, A. Tselepis, M. Elisaf (Ioannina, Greece)

105 THE HYPERTRIGLYCERIDAEMIC WAIST PHENOTYPE AS A MARKER OF THE 369ATHEROGENIC LIPOPROTEIN PROFILE IN METABOLIC SYNDROMEI. Gazi, V. Tsimihodimos, G. Liamis, M. Kostapanos, A. Tselepis, M. Elisaf(Ioannina, Greece)

106 CONSISTENCY AND CLASSIFICATION OF VARIOUS METABOLIC SYNDROME 369CRITERIA AMONG ETHNIC CHINESE: PATTERNS VARIED BY GENDER AND AGEK.L. Chien, T.C. Su, H.C. Hsu, M.F. Chen, F.C. Sung, Y.T. Lee (Taipei, Taichung andTaoyuang, Taiwan)

107 METABOLIC SYNDROME: EVALUATION OF RESPONSE TO METFORMIN, DIET AND 369PHYSICAL ACTIVITYG. Altamore, D. De Meo, R.E. Castracane, M. Fioravanti, M.A. Germani (Rome, Italy)

108 THE ASSOCIATION OF METABOLIC SYNDROME WITH NOVEL MARKERS OF 369ATHEROSCLEROSIS POTENTIATES CORONARY HEART DISEASE RISK IN PATIENTSWITH TYPE 2 DIABETESC. Bianchi, G. Penno, F. Caricato, M.G. Giovannitti, L. Malloggi, S. Del Prato, R. Miccoli(Pisa and Cisanello, Italy)

109 USEFULNESS OF CAVI (CARDIO-ANKLE VASCULAR INDEX) IN THE METABOLIC 369SYNDROME (MS) AND DIABETES MELLITUS (DM): A NEW INDEX OF ARTERIOSCLEROSISA. Fukuda, Y. Fujioka, K. Ninomiya, Y. Ishikawa, M. Yokoyama (Kobe, Japan)

110 EFFECT OF FENOFIBRATE ON THE HEMOSTATIC SYSTEM IN PATIENTS WITH THE 370METABOLIC SYNDROME IN RELATION TO SOME GENE POLYMORPHISMS ANDSMOKING STATUSM. Jastrzebska, I. Goracy, H. Bukowska, A. Mierzecki, K. Klimek, K. Chelstowski, M. Naruszewicz (Szczecin, Poland)

111 LIPID TRANSFER PROTEINS AND APOLIPOPROTEIN B-100 METABOLISM IN THE 370METABOLIC SYNDROME TREATED WITH FENOFIBRATEJ. Ji, P.H.R. Barrett, A.G. Johnson, D.C. Chan, A.P. Serone, K.A. Rye, G.F. Watts(Perth, WA, Sydney, NSW, Australia and King of Prussia, PA, USA)

112 EFFECT OF OMEGA-3 FATTY ACIDS ON RISK FACTORS FOR THE METABOLIC SYNDROME 370D. Dimitrov (Varna, Bulgaria)

113 INFLUENCE OF METABOLIC SYNDROME WITH AND WITHOUT DIABETES ON 370HOSPITAL OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTIONM. Farnier, M. Zeller, P.G. Steg, G. Dentan, Y. Laurent, M. Vincent-Martin, I. L’Huillier,J.C. Beer, L. Rochette, Y. Cottin (Dijon, Paris, Fontaine les Dijon, Semur en Auxois and Beaune, France)

114 DISCORDANCE BETWEEN INSULIN RESISTANCE AND METABOLIC SYNDROME 371A. Onat, G. Hergenc, S. Turkmen, M. Yazici, I. Sari, G. Can (Istanbul, Gaziantep and Duzce, Turkey)

115 EFFECT OF ACUTE HYPERINSULINAEMIA AND AT-1 RECEPTOR BLOCKADE ON 371PLASMA CONCENTRATIONS OF TNF ALPHA AND RESISTIN IN DIABETES MELLITUSE. Krusinova, J. Kopecky, Jr., M. Klementova, P. Wohl, L. Kazdova, T. Pelikanova (Prague, Czech Republic)

116 VARIANTS OF THE INTERLEUKIN-10 PROMOTER GENE ARE ASSOCIATED WITH OBESITY 371AND INSULIN RESISTANCE BUT NOT TYPE 2 DIABETES MELLITUS IN CAUCASIAN ITALIAND. Scarpelli, M. Cardellini, F. Andreozzi, E. Laratta, M. Perticone, M.L. Hribal, M.A. Marini, F. Perticone, D. Lauro, G. Sesti (Catanzaro and Rome, Italy)

117 ROSIGLITAZONE IMPROVES QUALITY OF LIPOPROTEINS IN PATIENTS WITH TYPE 2 371DIABETESM. Vrablik, M. Dobiasova, T. Stulc, Z. Kasalova, R. Ceska (Prague, Czech Republic)

WEDNESDAY

127

WEDNESDAY

128

118 PIOGLITAZONE INDUCES APOPTOSIS IN HUMAN VASCULAR SMOOTH MUSCLE 371CELLS FROM HYPERCHOLESTEROLEMIC PATIENTS BY INVOLVING THE TGF-B PATHWAYE. Ruiz, A. Gordillo-Moscoso, S. Redondo, T. Tejerina (Madrid, Spain)

119 3D STRUCTURE AND BIOLOGICAL ACTIVITY OF NOVEL DUAL PEROXISOME 372PROLIFERATOR-ACTIVATED RECEPTORS ALPHA/GAMMA LIGANDSC. Godio, V. Cafiero, N. Mitro, F. Loiodice, A. Lavecchia, E. Novellino, V. Tortorella, G. Pochetti, F. Mazza, M. Crestani (Milan, Bari, Naples and Rome, Italy)

120 ROLE OF PEROXISOME PROLIFERATORS ACTIVATED RECEPTOR-GAMMA IN MEDIATING 372PROLIFERATION OF RAT VASCULAR SMOOTH MUSCLE CELLS INDUCED BY ADVANCED GLYCATION END PRODUCTSX. Yuan, N. Liu (Nanjing, China)

121 PROTECTIVE EFFECT OF PIOGLITAZONE ON MYOCARDIAL ISCHEMIA-REPERFUSION 372INJURY IN RATSP. Ye, Z.L. Cao, C.L. Long, K. Chen (Beijing, China)

122 INCREASED TNF-ÁLPHA IN PATIENTS AFFECTED BY CORONARY ARTERY DISEASE 372IS ASSOCIATED TO UNDIAGNOSED IMPAIRED GLUCOSE METABOLISM. ROLE OF PIOGLITAZONES. Rizza, F. Clementi, M. Cardellini, A. Savo, O. Porzio, M. Serino, D. Lauro, R. Lauro, M. Federici (Rome, Italy)

123 LONG-TERM EFFECTS OF PIOGLITAZONE ON CARDIOVASCULAR RISK FACTORS IN 373SUCROSE FED RATSV. Zidek, M. Pravenec, P. Mlejnek, L. Kazdova, T.W. Kurtz (Prague, Czech Republic and San Francisco, CA, USA)

124 EFFECTS OF PIOGLITAZONE AND METFORMIN ON BODY WEIGHT AND THE INSULIN 373RESISTANCE PARAMETERS IN OBESE PATIENTS WITH PUBERTAL HYPOTHALAMIC SYNDROMEO. Oleksyk, A. Serhiyenko, V. Serhiyenko (Lviv, Ukraine)

125 EFFECT OF TROGLITAZONE ON SERUM GAMMA-GLUTAMYLTRANSFERASE ACTIVITY 373AND PLASMA T-PA/PAI-1 COMPLEX IN TYPE 2 DIABETIC PATIENTSH. Koh, Y. Akiyama, K. Yui (Tokyo, Japan)

126 LEPTIN, HYPERTENSION AND OBESITY 373S. Trajkovska, B. Sidovska-Ivanovska, S. Shubevska, M. Krstevska, G. Bosilkova(Skopje, Macedonia)

127 OBESITY AND ITS ASSOCIATION WITH OTHER CARDIOVASCULAR RISK FACTORS IN 374WOMEN IN CENTRAL IRAN - WOMEN'S HEALTHY HEART PROJECTM. Sadeghi, H. Roohafza (Isfahan, Iran)

128 POLYCYSTIC OVARY SYNDROME ACCOMPANIED BY HYPERTENSION AND OBESITY: 374A PREMATURE ASSOCIATION?S. Popova (Kharkov, Ukraine)

129 HYPERTENSION AND OBESITY AT PATIENTS WITH POLYCYSTIC OVARY SYNDROME: 374CLINICAL AND HORMONAL CORRELATIONS. Popova (Kharkov, Ukraine)

130 EVOLUTION AND IMPROVEMENT OF RISK FACTORS ASSOCIATED WITH MORBID 374OBESITY IN BARIATRIC SURGERYR. Llamas, M. Cubells, R. Catalán, J.M. Fort, R. Galard, A. Lecube, J.A. Baena, J. Peinado-Onsurbe (Barcelona, Spain)

131 THE WEIGHT OF BODY WEIGHT IN CAROTID ATHEROSCLEROSIS 374C. Irace, C. Cortese, C. Carallo, A. Gnasso (Catanzaro and Rome, Italy)

132 ADIPONECTIN IN OBESE TYPE 2 DIABETICS AND GLUCOSE-INTOLERANT PATIENTS 375M.T. Gonzalez-Alegre, A. Pozo, E. Ulzurrun, M.J. Ariza, A. Hornos, J. Rioja,P. Gonzalez-Santos (Malaga, Spain)

133 PREVALENCE OF LEFT VENTRICULAR HYPERTROPHY IN ELDERLY MEN WITH 375HYPERTENSION AND OBESITY IN TALLINN, ESTONIA (2002-2003)J. Abina, M. Saava, P. Laane, M. Kalev (Tallinn, Estonia)

134 EFFECTS OF OBESITY AND DIET-INDUCED WEIGHT LOSS ON VASCULAR AND CARDIAC 375FUNCTION: INSIGHTS FROM IMAGINGC. Piantadosi, M. Worthley, A. McAinch, E. Nalivaiko, S.G. Worthley, G.A. Wittert(Adelaide, SA, Australia)

135 5-LIPOXYGENASE: PLEIOTROPIC EFFECTS ON ATHEROSCLEROSIS, OBESITY AND 375INSULIN RESISTANCEM. Mehrabian, J. Stockton, M. Suh, H. Allayee, L.W. Castellani, Z. Zhou, A.J. Lusis(Los Angeles, CA, USA)

136 METABOLIC SYNDROME (MS) IN EARLY PHASE OF ESSENTIAL HYPERTENSION (EH) 376B. Jelakovic, M. Laganovic, I. Pecin, G. Borso, D. Kuzmanic, T. Zeljkovic Vrkic, Z. Dika (Zagreb, Croatia)

137 RELATIONSHIPS BETWEEN INSULIN RESISTANCE, OBESITY AND DYSLIPIDEMIA 376WITH AMBULATORY BLOOD PRESSURE MONITORING IN AN URBAN ARGENTINEPOPULATIONC.A. Feldstein, M. Akopian, A. Renauld, D. Garrido (Buenos Aires, Argentina)

138 THE IDF DEFINITION OF METABOLIC SYNDROME IS A BETTER PREDICTOR OF CHD RISK 376THAN THE NCEP CRITERIA IN BRAZILIAN PATIENTS WITH DIFFERENT COMPONENTS OFTHE SYNDROMEM.C. Batista, A. Hirota, R.L. Borges, O. Kohlmann, M.T. Zanella, A.B. Ribeiro (São Paulo, Brazil)

139 USEFULNESS OF REPEATED OFFICE BLOOD PRESSURE TO DEFINE BP LEVELS OF 376THE METABOLIC SYNDROMEG. Crippa, A. Cassi, C. Venturi, P. Cavallotti (Piacenza, Italy)

140 EFFECTS OF ANTIOXIDANTS, ZINC AND VITAMIN C, ON BLOOD PRESSURE IN RATS 377H. Hashimoto, E. Amano, M. Atake, Y. Nakai, N. Takechi, M. Takenaka, N. Kurihara(Kobe, Japan)

141 CORRELATION BETWEEN BIOCHEMICAL AND BIOPHYSICAL MARKERS OF 377ENDOTHELIAL DYSFUNCTION IN CHILDREN WITH OBESITYM. Urban, B. Glowinska, J. Tolwinska, M. Kowalewski (Bialystok, Poland)

142 EFFECTS OF VERY LOW CALORIE DIET (VLCD) ON SERUM LEPTIN, INSULIN 377RESISTANCE AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITHMETABOLIC SYNDROMEE. Stokic, D. Tomic, B. Srdic, T. Ivkovic-Lazar (Novi Sad, Serbia-Montenegro)

143 CARDIOVASCULAR RISK FACTORS AND OBESITY 377L. Sokolova Djokic, S. Martinovic, D. Zivic, M. Bosnjak (Sombor and Novi Sad, Serbia-Montenegro)

144 BENIGN OBESITY AND MALIGNANT OBESITY 377M. Morihira, M. Chou, K. Haraguchi, A. Satoh, H. Yoshie, R. Kataoka, H. Kondoh, K. Kikuchi (Eniwa and Asahikawa, Japan)

145 ASSOCIATION OF T54 ALLELE OF THE FABP2 GENE TO CARDIOVASCULAR RISK 378FACTOR IN OBESE MEXICAN PATIENTSE. Martinez-Lopez, A. Hernandez-Nazara, B. Ruiz-Madrigal, M. Gonzalez-Hita, A. Panduro (Guadalajara, Mexico)

146 FAVORABLE IMPACT OF GROWTH HORMONE (GH) ON ATHEROGENIC RISKS IN 378PATIENTS WITH GH DEFICIENCYH. Kohno, S. Kinjo (Fukuoka, Japan)

147 RELATION BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND ABDOMINAL OBESITY 378C. Hotoleanu, O. Suciu (Cluj-Napoca, Romania)

148 LIPID PEROXIDES AND IMMUNOGLOBULIN PLASMA LEVELS ASSOCIATED WITH 378BODY MASS INDEXM. González-Hita, T. García-Iglesias, L. Aranda-Acosta, B.E. Bastidas-Ramírez, B. Ruíz-Madrigal, S. Sánchez-Enriquez (Guadalajara, Mexico)

149 ASSOCIATION OF C-REACTIVE PROTEIN WITH MEASURES OF OBESITY AND 378INSULIN SENSITIVITY IN SEVERE OBESE WOMEN WITH NORMAL AND IMPAIREDGLUCOSE TOLERANCEM. Sumarac-Dumanovic, D. Micic, D. Stamenkovic-Pejkovic, M. Georgiev, A. Kendereski, S. Zoric, G. Cvijovic, K. Cubrilo (Belgrade, Serbia-Montenegro)

150 TEN YEARS RISK FOR FATAL CORONARY DISEASE IN OBESE PERSONS WITH 379IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROMEP.B. Djordjevic, V. Kanjuh, V. Dimitrijevic-Sreckovic, M. Ostojic, F. Canovic, D. Gostiljac, T. Novakovic, E. Colak, R. Obrenovic (Belgrade, Serbia-Montenegro)

151 LEPTIN DOES NOT MODULATE THE RELATIONSHIP BETWEEN BLOOD PRESSURE 379AND OBESITY IN CHINESE SIBLINGS WITH A FAMILY HISTORY OF HYPERTENSIONT.T.W. Chu, Y.J. Fang, G.N. Thomas, B. Tomlinson (Shatin and Pokfulam, Hong Kong, China)

152 REDUCING CARDIOVSCULAR RISK FACTORS IN OBESE ADOLESCENTS 379T. Stølen, A.E. Tjønna, R. Ødegård, U. Wisløff (Trondheim, Norway)

153 CAROTID ARTERY INTIMA-MEDIA THICKNESS IN OBESE, PREOBESE AND NORMAL 379WEIGHT POSTMENOPAUSAL WOMENA. Starodubova, O. Kisliak, G. Storozhakov (Moscow, Russia)

154 CONTRIBUTING FACTORS FOR DYSLIPIDEMIA IN A POPULATION WITH TYPE 2 DIABETES 380J. Silva-Nunes, L. Gardete-Correia (Lisbon, Portugal)

WEDNESDAY

129

WEDNESDAY

130

155 CARDIOVASCULAR RISK FACTORS INCIDENCE IN BOTH, INDIGENOUS AND URBAN 380POPULATION GROUPS FROM WEST OF MEXICOP. Nuño-González, B. Ruiz-Madrigal, E. Zepeda-Carrillo, M.F. Bueno Cortés, A. Rodríguez Martínez, A. Panduro (Guadalajara and Tepic, Mexico)

156 VISCERAL BUT NOT SUBCUTANEOUS FAT REDUCTION IS RESPONSIBLE FOR 380METABOLIC IMPROVEMENTS (MI) AFTER WEIGHT LOSS (WL)G. Formoso, M. Taraborrelli, E. Ciccarone, A. Pandolfi, S. Martinotti, M.T. Guagnano, A. Tartaro, A. Consoli (Chieti-Pescara, Italy)

157 BODY COMPOSITION, PLASMA ADIPOCYTOKINES, AND CARDIOVASCULAR RISK 380FACTORS BEFORE AND AFTER WEIGHT LOSS IN OVERWEIGHT AND OBESE WOMENI. Demonty, S. Santosa, A.H. Lichtenstein, K. Cianflone, P.J.H. Jones (Montreal, Ste-Foy, QC, Canada and Boston, MA, USA)

158 FITNESS CAPACITY IS THE MAJOR PREDICTOR OF THE NUMBER OF 381CARDIOVASCULAR RISK FACTORS IN OBESE ADOLESCENTSP.A. Velasquez-Mieyer, P.A. Cowan, B.S. Alpert, C. Villegas-Barreto, S. Perez-Faustinelli, G. Burghen, A.J. Mendez, F. Tylavsky (Memphis, TN and Miami, FL, USA)

159 HYPOCALORIC DIET RAPIDLY AND SIGNIFICANTLY REDUCES IN SHORT TERM 381CARDIOVASCULAR INFLAMMATORY MARKERS IN OVERWEIGHT AND OBESE PATIENTSP. Giordano Sciacca, F. Graziani, A. Sica, M. Conte, A. Rebuzzi, L.M. Biasucci, F. Crea(Rome, Italy)

160 CARDIOVASCULAR RISK FACTORS IN CHINESE-AMERICAN CHILDREN 381J. Chen, Y. Wu (San Francisco, CA, USA)

161 PLASMA LEPTIN CONCENTRATION IN SERBIAN PATIENTS WITH TYPE 2 DIABETES 381MELLITUS: RELATIONSHIP TO OBESITY AND CHD RISK FACTORSA. Stefanovic, J. Kotur-Stevuljevic, S. Spasic, N. Bujisic (Belgrade and Zemun, Serbia-Montenegro)

162 BARIATRIC SURGERY, ALBUMINURIA AND CARDIOVASCULAR RISK – INITIAL CHANGES 381M. Phillips, S. Wahlroos, L. Kow, J. Slavotinek, J. Toouli, C. Thompson (Adelaide, SA, Australia)

163 ADIPONECTIN LEVELS IN PATIENTS REFERRED TO ELECTIVE CORONARY ANGIOGRAPHY 382J.G. Rasmussen, E.B. Schmidt, E. Toft, J.H. Christensen (Aalborg, Denmark)

164 GUIDELINES FOR EARLY PREVENTION OF ATHEROSCLEROSIS IN PATIENTS WITH 382FAMILY HISTORY OF ATHEROSCLEROSISJ. Tyaneva, I.V. Sterev, D. Kostov, K. Nenova (Varna, Bulgaria)

165 ADIPONECTIN AND SUBCLINICAL ATHEROSCLEROSIS IN 64-YEAR OLD WOMEN WITH 382VARYING DEGREES OF GLUCOSE TOLERANCEC.J. Behre, G. Brohall, J. Hulthe, J. Wikstrand, B. Fagerberg (Goteborg, Sweden)

166 INVESTIGATION OF DIETARY HABITS IN PATIENTS WITH PRIMARY HYPERTENSION IN 382INTERNAL AND HEART CLINIC IN TEHRAN UNIVERSITY OF MEDICAL SCIENCES HOSPITALSM. Zakerimoghadam, M. Salsali, Z. Monjamed (Tehran, Iran)

167 LIPID SOLUBLE SMOKING PARTICLES ENHANCE ENDOTHELIN RECEPTOR EXPRESSION 382IN VASCULATUREC.-B. Xu, P. Vikman, T. Krag, L. Edvinsson (Lund, Sweden and Copenhagen, Denmark)

168 PATIENTS WITH ESSENTIAL HYPERTENSION HAVE HIGH PREVALENCE OF METABOLIC 383SYNDROMEJ.A. Papadakis, G.E. Vrentzos, A. Repa, G. Roditakis, E. Mavrogeni, E.S. Ganotakis(Heraklion, Greece)

169 ESSENTIAL HYPERTENSION PECULIARITIES AT METABOLIC SYNDROM PATIENTS 383N. Velykykh, I. Snegurskaya, D. Myloslavsky, S. Koval, Y. Karachentsev, N. Kravchun (Kharkov, Ukraine)

170 C-REACTIVE PROTEIN IS CORRELATED WITH MICROVASCULAR DYSFUNCTION BUT NOT 383LARGE ARTERY STIFFNESS IN ESSENTIAL HYPERTENSIVE PATIENTSW.C. Tsai, C.C. Lin, C.H. Lee, W.T. Li, J.H. Chen (Dou-Liou and Tainan, Taiwan)

171 HAPLOTYPES IN THE KCNMA1 POTASSIUM CHANNEL ALPHA-SUBUNIT GENE AS 383RISK FACTORS FOR HUMAN ESSENTIAL HYPERTENSIONM. Tomas, E. Vazquez, M. Fernandez-Fernandez, R. Elosua, I. Subirana, G. Latorre, C. Plata, M.A. Valverde, J. Marrugat, M. Senti (Barcelona, Spain)

172 HAPLOTYPES OF THE KCNMB1 POTASSIUM CHANNEL SUBUNIT AS GENETIC 384MARKERS FOR HYPERTENSION AND RESPONSE TO ANTIHYPERTENSIVE THERAPYM. Sentí, M. Tomás, J.M. Fernández-Fernández, M.A. Valverde, J. Marrugat (Barcelona, Spain)

173 LIPID PROFILE IN UNCOMPLICATED NON DIABETIC HYPERTENSIVE 384M. Sadeghi, H. Roohafza (Isfahan, Iran)

174 COMPARISON OF CARDIAC GEOMETRY AND FUNCTION IN NORMOALBUMINURIC 384PATIENTS WITH SYSTO-DIASTOLIC AND ISOLATED SYSTOLIC ARTERIAL HYPERTENSIONM. Picca, F. Agozzino, G.C. Pelosi (Milan, Italy)

175 APO E AND ACE GENES IN MILD ESSENTIAL HYPERTENSION (EH) 384I. Pecin, M. Laganovic, J. Sertic, Z. Reiner, D. Kuzmanic, B. Jelakovic (Zagreb, Croatia)

176 ADMINISTRATION OF DOXAZOSIN COULD IMPROVE ATHEROSCLEROSIS AND 384INFLAMMATION IN THE PATIENTS WITH HYPERTENSION IN THE MORNINGY. Miyashita, I. Saito (Shizuoka and Tokyo, Japan)

177 STUDY 0F INCIDENCE OF NUTRIENT CANALS IN HYPERTENSIVE AND NON 385HYPERTENSIVE PATIENTSM. Mehdizadeh, A. Azimipour (Isfahan, Iran)

178 INTRAVENOUS INFUSION OF SODIUM SELENITE DECREASES BLOOD PRESSURE IN 385NORMOTENSIVE RATSE. Amano, H. Hashimoto, Y. Nakai, M. Atake, N. Takechi, M. Takenaka, N. Kurihara(Kobe, Japan)

179 GENETIC POLYMORPHISMS OF CHOSEN CANDIDATE GENES IN ESSENTIAL 385HYPERTENSION CONTROLLED AND RESISTANT TO THE ANTIHYPERTENSIVE THERAPYM. Jáchymová, K. Horky, Z. Hlubocká, V. Lánská (Prague, Czech Republic)

180 PREVENTION OF CARDIOVASCULAR AND RENAL EVENTS WITH AN 385ANTIHYPERTENSIVE REGIMEN OF PRETERAX (NOLIPREL) ADDING SIMVASTATIN IN PATIENTS WITH DIABETESK. Gogoladze, N. Chachanidze (Tbilisi, Georgia)

181 EFFECTS OF LONG-TERM ANTIHYPERTENSIVE THERAPY WITH LACIDIPINE ON 385AMBULATORY BLOOD PRESSURE AND ON CARDIOVASCULAR REMODELING PROCESSESSh.D. Chumburidze, G.V. Lomtatidze, G.D. Shelia, T.I. Kurtanidze (Tbilisi, Georgia)

182 CIRCULATING LEVELS OF OXLDL AND CRP IN PREHYPERTENSION 386Z. Caparevic, N. Kostic, M. Dekleva, B. Pencic, S. Ilic (Belgrade, Serbia-Montenegro)

183 HYPERTENSION 386M. Bosnjak, L. Sokolova Djokic, S. Martinovic, M. Stic (Sombor, Serbia-Montenegro)

184 ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS) GLU298ASP AND T-786C GENE 386POLYMORPHISM AND METABOLIC SYNDROME IN ESSENTIAL HYPERTENSIONL. Pucci, D. Lucchesi, C. Fotino, S. Triscornia, G. Dell'Omo, R. Pedrinelli, R. Miccoli,S. Del Prato, G. Penno (Pisa, Italy)

185 A LIFESTYLE PROGRAM FOR TREATED HYPERTENSIVES IMPROVES 386CARDIOVASCULAR RISK FACTORS: A RANDOMIZED CONTROLLED TRIALV. Burke, L. Beilin, H. Cutt, J. Mansour, A. Williams, T. Mori (Perth, WA, Australia)

186 ENDOTHELIAL NITRIC OXIDE SYNTHASE E298D AND T-786C POLYMORPHISMS DO 387NOT AFFECT POST-CHALLENGE GLUCOSE AND INSULIN IN NONDIABETICHYPERTENSIVE MEND. Lucchesi, L. Pucci, C. Fotino, S. Triscornia, G. Dell'Omo, R. Pedrinelli, R. Miccoli, G. Penno, S. Del Prato (Pisa, Italy)

187 MONOCYTE/MACROPHAGE STATUS AND THE LEVELS OF SOLUBLE CELL ADHESION 387MOLECULES AND INTERLEUKIN-6 IN YOUNG PATIENTS WITH ESSENTIAL HYPERTENSIOND. Zapolska-Downar, A. Siennicka, K. Chelstowski, K. Widecka, I. Goracy, B. Millo, M. Naruszewicz (Szczecin and Warsaw, Poland)

188 REDUCED AORTIC ROOT COMPLIANCE STATUS AND LIKELIHOOD OF ASSOCIATED 387CORONARY ARTERY DISEASE IN HYPERTENSIVE PATIENTSA.M. Hegazy, B.A. Abdulkader (Farwania, Kuwait)

189 ARTERIAL HYPERTENSION IN PATIENTS SUFFERING OF PERIPHERAL ARTERITIS 387A. Berrah, N. Ouadahi, D. Hakem, M. Boucelma, D. Zemmour, C. Farad, M. Ibrir(Algiers, Algeria)

190 ASSOCIATION OF INTERLEUKIN-6 GENE POLYMORPHISM WITH ESSENTIAL 387HYPERTENSION IN TATARS FROM RUSSIAY.R. Timasheva, T.R. Nasibullin, A.N. Zakirova, O.E. Mustafina (Ufa, Russia)

191 THE RESULTS OF PROLONGED TREATMENT OF PATIENTS WITH DIABETES MELLITUS 388AND ARTERIAL HYPERTENSION WITH PERINDOPRILL.S. Pachulia, Sh.D. Chumburidze (Tbilisi, Georgia)

192 ANTIHYPERTENSIVE AND ANTIOXIDANT EFFECTS OF CARBON MONOXIDE 388SUPPRESSES ANGIOTENSIN II MEDIATED CARDIAC HYPERTROPHY INLDL-RECEPTOR KNOCKOUT MICEA. Kobayashi, K. Ishikawa, S. Kimura, Y. Kamiyama, H. Matsumoto, Y. Maruyama (Fukushima, Japan)

WEDNESDAY

131

WEDNESDAY

132

193 ACE2 ACTIVITY IS INCREASED IN MONOCYTES DERIVED MACROPHAGES FROM 388PREHYPERTENSIVE SUBJECTSA. Raz, A. Strizevsky, A. Gamliel-Lazarovich, S. Keidar (Haifa, Israel)

194 TIME STRUCTURE OF BLOOD PRESSURE VARIATION AND RISK FACTORS IN 388NON-DIPPER KAZAKHSH. Kawamura, Y. Izumi, H. Mitsubayashi, Y. Ozawa, R. Masum (Tokyo, Japan and Urumqi, China)

195 COMPARISON OF CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH PRIMARY 389AND SECONDARY HYPERTENSIONR. Holaj, B. Strauch, O. Petrak, T. Zelinka, J. Widimsky (Prague, Czech Republic)

196 ANTIAGGREGATION AND HIGH BLOOD PRESSURE 389M. Ferraro, V. Spagnuolo, G.F. Mauro (San Giovanni in Fiore and Cosenza, Italy)

197 THIOREDOXIN AND GLUTATHIONE SYSTEMS MRNA LEVELS IN HUMAN HYPERTENSION 389M.L. Mansego, S. Blesa, V. Gonzalez, M.C. Tormos, O. Espinosa, G. Saez, J. Redon, F.J. Chaves (Valencia, Spain)

198 DYSLIPIDEMIA AND STATE OF THE CARDIOVASCULAR SYSTEM AND CIRCADIAN 389BLOOD PRESSURE RHYTHM IN MEN WITH MILD TO MODERATE HYPERTENSIONK. Chagunava, T. Kurtanidze, D. Tsiskarishvili, G. Lomtatidze (Tbilisi, Georgia)

199 ACHIEVEMENT OF THE THERAPEUTIC GOAL IN A SELECTED HYPERTENSIVE 389POPULATION OF OVER 50 YEAR OLDM. Ferraro, V. Spagnuolo, G.F. Mauro (San Giovanni in Fiore and Cosenza, Italy)

200 MORE PRONOUNCED ANTIOXIDATIVE EFFECT OF LONG-TERM TREATMENT WITH 390CARVEDILOL COMPARED TO ATENOLOL IN POST-MYOCARDIAL INFARCTION PATIENTSG. Jonsson, M. Abdelnoor, I. Seljeflot, H. Arnesen, A.T. Hostmark, S.E. Kjeldsen, I. Os, A. Westheim (Oslo, Norway)

201 METABONOMIC CHARACTERIZATION OF NUTRITIONAL AND ENVIRONMENTAL 390SIGNATURES IN HUMAN POPULATION STUDIESL.M. Smith, E. Maibaum, A. Maher, Q. Chan, P. Elliott, J. Mancilha-Carvalho, J. Stamler, H. Kesteloot, J.K. Nicholson, E. Holmes (London, UK, Rio de Janeiro, Brazil, Chicago, IL, USA and Leuven, Belgium)

202 COMPLEMENTARY ROLES OF COLLAGEN AND TISSUE FACTOR OF ATHEROSCLEROTIC 390LESIONS IN SHEAR-INDUCED THROMBUS FORMATION VIA PLATELET GLYCOPROTEIN VIJ. Cosemans, I. Munnix, P. van der Meijden, M. Kuijpers, J. Auger, S. Watson, S. Heeneman, M. oude Egbrink, M. Jandrot-Perrus, J. Heemskerk (Maastricht, The Netherlands, Birmingham, UK and Paris, France)

203 PLATELET-DEPENDENT THROMBIN GENERATION IS REQUIRED FOR TISSUE 390FACTOR- AND COLLAGEN TRIGGERED THROMBOSIS IN VIVOM.J.E. Kuijpers, I.C.A. Munnix, C.P.M. Reutelingsperger, M.G.A. Oude Egbrink, J.W.M. Heemskerk (Maastricht, The Netherlands)

204 PLASMA CD40L LEVELS AND THROMBIN GENERATION AFTER LIPID-LOWERING 391THERAPY AND FOLIC ACID SUPPLEMENTATIONT.B. Domagala, M. Celinska-Lowehoff, J. Dropinski, M. Gnass, T. Iwaniec, A. Borkowska-Mosur, A. Szczeklik (Cracow, Poland)

205 ANTI-INFLAMMATORY ACTION OF A NEW LOW MOLECULAR WEIGHT HEPARIN-LIKE 391DERIVATIVE IN AN ACUTE EXPERIMENTAL INFLAMMATORY MODELE. Masini, A.M. Gori, C. Mazzocca, D. Bani, L. Giannini, M. Falciani, M. Manoni, I. Lapini, R. Abbate, G.F. Gensini (Florence and Pistoia, Italy)

206 INDOBUFEN INHIBITS TISSUE FACTOR IN HUMAN MONOCYTES THROUGH A 391THROMBOXANE-MEDIATED MECHANISMS. Eligini, F. Violi, C. Banfi, S.S. Barbieri, M. Brambilla, E. Tremoli, S. Colli(Milan and Rome, Italy)

207 ANTI-THROMBIC ACTIVITY OF KOREAN HERBAL MEDICINE, DAE-JO-WHAN AND 391ITS HERBSJ. Kim, G. Chang, C. Kim (Seoul and Gyeoingju, South Korea)

208 PHARMACOLOGICAL CHARACTERIZATION OF 2NTX-99, A POTENTIAL 392ANTIATHEROTHROMBOTIC AGENT WITH ANTITHROMBOXANE AND NO-DONOR ACTIVITYC. Buccellati, A. Sala, G. Rossoni, V. Capra, G. Rovati, A. Di Gennaro, G. Folco, S. Colli, C. Casagrande (Milan, Italy)

209 PURIFICATION AND CHARACTERIZATION OF A NEW ANTICOAGULANT PROTEIN, 392PP27, FROM PLACENTAG. Chang, J. Kim, C. Kim (Gyeongju and Seoul, South Korea)

210 EVALUATION OF NOVEL PHOSPHATIDIC ACID DERIVATIVES AS ANTAGONISTS OF 392PLATELET ACTIVATION INDUCED BY THE PLAQUE LIPID LYSOPHOSPHATIDIC ACIDP. Goyal, G.G. Durgam, N. Wilke, D.D. Miller, G. Tigyi, W. Siess(München, Germany and Memphis, TN, USA)

211 AGI-1067, AN ANTIOXIDANT, ANTI-INFLAMMATORY VASCULAR PROTECTANT, 392REDUCES ACTIVITY OF HUMAN PLATELETSV. Serebruany, A. Malinin, R. Scott (Baltimore, MD and Alpharetta, GA, USA)

212 PLATELET INHIBITION WITH PRASUGREL (CS-747) VERSUS CLOPIDOGREL IN 393PATIENTS UNDERGOING CORONARY STENTING (JUMBO PLATELET SUBSTUDY)V. Serebruany, M. Midei, H. Meilman, A. Malinin, D. Lowry (Baltimore, MD, USA)

213 POSTER WITHDRAWN –214 CLOPIDOGREL IN THERAPY OF PATIENTS WITH ACS WITHOUT ST SEGMENT 393

ELEVATION. OUR FIRST EXPERIENCE M. Burazor, I. Burazor, S. Ciric-Zdravkovic, L. Todorovic, S. Nagorni, M. Zivkovic, M. Lazovic, L. Pesic, V. Stojanovic, V. Erakovic (Nis, Serbia-Montenegro)

215 THE THROMBOXANE RECEPTOR ANTAGONIST S 18886 (TERUTROBAN) FAVORED 393ATHEROSCLEROSIS REGRESSION IN APOE*3 LEIDEN TRANSGENIC MICEJ.W.A. van der Hoorn, J.W. Jukema, H.M.G. Princen, L. Chancharme, J.J. Emeis(Leiden, The Netherlands and Courbevoie, France)

216 CD137 AND CD137 LIGAND IN VASCULAR SMOOTH MUSCLE CELLS 393D. Wågsäter, P.S. Olofsson, A. Sirsjö (Stockholm and Örebro, Sweden)

217 EFFECT ON RAT VASCULAR SMOOTH MUSCLE CELLS /MONOCYTES ADHESION BY 393STROMAL CELL DERIVED-FACTOR 1 ALPHAG.H. Li, Y.L. Tu, Z. W, Y.C. Lv, D.H. W, Z.Y. T, F. Y, Z.S. J, G.H. Y, Y.Z. Y (Heng Yang, China)

218 THROMBIN INHIBITION PREVENTS RUPTURE OF ESTABLISHED PLAQUES IN 394APOLIPOPROTEIN E KNOCKOUT MICES. Karanam, R. Fritsche-Danielson, C.L. Jackson (Bristol, UK and Mölndal, Sweden)

219 BENEFICIAL EFFECT OF CILOSTAZOL ON ATHEROSCLEROSIS DEVELOPMENT IN 394APOLIPOPROTEIN-E KNOCKOUT MICE.H. Takase, A. Hashimoto, R. Okutsu, Y. Hirose, H. Ito, T. Imaizumi, G. Miyakoda, T. Mori (Tokushima, Japan)

220 EFFECTS OF CLOPIDOGREL ON KEY EVENTS OF RESTENOSIS IN VITRO: 394EVALUATION OF THE CLINICAL RELEVANCE OF THE DATA WITH THE SI/MPL-RATIOR. Voisard, B. Eisler, R. Baur, V. Hombach (Ulm, Germany)

221 PLATELET ACTIVATION AND RED BLOOD CELLS ABNORMALITIES IN CORONARY 394HEART DISEASE PATIENTST.E. Pogorelova, A.B. Sumarokov, L.I. Buriachkovskaia, I.A. Uchitel (Moscow, Russia)

222 THE EFFECT OF OPIUM ADDICTION ON THE PLASMA LEVELS OF FIBRINOGEN, 394FACTOR VII AND CRPG.H. Naderi, S. Asgary, H. Oroojy, N. Bashardoost (Isfahan, Iran)

223 IS MORPHINE USE EFFECTIVE IN PREVENTING ATHEROSCLEROSIS IN ANIMALS ON 395NORMAL AND HIGH-CHOLESTEROL DIET?S. Asgary, H.R. Barkhordari, H. Hojjat, G.H. Naderi, G. Dashti (Isfahan, Iran)

224 LEVELS OF ACTIVATED PROTEIN C INVERSELY CORRELATED WITH THREE CORONARY 395ARTERIOSCLEROSIS SCORES IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION (MI)P. Cubillo, E. Zorio, S. Navarro, P. Medina, M.A. Arnau, J. Rueda, M. Palencia, A. Salvador,A. Estellés, F. España (Valencia, Spain)

225 CHANGES OF COAGULATION FACTORS AND NORMAL INHIBITORS OF COAGULATION 395DURING ACUTE PHASE OF MYOCARDIAL INFARCTIONI. Moyssakis, M. Daskalaki, D. Papadopoulos, E. Gialafos, K.R. Georgakopoulos, E.A. Sanidas, V. Votteas (Athens, Greece)

226 THE EFFECT OF FIBRINOGEN AND PLATELET AGGREGATION ON CARDIOVASCULAR 395RISK IN PREDIABETIC SUBJECTST. Dogru, A. Sonmez, H. Genc, I. Tasci, A.U. Ural, F. Avcu, M.I. Yilmaz, M. Gok, S. Savasci, S. Kilic (Ankara, Turkey)

227 HYPERVISCOSITY AS A POSSIBLE RISK FACTOR FOR CEREBRAL ISCHEMIC 396COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION PATIENTSE. Cecchi, R. Marcucci, S. Poli, G. Ciuti, D. Poli, S. Ferrini, E. Antonucci, R. Abbate, G.F. Gensini, L. Mannini (Florence and Impruneta, Italy)

228 ASSOCIATION OF THE -308 G/A POLYMORPHISM OF TUMOR NECROSIS FACTOR 396ALPHA GENE WITH MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATHG.H. Tulyakova, T.R. Nasibullin, A.N. Zakirova, E.K. Khusnutdinova, O.E. Mustafina(Ufa, Russia)

WEDNESDAY

133

WEDNESDAY

134

229 APOLIPOPROTEIN A5 GENE POLYMORPHISMS, -1131T>C AND C.553G>T WERE IN 396STRONG LINKAGE DISEQUILIBRIA AND ASSOCIATED WITH HYPERTRIGLYCERIDEMIA IN JAPANESEA. Matsunaga, H. Arishima, Y. Uehara, B. Zhang, H. Niimura, K. Saku (Fukuoka, Japan)

230 MUTATION SCREENING ANALYSIS OF PEROXISOME PROLIFERATOR-ACTIVATED 396RECEPTORS-GAMMA (PPARG) PROMOTERS IN CAD PATIENTS AND CONTROLL. Evangelisti, M. Attanasio, L. Lucarini, L. Rossi, E. Romano, M. Lenti, P. Bolli, G. Pepe, R. Abbate, G.F. Gensini (Florence, Italy)

231 C161T POLYMORPHISM OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 397GAMMA GENE IS ASSOCIATED WITH PROGNOSIS OF MYOCARDIAL INFARCTIONT.H. Chao, Y.H. Li, H.L. Wu, G.Y. Shi, J.H. Chen, W.C. Tsai, L.M. Tsai, L.J. Lin (Tainan, Taiwan)

232 GENETIC VARIANT C677T IN THE METHYLENTETRAHYDROFOLATE REDUCTASE 397GENE IN PATIENT WITH RECURRENT INCIDENCE OF ARTERIAL AND VENOUS THROMBOSISP. Ivanov, S. Gecheva, R. Komsa-Penkova, O. Matkov, K. Kovacheva, A. Kamenova(Pleven, Bulgaria)

233 INFLUENCE OF AMPD1 GENE POLYMORPHISM ON COAGULATION FACTORS IN 397PATIENTS WITH CORONARY HEART DISEASES. Agewall, B. Norman (Stockholm, Sweden)

234 HEPATIC NUCLEAR FACTOR 4 ALPHA GENE IMPLICATED IN FINNISH AND MEXICAN 397FAMILIAL COMBINED HYPERLIPIDEMIA FAMILIESA. Huertas-Vazquez, D. Weissglas, T. Tusie, C. Aguilar-Salinas, M.R. Taskinen, P. Pajukanta (Los Angeles, CA, USA, Mexico City, Mexico and Helsinki, Finland)

235 TREATMENT OF PATIENTS WITH VASCULAR DISEASE WITH LOW-DOSE ASPIRIN. IS 397BLOCKADE OF PLATELET THROMBOXANE A2 SYNTHESIS ALWAYS ACHIEVED?M.T. Santos, J. Valles, A. Lago, J. Tembl, J. Cosin, A. Moscardo, M.P. Fuset, S. Breña(Valencia, Spain)

236 ACETYLSALICYLIC ACID AND CLOPIDOGREL RESISTANCE: POSSIBLE ROLE OF 398RISK FACTORS, MEDICATION AND HEMORHEOLOGICAL VARIABLESG. Feher, K. Koltai, E. Papp, Z. Keszthelyi, B. Alkonyi, P. Kenyeres, H. Rapp, G. Kesmarky, K. Toth (Pecs, Hungary)

237 ASPIRIN RESISTANCE IS ASSOCIATED WITH ASPIRIN DOSAGE, MEAN PLATELET 398VOLUME AND PLATELET COUNT IN PATIENTS WITH ACUTE CORONARY SYNDROMESS. Acikel, A. Yildirir, A. Aydinalp, U. Bal, G. Kaynar, K. Demirtas, B. Ozin, H. Muderrisoglu(Ankara, Turkey)

238 EFFECT OF TWO DIFFERENT DOSES OF ASPIRIN ON PLATELET AGGREGATION AND 398THROMBOXANE FORMATION IN PATIENTS UNDERGOING CABGM. Brambilla, A. Anselmo, C. Centenaro, E. Tremoli, A. Parolari, M. Camera (Milan, Italy)

239 ERYTHROCYTE DEFORMABILITY AND WHITE BLOOD CELL COUNT ARE 398ASSOCIATED WITH ASPIRIN RESISTANCE IN HIGH-RISK VASCULAR PATIENTSL. Mannini, R. Marcucci, R. Paniccia, E. Antonucci, L. Evangelisti, L. Lucarini, A.M. Gori, D. Prisco, G.F. Gensini, R. Abbate (Florence and Impruneta, Italy)

240 EFFECTS OF POMACE OLIVE OIL ON THE POSTPRANDIAL METABOLISM IN HIV PATIENTS 399F. Rivas-Garcia, J.S. Perona, M.J. Aguilar, M. Garcia, J.L. Prada, A. del Arco, V. Ruiz-Gutierrez(Seville and Marbella, Spain)

241 CARDIOVASCULAR RISK REDUCTION IN HIV+ PATIENTS: RESULTS FROM 399SHORT-TERM PHARMACOLOGICAL AND LIFESTYLE INTERVENTIONC.Y. Pai, D. Calderaro, C.L. Zilli Vieira, E. de Oliveira Lima, I. Giuliano, B. Caramelli (São Paulo, Brazil)

242 CARDIOVASCULAR RISK DUE TO LIPOPROTEIN (A) IN HIV-INFECTED SUBJECTS 399W.O. Richter, E. Schnaitmann, A. Trein (Windach and Stuttgart, Germany)

243 PON1 ACTIVITY IS NOT IMPAIRED IN HIV POSITIVE PATIENTS 399L.P. Pucillo, E. Foschi, E. Valente, M. Brescia, F. Soldani, A. Antinori (Rome, Italy)

244 OXIDIZED LDL IN HIV INFECTED PERSONS 399L.P. Pucillo, M. Brescia, E. Valente, E. Foschi, F. Soldani, A. Antinori (Rome, Italy)

245 ATHEROSCLEROTIC RISK IN CHILDREN WITH ACQUIRED IMMUNODEFICIENCY 400SYNDROME (AIDS) – PERI STUDYI. Giuliano, M. Grimaldi, D. Blanco, E. Lima, P. Yu, D. Calderaro, M. Silva, B. Caramelli(Santa Catarina and São Paulo, Brazil)

246 A NEW BIOMARKER TO ASSESS CARDIOCYTOTOXICITY AND LIPODYSTROPHY IN 400HIV PATIENTS UNDERGOING ARTM. Gidlund, K. Ronchini, H. Goto (São Paulo, Brazil)

247 PROTEASE INHIBITOR-ASSOCIATED DYSLIPIDEMIA IN HIV PATIENTS IS STRONGLY 400INFLUENCED BY THE APOLIPOPROTEIN A5 GENEM. Guardiola, R. Ferré, C. Alonso-Villaverde, B. Coll, J. Salazar, J. Ribalta, L. Masana (Reus, Spain)

248 HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FOR HIV-INFECTION INCREASES 400PLASMA HOMOCYSTEINE CONCENTRATIONSN. Weiss, P. Koelle, J. Bogner, F.D. Goebel (Munich, Germany)

249 INCREASED ENDOTHELIAL ACTIVATION IN A HUMAN MODEL OF ISOLATED 400ENDOTHELIAL VASOMOTOR DYSFUNCTIONS.S. Shankar, H.O. Steinberg (Indianapolis, IN, USA)

250 EFFECTS OF NEVIRAPINE AS COMPARED TO LAMIVUDINE ON LIPIDS AND 401LIPOPROTEINS IN HIV-1 UNINFECTED NEWBORNS: THE SIMBA LIPID SUBSTUDYR.R. Sankatsing, F.W. Wit, N. Pakker, J. Vyankandondera, F. Mmiro, P. Okong, J.J.P. Kastelein, J.M. Lange, E.S.G. Stroes, P. Reiss (Amsterdam, The Netherlands, Kigali, Rwanda and Kampala, Uganda)

251 SMALL DENSE LDL IN HIV-INFECTED PATIENTS TREATED WITH LOPINAVIR/RITONAVIR 401OR ATAZANAVIRW.O. Richter, F. Berger, S. Mauss (Munich and Duesseldorf, Germany)

252 PLASMA CHOLESTEROL CONCENTRATIONS IN DEPRESSION AND POSTTRAUMATIC 401STRESS DISORDERJ. Bremner, V. Vaccarino (Atlanta, GA, USA)

253 INTERLEUKIN-6 PLASMA LEVELS ARE INCREASED IN SUBJECTS WITH VASCULAR 401DEMENTIA BUT NOT WITH LATE ONSET ALZHEIMER'S DISEASEG. Guerra, M. Ranzini, L. Rossi, M.R. Munari, A. Zurlo, A.R. Atti, A. Ble', G. Zuliani(Ferrara and Treviso, Italy)

254 ATHEROSCLEROSIS AND DEMENTIA: IMPLICATION OF OXIDATIVE STRESS IN THE 402IMPAIREMENT OF COGNITIVE FUNCTIONI. Squellerio, F. Veglia, M. Alimento, L. Boccotti, J. Campodonico, E. Tremoli, V. Cavalca(Milan, Italy)

255 VASCULAR RISK FACTORS, MILD COGNITIVE IMPAIRMENT, AND CONVERSION TO 402DEMENTIA. THE ITALIAN LONGITUDINAL STUDY ON AGINGF. Panza, C. Capurso, A. D'Introno, A.M. Colacicco, A. Capurso, V. Solfrizzi (Bari, Italy)

256 DYSLIPIDEMIA-RELATED MEMORY IMPAIRMENT IN TYPE 2 DIABETES 402S. Miclea, N. Hancu (Cluj-Napoca, Romania)

257 PERCEPTION OF STRESSORS BY SELECTED PATIENTS OF CORONARY CARE 402UNITS IN YAZD, IRANZ. Kalani, H. Abdi, M.R. Aminipour (Yazd, Iran)

258 PHYSICAL CHARACTERIZATION OF A POLYMERIC CARRIER FOR AN ANTIBODY 402ELUTING STENTL.L. Luo, G.X. Wang, T.Y. Yin, C.G. Ruan, R. Guidoin (Chongqing, Suzhou, China and Quebec, QC, Canada)

259 SURFACE TREATMENT EFFECTS ON BIOCOMPATIBILITY OF NITINOL ALLOY STENTS 403G.X. Wang, Y. Shen, S.S. Luo, Q.S. Yu (Chongqing, China and Columbia, MO, USA)

260 ELUTING CHARACTERISTICS OF A PLATELET GLYCOPROTEIN RECEPTOR ANTIBODY 403POLYMER-COATED STENTT.Y. Yin, G.X. Wang, L.L. Luo, C.G. Ruan, R. Guidoin (Chongqing, Suzhou, China andQuebec, QC, Canada)

261 FLUORESCENCE STAINING AND SEMI-QUANTITATIVE IMAGE ANALYSIS OF DRUG 403ELUTING STENTST.Y. Yin, G.X. Wang, L.L. Luo, C.G. Ruan, R. Guidoin (Chongqing, Suzhou, China and Quebec, QC, Canada)

262 PLASMA SURFACE TREATMENT EFFECTS ON ADHESION PROPERTY OF STAINLESS 403STEEL STENTS TO ENDOTHELIAL CELLSS.S. Luo, G.X. Wang, C.J. Tang, L.S. Liu, Q.S. Yu (Chongqing, China and Columbia, MO, USA)

263 INTERLEUKIN 6 IS ASSOCIATED WITH RESTENOSIS AFTER IMPLANTATION OF 404DRUG-ELUTING CORONARY STENTSV.G. Naumov, M.V. Ezhov, I.R. Raimbekova, A.B. Sumarokov, A.N. Samko, V.P. Masenko (Moscow, Russia)

264 USE OF STENTS WITH SIROLIMUS IS SIGNIFICANTLY ASSOCIATED WITH A REDUCTION 404IN MORTALITY AND CARDIOVASCULAR MORBIDITY AT 6- AND 12-MONTHS POST-PTCAM. Rizzo, L. Campolo, A. Frasheri, V. Pernice, G. Barone, F. Contorno, S. Amato,C.M. Barbagallo, A. Notarbartolo, M.R. Averna (Palermo and Milan, Italy)

WEDNESDAY

135

WEDNESDAY

136

265 BIOARTIFICIAL VASCULAR GRAFTS: A NOVEL APPROACH TO TREATMENT OF BLOOD 404VESSELS DAMAGED BY VASCULAR DISEASESL. Bacakova, E. Filova, D. Kubies, L. Machova, V. Proks, V. Malinova, F. Rypacek (Prague, Czech Republic)

266 ERECTILE DYSFUNCTION AS PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS 404IN DIABETIC PATIENTS WITH SILENT CORONARY ARTERY DISEASEC. Gazzaruso, A. Pujia, C. Falcone, F. Salvucci, D. Geroldi, E. Emanuele, B. Solerte, A. Garzaniti (Pavia, Catanzaro and Vigevano, Italy)

267 CARDIOVASCULAR SAFETY OF VARDENAFIL IN PATIENTS ON ANTIHYPERTENSIVES 404AND / OR ALPHA BLOCKERS: ANALYSIS OF 17 PLACEBO-CONTROLLED TRIALS

P. Montorsi, H. van Ahlen, P. Kell, F. Montorsi (Milan, Italy, Osnabrück, Germany and London, UK)

268 CARDIOVASCULAR RISK FACTORS DETERMINE ERECTILE AND ARTERIAL RESPONSE 405TO SILDENAFILA. Wierzbicki, H. Solomon, P. Lumb, G. Jackson (London, UK)

269 RELATIVE HYPOGONADISM AS AN INDEPENDENT DETERMINANT OF ENDOTHELIAL 405DYSFUNCTION IN MENM. Akishita, M. Hashimoto, Y. Ohike, K. Iijima, M. Eto, Y. Ouchi (Tokyo and Kobe, Japan)

270 CLINICAL AND IMMUNOLOGICAL EFFECTS OF ONE-WEEK TREATMENT WITH 405INTRAVENOUS ILOPROST IN CRITICAL LIMB ISCHEMIA PATIENTSS. Meini, D. Pieragalli, M. Di Renzo, V. De Franco, A.L. Pasqui, A. Auteri (Siena, Italy)

271 HUMORAL RESPONSE AGAINST HIGH DENSITY LIPOPROTEINS (HDL) IN NORMAL 405POPULATIONJ. Batuca, J. Delgado Alves (Lisbon, Portugal)

272 INVARIANT NKT CELLS PRESENT IN HUMAN ATHEROSCLEROTIC LESIONS 406H.E. Agardh, P. Eriksson, E. Tupin, M. Kazi, U. Hedin, A. Olsson, G.K. Hansson, J. Swedenborg, G. Paulsson-Berne (Stockholm, Sweden and San Diego, CA, USA)

273 IMMUNOMODULATORY PROPERTIES OF APOB-100 DERIVED PEPTIDES ON DENDRITIC 406CELLS AND T-LYMPHOCYTESA. Bermudez-Fajardo, N. Milioti, G. Nordin Fredrikson, J. Nilsson, E. Oviedo-Orta(Guildford, UK and Malmo, Sweden)

274 CHLAMYDOPHILA PNEUMONIAE, GROWTH FACTORS AND MEMBRANE ATTACK 406COMPLEX IN ACCELERATED GRAFT CORONARY ATHEROSCLEROSIS (AGCA)M.L. Higuchi, M.M. Reis, N.V. Sambiase, S.A.P. Palomino, N. Stolf, J.A.F. Ramires (São Paulo, Brazil)

275 ANALYSIS OF TLR-4 AND CD14 POLYMORPHISMS IN FAMILIAL 406HYPERCHOLESTEROLAEMIA PATIENTSD. Recalde, P. Martin-Fuentes, B. Puisac, A.L. Garcia-Otin, A. Cenarro, E. Jarauta, J.A. Lopez-Cabañas, F. Civeira (Zaragoza, Spain)

276 THE IMMUNOMODULATOR FTY720 INHIBITS EARLY ATHEROSCLEROSIS IN 407APOE-/- MICER. Klingenberg, F. Bea, E. Blessing, M. Preusch, H.-J. Groene, V. Brinkmann, F. Picard, H.A. Katus, G.K. Hansson, T.J. Dengler (Heidelberg, Germany, Basel, Switzerland and Stockholm, Sweden)

277 ANTIMICROBIAL PEPTIDE LL-37 IN HUMAN ATHEROSCLEROSIS 407K. Edfeldt, B. Agerberth, M.E. Rottenberg, G.H. Gudmundsson, K. Mandal, Q.B. Xu, G.K. Hansson, Z.Q. Yan (Stockholm, Sweden, Reykjavik, Iceland and London, UK)




OPTIMAL ATHEROSCLEROSISMANAGEMENT (2nd part)

278 ESTROGEN REPLACEMENT THERAPY DECREASES RLP CONCENTRATION IN 407PLASMA: ORAL AND TRANSDERMAL ERT COMPARISONM. Vrablik, T. Fait, J. Kovar, L. Zlatohlavek, R. Poledne, R. Ceska (Prague, Czech Republic)

279 SOME OF ARTERIOSCLEROTIC RISK FACTORS RELATED TO SERUM ESTRADIOL 407LEVEL IN WOMEN DURING MENOPAUSES. Petrovska, B. Dejanova, P. Kandikjan (Skopje, Macedonia)

280 METABOLIC ABERRATIONS AT THE WOMEN WITH POLYCYSTIC OVARY SYNDROME 407IN ANAMNESIST. Arkhypkina, L. Liubimova (Kharkov, Ukraine)

281 ANTIOXIDANTS IN MENOPAUSAL WOMEN WITH CORONARY ARTERY DISEASE 408M. Andonovska (Kumanovo, Macedonia)

282 HORMONE REPLACEMENT THERAPY AND RISK OF CORONARY HEART DISEASE IN 408THE CORA-STUDYE. Windler, B. Zyriax, B. Eidenmüller, H. Boeing (Hamburg and Potsdam-Rehbrücke, Germany)

283 EFFECTS OF SEXUAL STEROIDS ON MICROVESSELS 408G.L. Nádasy, B. Székács, M. Mericli, S. Várbíró, N. Ács, M. Szekeres, R. Kakucs, M. Mátrai, E. Monos (Budapest, Hungary)

284 OESTROGEN AND FEMALES ISCHEMICAL HEART DISEASE 408V. Stevitsh Gajitsh, M. Borzanovitsh, R. Obrenovitsh (Krusevac and Belgrade, Serbia-Montenegro)

285 THE EFFECTS ON LIPIDS OF A 2-YEAR ADJUVANT TREATMENT WITH EXEMESTANE 409AFTER TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCERS. Gonnelli, A. Montagnani, A. Cadirni, C. Caffarelli, M. Montomoli, M.S. Campagna,R. Petrioli, K. Del Santo, C. Cuda, R. Nuti (Siena, Italy)

286 THE EFFECT OF MOXONIDINE IN COMPARISON WITH PRESTARIUM ON 409PARAMETERS OF LIPID METABOLISM IN POSTMENOPAUSAL WOMENG.M. Dadashova, A.B. Bakhshaliyev (Baku, Azerbaijan)

287 HIGH ORAL DOSE OF ESTROGEN INHIBITS ATHEROSCLEROSIS BY INHIBITING NADPH 409OXIDASE AND INCREASING OXIDATIVE STRESS SCAVENGERS IN APO E-DEFICIENT MICEY.C. Chen, L.Y.C. Wing, Y.Y. Shih, J.C. Cheng, M.J. Jiang (Tainan, Taiwan)

288 INDUCTION OF MACROPHAGE RECEPTOR WITH COLLAGENOUS STRUCTURE 409(MARCO) SUGGESTS POSSIBLE INVOLVEMENT OF ENDOTOXIN IN NONALCOHOLICSTEATOHEPATITIS (NASH)M. Takeya, M. Terasaki, Y. Terasaki, N. Sakashita, H. Sato (Kumamoto, Japan)

289 STRUCTURE AND CONCENTRATION OF DIFFERENT FATTY ACIDS (FFAS) AFFECT 410STEATOSIS EXTENT AND APOPTOSIS IN HEPATOCYTE CULTURESM. Ricchi, L. Carulli, M.R. Odoardi, M.L. Bormioli, C. Anzivino, A. Lonardo, M. Bertolotti, N. Carulli, P. Loria (Modena, Italy)

290 ENDOTHELIAL FUNCTION IS IMPAIRED IN NON-ALCOHOLIC STEATOHEPATITIS 410S.S. Shankar, N.P. Chalasani, H.O. Steinberg (Indianapolis, IN, USA)

291 THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE WITH METFORMIN 410AND LACTULOSEM. Meparidze, N.N. Kipshidze, T. Kodua, M. Jebashvili, N. Kakauridze, M. Khelashvili, M. Mosistrapishvili (Tbilisi, Georgia)

POSTER AREA “A” WEDNESDAY, June 21 278-311

WEDNESDAY

137


posterboard no.:

WEDNESDAY

138

292 HEPATIC APOLIPOPROTEIN-A5 MRNA EXPRESSION DECREASES WITH WEIGHT LOSS 410IN MORBIDLY OBESE SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASES. Kaser, A. Sandhofer, A. Moschen, H. Tilg, C. Ebenbichler, J. Patsch (Innsbruck, Austria)

293 ASSOCIATIONS BETWEEN CAROTID ARTERY WALL THICKNESS AND LIVER 411HISTOLOGY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASEG. Targher, L. Bertolini, R. Padovani, S. Rodella, L. Zenari, M. Cigolini, G. Falezza, G. Arcaro (Negrar and Arzignano, Italy)

294 DOES FATTY LIVER ASSOCIATE WITH CAROTID ATHEROSCLEROSIS? 411F. Scaglioni, S. Lombardini, M. Ricchi, A.M. Verrone, S. Ballestri, L. Carulli, A. Lonardo, N. Carulli, P. Loria (Modena, Italy)

295 ASSOCIATION BETWEEN BONE MINERAL DENSITY AND ATHEROSCLEROSIS IN 411POSTMENOPAUSAL WOMENR. Sato, M. Okabayashi, H. Akao, K. Kajinami (Ishikawa, Japan)

296 EXPRESSION OF OSTEOPROTEGERIN IN THP-1 CELLS. INFLUENCE OF MACROPHAGE 411TRANSFORMATION AND CO-CULTURE WITH SMOOTH MUSCLE CELLSY. Nagano, K. Nakai, M. Daito, N. Domae (Hirakata, Japan)

297 HIGH PREVALENCE OF PERIPHERAL ARTERIAL DISEASE AMONG OSTEOPOROTIC 411POSTMENOPAUSAL WOMENR. Mangiafico, E. Russo, S. Riccobene, P. Pennisi, M. Mangiafico, F. D'Amico, N. Parisi, C. Fiore (Catania, Italy)

298 EFFECT OF SHORT-TERM RHG-CSF STIMULATION ON LIPOPROTEIN PROFILE AND 412OSTEOPROTEGERINS. Bergmann, G. Siegert, F. Kroschinsky (Dresden, Germany)

299 ASSESSMENT OF PERIODONTAL STATE IN PATIENTS WITH CORONARY HEART 412DISEASEL. Pawlicki, M. Kowalski, J. Kowalski, J. Blaszczyk, M. Barylski, A. Lewinski (Lodz, Poland)

300 THE FIMBRIAE OF PORPHYROMONAS GINGIVALIS INCREASED ATHEROSCLEROSIS 412RISKL.P. Nucci da Silva, J.L. Sinone, C. Gun (Sao Paolo, Brazil)

301 PERIODONTAL DISEASE AND ATHEROSCLEROSIS: CAN BRUSHING AND FLOSSING 412PREVENT CARDIOVASCULAR DISEASE?M. Trevisan, R.J. Genco, O.M. Andriankaja, J. Dorn, K.L. Falkner, S.G. Grossi (Buffalo, NY, USA)

302 PERIODONTAL DISEASE AND CORONARY ARTERY DISEASE: A TALE OF TWO 412DISEASES?S. Abou-Raya, A. Abou-Raya, A. Naim, H. Abuelkheir (Alexandria, Egypt)

303 PERIODONTAL MICROBIOTA AND CORONARY ARTERY DISEASE 413B. Shivalkar, W. Hoisington, P. Camp, I. Micholt, J. Bosmans, C. Vrints, M. Toelken(Antwerp and Ninove, Belgium)

304 SEROLOGICAL ANALYSIS OF THE IMPLICATIONS OF PERIODONTITIS IN VASCULAR 413DISEASESY.W. Chen, M. Umeda, Y. Huang, Y. Takeuchi, Y. Inoue, T. Iwai, I. Ishikawa (Tokyo, Japan)

305 PORPHYROMONAS GINGIVALIS INDUCES PLATELET AGGREGATION AND BLOOD 413COAGULATION - ROLE OF GINGIPAINS AND LIPOPOLYSACCHARIDEST. Bengtsson, M. Nylander, C. Skoglund, N. Tynngård, H. Kälvegren, L. Wallin, M. Grenegård, T. Lindahl (Linköping, Sweden)

306 PERIODONTAL DISEASE AND PRESENCE OF CORONARY ARTERY DISEASE IN 413PATIENTS UNDERGOING CORONARY ANGIOGRAPHYJ. Auer, G. Szuesz, G. Lamm, G. Krennmair, R. Berent, T. Weber, B. Eber (Wels and Vienna, Austria)

307 EFFECT OF ANTI-TNFA ADMINISTRATION ON THE LIPID PROFILE IN PATIENTS WITH 414INFLAMMATORY DISEASESJ.A. Papadakis, E.K. Spanakis, G.E. Vrentzos, G. Katsikas, S.T. Karvounaris, H.D. Kritikos,P.I. Sidiropoulos, E.S. Ganotakis, D.T. Boumpas (Heraklion, Greece)

308 INFLAMMATION AND PLATELET ACTIVATION IN PATIENTS WITH RHEUMATOID 414ARTHRITIS: POSSIBLE DETERMINANTS OF INCREASED CARDIOVASCULAR RISKC. Jurcut, R. Jurcut, S. Blaj, C. Tanasescu (Bucharest, Romania)

309 RHEUMATHOID ARTHRITIS (RA) AND ATHEROSCLEROSIS: OSTEOPONTIN (OPN) A 414COMMON INFLAMMATORY MARKER ASSOCIATED WITH CARDIOVASCULAR RISKL. Bazzichi, A. Mazzone, A. Consensi, T. Giuliano, F. De Feo, M. Lanza, C. Giacomelli, S. Bombardieri (Pisa, Italy)

310 TNF ALPHA -1031 T>C POLYMORPHISM IS ASSOCIATED WITH ELEVATED MARKERS 414OF OXIDATION AND WITH SMALLER LDL SIZE IN SUBJECTS WITH RHEUMATOID ARTHRITISJ.C. Vallvé, J. Girona, S. Paredes, E. Hurt-Camejo, L. Masana (Reus, Spain and Mölndal, Sweden)

311 ATHEROSCLEROSIS, INFLAMMATION, CRP AND STATINS IN RHEUMATOID 415ARTHRITISA. Abou-Raya, S. Abou-Raya, A. Naim (Alexandria, Egypt)

WEDNESDAY

139

WEDNESDAY

140




METABOLIC SYNDROME

312 FUNCTIONAL FEATURES OF A CYCLE GLUCOSE - FAT ACIDS IN WOMEN WITH RISK 415FACTORS OF A METABOLIC SYNDROMEZ.A.E. Bakhtina, A.V. Strelkova, T.A. Zykova (Arkhangelsk, Russia)

313 THE METABOLIC SYNDROME IS A POWERFUL DETERMINANT FACTOR OF 415INFLAMMATION IN THE CALCIFIED AORTIC VALVEC. Côté, A. Cartier, Z. Castonguay-Lebel, R. Shetty, A. Pépin, M. Briand, J.P. Després, P. Pibarot, P. Mathieu (Québec, QC, Canada)

314 LDL FROM OBESE PATIENTS INDUCE AN INCREASE IN SCAVENGER RECEPTORS 415CD36 AND LOX-1 GENE EXPRESSION IN HUMAN ENDOTHELIAL CELLSC. Stancu, G. Botez, D. Alexandru, M. Vladica, A. Sima (Bucharest, Romania)

315 ELEVATED LEVELS OF THE PROINFLAMMATORY MEDIATOR SCD40L IN THE 415METABOLIC SYNDROMEN. Varo, C. Natal, I. Colina, J. Díez (Navarra, Spain)

316 GLYCEMIA AND TRIGLYCERIDES, BUT NOT TOTAL OR HDL CHOLESTEROL LEVELS, 416ARE ASSOCIATED WITH HIGHER PLATELET ACTIVITYP. Osmancik, F. Bednar, P. Stros, M. Jares, P. Widimsky (Prague, Czech Republic)

317 PLASMA LIPOLYTIC ACTIVITY AND HEMOSTATIC PARAMETERS IN PATIENTS WITH 416METABOLIC SYNDROMEL.V. Javashvili, D.K. Virsaladze, N. Esakia (Tbilisi, Georgia)

318 CD4+T CELLS ARE RELATED TO THE METABOLIC SYNDROME OF HIV-INFECTED 416PATIENTSG. Aragones, B. Coll, S. Parra, C. Alonso-Villaverde, J. Joven, L. Masana (Reus, Spain)

319 LEPTIN TO ADIPONECTIN RATIO AS THE NOVEL ATHEROGENESIS RISK INDICATOR 416M. Malczewska-Malec, L. Partyka, I. Lesczynska-Golabek, A. Zdzienicka, M. Szopa, A. Dembinska-Kiec (Cracow, Poland)

320 THE CLINICAL SIGNIFICANCE OF SERUM 7-KETOCHOLESTEROL LEVELS IN 417PATIENTS WITH METABOLIC SYNDROME OR ACUTE MYOCARDIAL INFARCTIONY. Miyashita, M. Ebisuno, M. Ohira, K. Endoh, A. Saiki, N. Koide, T. Oyama, T. Murano, H. Watanabe, K. Shirai (Chiba, Japan)

321 CLINICAL SIGNIFICANCE OF ELEVATED LEVELS OF VERY LONG-CHAIN SATURATED FATTY 417ACID (HEXACOSANOIC ACID; C26:0) IN WHOLE BLOOD CELL IN METABOLIC SYNDROMEA. Kume, T. Miyazaki, T. Kiyanagi, H. Ohmura, Y. Kitamura, K. Oshida, N. Yanagisawa,K. Shimada, H. Mokuno, H. Daida (Hongo and Zama, Japan)

322 INFLAMMATORY CYTOKINES IN METABOLIC SYNDROME (MS) A COMPARISON 417BETWEEN MS AND SIMPLE OBESITYM. Ohni, S. Mizukawa, H. Ohnuki, K. Nakajima, Y. Suemitsu, M. Kaneko, K. Toba, Y. Hata (Mitaka-city, Japan)

323 LEPTIN LEVELS IN YOUNG, NON-OBESE, MALE SMOKERS AND NON-SMOKERS 417B. Koc, A. Sonmez, T. Dogru, I. Tasci, H. Genc, M. Gok, E. Bozoglu, M.I. Yilmaz, G. Erdem, S. Erikci (Ankara, Turkey)

324 HYPERTENSION DIFFERENTIATES THE GROUP OF PATIENTS WITH METABOLIC 417SYNDROMEL. Partyka, M. Malczewska-Malec, I. Leszczynska-Golabek, M. Trzos, D. Siedlecka, A. Dembinska-Kiec (Cracow, Poland)



posterboard no.:

325 METABOLIC SYNDROME IN HD PATIENTS: INSULIN RESISTANCE, VISCERAL 418ADIPOSITY, INFLAMMATION AND IRONZ. Rasic-Milutinovic, G. Perunicic-Pekovic, S. Pljesa, M. Ilic, S. Stankovic (Belgrade, Serbia-Montenegro)

326 DYSLIPIDEMIC PROFILE IN RELATION TO ANTHROPOMETRIC INDEXES OF 418VISCERAL OBESITY IN METABOLIC SYNDROMES. Subeska Stratrova, B. Dejanova, V. Arsova, P. Kandikijan (Skopje, Macedonia)

327 LEPTINE LEVELS AND INSULIN RESISTANCE INDEX ARE MARKERS OF EARLY 418METABOLIC DISTURBANCES AT PATIENTS WITH ESSENTIAL HYPERTENSIONN. Velykykh, S. Koval, I. Snegurskaya, D. Myloslavsky, Y. Karachentsev, N. Kravchun(Kharkov, Ukraine)

328 METABOLIC SYNDROME IS ASSOCIATED WITH INFLAMMATION BUT NOT 418PROTHROMBOGENESIS AND ENDOTHELIAL DYSFUNCTIONK. Yusoff, H. Nawawi, R. Ibrahim (Shah Alam, Malaysia)

329 SYMPATHETIC ACTIVATION AND RISK OF ATHEROSCLEROSIS IN PATIENTS 419WITH DIABETES MELLITUS TYPE 1T. Zykova, A. Strelkova, K. Balandina, O. Batrakova (Arkhangelsk, Russia)

330 ASSOCIATION BETWEEN PLASMA MYELOPEROXIDASE LEVELS AND METABOLIC 419SYNDROMEH. Ghanbari, B. Hassunizadeh, H. Manyam, R. Dandamudi, D. Cunningham, S. David, C. Machado (Southfield, MI, USA)

331 COMPLEX ADAPTIVE RESPONSE IN THE METABOLIC SYNDROME (MS): CLINICAL, 419FUNCTIONAL AND GENETIC STUDYV. Palmieri, P. Portincasa, I. Grattagliano, A. Genovese, G. Cardinale, G. Palasciano (Bari, Italy)

332 URIC ACID IS ASSOCIATED WITH CORONARY ARTERY CALCIFICATION AMONG 419ASYMPTOMATIC MEN WITH METABOLIC SYNDROMER.D. Santos, K. Nasir, R. Orakzai, S. Orakzai, R. Meneghelo, J.A.M. Carvalho, R. Blumenthal(São Paulo, Brazil, Pittsburgh, PA and Baltimore, MD, USA)

333 ADJUSTMENT BY HEIGHT IMPROVES THE CORRELATION OF WAIST 420CIRCUMFERENCE WITH SUBCLINICAL ORGAN DAMAGE IN HYPERTENSIVE MENG. Lupattelli, G. Schillaci, M.R. Mannarino, G. Pucci, J. Helou, G. Savarese, M. Pirro, E. Mannarino (Perugia, Italy)

334 METABOLIC SYNDROME DIAGNOSTIC CRITERIA. DIVERGING TO THE POINT? A 420MASSA LOMBARDA PROGRAM COHORT PRELIMINARY ANALYSISE. Pedro, M. Manca, S. Nascetti, M. Gaddoni, G. Noera, A.M. Bargossi, A. Gaddi (Lisbon, Portugal and Bologna, Italy)

335 ASSOCIATION BETWEEN HIGH-SENSITIVE C-REACTIVE PROTEIN AND 420HIGH-MOLECULAR WEIGHT ADIPONECTIN IN JAPANESE GENERAL POPULATIONS. Nakano, M. Tsusima, Y. Nakano, S. Kyotani, T. Nakamori, C. Maruyama, T. Maruyama(Utsunomiya, Atami, Shinagawa, Osaka, Nagoya, Bunkyou and Saitama, Japan)

336 HAEMOSTATIC AND FIBRINOLYTIC ABNORMALITIES IN OBESE PATIENTS AND IN 420PATIENTS WITH TYPE 2 DIABETES WITH METABOLIC SYNDROMEG. Avellone, V. Di Garbo, R. Scaglione, P. Fernandez, R. De Simone, G. Raneli, G. Licata(Palermo, Italy)

337 METABOLIC SYNDROME IN ACUTE CORONARY SYNDROMES 421I. Burazor, M. Burazor, S. Nagorni, S. Ciric-Zdravkovic, Z. Burazor, N. Burazor (Nis, Serbia-Montenegro)

338 SERUM URIC ACID LEVELS AND RISK FOR CARDIOVASCULAR DISEASES IN 421PATIENTS WITH AND WITHOUT THE METABOLIC SYNDROMEJ. Hjortnaes, A. Algra, J. Olijhoek, M. Huisman, H. Jacobs, Y. Van der Graaf, F.L.J. Visseren(Utrecht, The Netherlands)

339 THE CORTISOL AWAKENING RESPONSE AND THE METABOLIC SYNDROME - A 421GENDER SPECIFIC ASSOCIATION?I. Bengtsson, L. Lissner, T. Ljung, A. Rosengren, D. Thelle, P. Währborg (Göteborg, Sweden)

340 INCREASED GLOBAL INFLAMMATION SCORE AMONG MEN WITH THE METABOLIC 421SYNDROME IDENTIFIED WITH NCEP-ATP III CRITERIA OR HYPERTRIGLYCERIDEMIC WAISTA. Cartier, M. Côté, J. Bergeron, N. Alméras, A. Tremblay, P. Mauriège, I. Lemieux, J.P. Després (Québec, QC, Canada)

341 REDUCED ANTIOXIDATIVE DEFENSE IN CHILDREN AND ADOLESCENTS WITH 421METABOLIC SYNDROMEV. Dimitrijevic-Sreckovic, E. Colak, P. Djordjevic, D. Gostiljac, T. Novakovic, B. Sreckovic,S. Popovic, R. Obrenovic, F. Canovic, T. Nisic (Beograd, Serbia-Montenegro)

WEDNESDAY

141

WEDNESDAY

142

342 PSYCHOSOCIAL FACTORS AND HEALTH RELATED QUALITY OF LIFE AMONG 422MIDDLE-AGED INDIVIDUALS WITH AND WITHOUT THE METABOLIC SYNDROMEG. Hollman, M. Kristenson (Linköping, Sweden)

343 OBSTRUCTIVE SLEEP APNEA: RELATIONSHIP WITH METABOLIC SYNDROME AND 422LOW GRADE INFLAMMATIONA.M. Maresca, E. Laurita, C. Marchesi, E. Nicolini, F. Solbiati, M. Gianni, D. Tomassetti, M. Marogna, F. Colombo, A.M. Grandi (Varese, Italy)

344 C-REACTIVE PROTEIN, THEIR RELATIONSHIPS WITH METABOLIC SYNDROME AND 422INSULIN RESISTANCE IN MEXICAN ADOLESCENTSG. Cardoso-Saldaña, J. Juarez-Rojas, J. Zamora-Gonzalez, M. Raygoza-Perez, R. Martinez-Alvarado, R. Posadas-Romero, C. Posadas-Romero (Mexico City, Mexico)

345 OBESE WOMEN AND WAIST CIRCUMFERENCE 422D. Stojsic, M. Novkovic, J. Stojsic, M. Vejnovic (Sombor and Vrbas, Serbia-Montenegro)

346 METABOLIC SYNDROME, HYPERTENSION AND CAROTID ATHEROSCLEROSIS 423C. Irace, C. Cortese, C. Carallo, A. Gnasso (Catanzaro and Rome, Italy)

347 LOWER WAIST CIRCUMFERENCE THRESHOLD FOR METABOLIC SYNDROME IN A 423MALAY ASIAN POPULATIONH. Nawawi, T. Ismail, N.M. Mansor, M.M. Mahyuddin, R. Razali, S. Muid, A.R. Azlina, K. Yusoff (Shah Alam, Malaysia)

348 OBESITY AND METABOLIC SYNDROME IN CHILDREN AND ADOLESCENTS 423I. Schusterova, J. Saligova, L. Potocnakova, M. Andrejkova, I. Marinova, I. Riecansky(Kosice and Bratislava, Slovak Republic)

349 THE PREVALENCE OF METABOLIC SYNDROME IN THE KOREAN PATIENTS WITH 423CORONARY ARTERY DISEASEJ.H. Choi, J. Sung, M.K. Kang, W.J. Lee, Y.H. Choi, M.K. Lee, J.E. Park (Seoul, South Korea)

350 PREVALANCE OF METABOLIC SYNDROME IN A MEDITERRANEAN COHORT OF 423ANKYLOSING SPONDYLITIS PATIENTSJ.A. Papadakis, E.K. Spanakis, G.E. Vrentzos, G. Katsikas, P.I. Sidiropoulos, E.S. Ganotakis, D.T. Boumpas (Heraklion, Greece)

351 METABOLIC SYNDROME RISK FACTORS CORRELATION NETWORKS IN MASSA 424LOMBARDA POPULATION. RELEVANT STRUCTURAL DIFFERENCES BETWEENHEALTHY AND AFFECTED GROUPSE. Pedro, M. Manca, A.F.G. Cicero, C. Altini, G. Noera, R. Fellin, A. Gaddi (Lisbon, Portugal, Bologna and Ferrara, Italy)

352 PREDICTIVE VALUE OF NEW METABOLIC SYNDROME DEFINITION 424J. Bellwon, K. Chlebus, R. Dworakowski, W. Sobiczewski, D. Ciecwierz, J. Siebert, A. Rynkiewicz (Gdansk, Poland)

353 RELATIONSHIP OF DEFINITIONS OF THE METABOLIC SYNDROME TO CORONARY 424ARTERY DISEASE BURDEN IN PAKISTANISA. Wierzbicki, S. Nishtar, P. Lumb, M. Crook, J. Gill (London, UK and Islamabad, Pakistan)

354 METABOLIC SYNDROME, DIABETES AND CARDIOVASCULAR DISEASE IN AN 424ELDERLY CAUCASIAN COHORT. THE ITALIAN LONGITUDINAL STUDY ON AGINGS. Maggi, M. Noale, G. Crepaldi (Padua, Italy)

355 HERITABILITIES OF THE METABOLIC SYNDROME AND ITS COMPONENT TRAITS IN A 425CAUCASIAN GENETIC ISOLATEA. Bellia, D. Lauro, P. Sbraccia, M. Federici, M. Tesauro, G.B. Rini, G. Novelli, M. D'Adamo, E. Giardina, R. Lauro (Rome and Palermo, Italy)

356 ESTIMATION OF METABOLIC SYNDROME (MS) OCCURRENCE ACCORDING TO NCEP ATP 425III AND IDF CRITERIA IN THE POPULATION OF RESIDENTS OF LODZ (POLAND)J. Kowalski, J. Blaszczyk, M. Barylski, L. Pawlicki, M. Godala, A. Lewinski (Lodz, Poland)

357 PREVALENCE OF METABOLIC SYNDROME AMONG SCHOOL CHILDREN IN TAIWAN 425N.F. Chu, H.C. Chin, S.C. Wang, D.M. Wu (Taipei, Taiwan)

358 HYPERTENSION AND METABOLIC SYNDROME IN THE BRISIGHELLA STUDY (BS) 425S. D'Addato, A. Dormi, L. Laghi, A.V. Gaddi, C. Borghi (Bologna, Italy)

359 PREVALENCE OF METABOLIC SYNDROME IN THE JAPANESE 425K. Homma, Y. Homma, H. Yamaguchi, G. Uehara, T. Sakai, Y. Morita, M. Igarashi, M. Matsuda, K. Ishiwata (Tokyo and Isehara, Japan)

360 A PRELIMINARY SURVEY ON THE PREVALENCE OF METABOLIC SYNDROME - A 426HOSPITAL DATA BASED STUDYK. Priya, V.K. Nampoothiri (Kerala, India)

361 TO DETERMINE THE PREVALENCE OF PHENOTYPES OF METABOLIC SYNDROME 426AMONG HYPERTENSIVE PATIENTS IN CENTRAL AREAS OF IRANR. Ansari, M. Abdar, R. Kelishadi, A. Khosravi (Isfahan, Iran)

362 PREVALENCE OF A METABOLIC SYNDROME AMONG A PEDIATRIC CASISTIC FROM 426THE MOUNTAIN COMMUNITY (SERRE CALABRE)F. Martino, E. Martino, F. Morrone, R. Papa, T. Niglio, E. Tocci, F. Vecchio, D. Noto, M.R. Averna (Rome, Serra San Bruno, Catanzaro and Palermo, Italy)

363 PREVALENCE OF METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARY 426SYNDROMEB. Popovic, D. Macut, I. Bozic, M. Petakov, S. Ognjanovic, T. Isailovic, S. Damjanovic (Belgrade, Serbia-Montenegro)

364 THE PREVALENCE OF METABOLIC SYNDROME AND CARDIOVASCULAR EVENTS 427INCIDENCE RELATED TO ITS COMPONENTSC. Tudor, R.A. Jeberean, R. Buzas, A. Popescu, V. Lungu (Timisoara, Romania)

365 PREVALENCE AND CHARACTERISTIC FEATURES OF METABOLIC SYNDROME WITH 427AND WITHOUT DIABETES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONM. Zeller, M. Farnier, P.G. Steg, L. Mock, Y. Laurent, L. Janin-Manificat, P. Sicard, H. Makki, B. Verges, Y. Cottin (Dijon, Paris, Fontaine les Dijon, Semur en Auxois, Beaune and Chatillon sur Seine, France)

366 THE PREVALENCE OF METABOLIC SYNDROME AMONG THE PEOPLE UNDERGOING 427ANNUAL HEALTH CHECKS IN OUR INSTITUTEJ. Suwa, S. Hiramatsu (Tokyo, Japan)

367 IS THE PREVALENCE OF THE METABOLIC SYNDROME INCREASING AMONG 427MIDDLE-AGED SWEDES?G. Hollman, M. Kristenson (Linköping, Sweden)

368 GENDER - SPECIFIC ISSUES IN METABOLIC SYNDROME IN IRANIAN WOMEN 427N. Sarrafzadegan, R. Kellishadi, N. Mohammadifard, K. Rabiei (Isfahan, Iran)

369 REVERSING METABOLIC SYNDROME WITH HIGH INTENSITY TRAINING 428A.E. Tjonna, O. Rognmo, P.M. Haram, T. Stolen, J.P. Loennechen, S. Slordahl, U. Wisloff (Trondheim, Norway)

370 CLINICAL RELEVANCE OF VLDL CHOLESTEROL REDUCTION TO INCREASED SERUM 428ADIPONECTIN WHEN ASSESSING SERUM LIPID AMELIORATION ACHIEVED BYEXERCISE TRAININGH. Yoshida, H. Yanai, Y. Hirowatari, T. Ishikawa, N. Sato, N. Tada (Kashiwa, Ayase andShinagawa, Japan)

371 REGULAR AEROBIC EXERCISE CAN REDUCE ARTERIAL STIFFNESS AND VASCULAR 428INFLAMMATION IN SUBJECTS WITH METABOLIC SYNDROMES. Sha, S. Tanaka, T. Miki (Hidaka, Japan)

372 REDUCTION OF VISCERAL ADIPOSITY UNDERLIES THE IMPROVEMENT OF ARTERIAL 428STIFFNESS THROUGH EXERCISE TRAINING IN MIDDLE-AGED MEN WITH ABDOMINAL OBESITYY. Takanami, F. Kinoshita, Y. Kawai, O. Mohira, T. Shimomitsu, T. Yoshikawa(Tokyo, Wakayama and Kyoto, Japan)

373 THE INFLUENCE OF DIET AND PHYSICAL EXERCICE ON PATIENTS WITH DISMETABOLIC 429SYNDROME X WHO WERE MONITORED BY THE HEALTH CENTER OF SKIATHOSA. Sianni, A. Ganotopoulou (Skiathos and Volos, Greece)

374 CLINICAL UTILITY OF HOMEOSTASIS MODEL ASSESSMENT IN THE PREVENTION OF 429TYPE 2 DIABETES AND CARDIOVASCULAR DISEASESL.L. Faleiro, M.C. Martins, A.E. Fonseca (Lisbon, Portugal)

375 METABOLIC SYNDROME IN PREMATURE CORONARY HEART DISEASE IN A 429HUNGARIAN PATIENT GROUPL. Szollár (Budapest, Hungary)

376 INTRAPERITONEAL LEPTIN REGULATES LIPID AND LIPOPROTEIN 429METABOLISM IN MICE FED A HIGH-FAT DIETN. Nalini, J. Kalaivani Sailaja (Chidambaram, India)

WEDNESDAY

143

WEDNESDAY

144




NUTRITIONAL APPROACHES

377 PALM TOCOTRIENOL SUPPRESSES INSULIN-INDUCED ADIPOGENESIS 430H. Uto, E. Yoshioka, C. Yanagisawa, Y. Kishimoto, M. Machida, M. Hasagawa, H. Saito, C. Kiyose, K. Shimokado, K. Kondo (Hirosaki City, Sakato City and Bunkyo-Ku, Japan)

378 ERYTHROCYTE FATTY ACID COMPOSITION IN OBESE PATIENTS WITH 430HYPERLIPIDEMIAM. Postic, D. Ristic-Medic, A. Arsic, M. Glibetic (Belgrade, Serbia-Montenegro)

379 ASSESSING DIETARY BEHAVIOUR BY MICRODIET SOFTWARE AS EDUCATIONAL TOOL 430M. Mariotti, O. Giampietro, E. Matteucci (Pisa, Italy)

380 DIETARY MEDIUM- AND LONG-CHAIN TRIACYLGLYCEROLS (MLCT) SUPPRESS 430ACCUMULATION OF BODY FATM. Kasai, S. Negishi, H. Uto, M. Okazaki, O. Igarashi, K. Kondo (Kanagawa, Tokyo, Sitamaand Ibaraki, Japan)

381 METABONOMICS TO ASSESS SELF-REPORTED DATA: THE INTERNATIONAL STUDY 430ON MACRONUTRIENTS AND BLOOD PRESSURE (INTERMAP)R.L. Loo, E. Holmes, E. Maibaum, M. Coen, T. Ebbels, Q. Chan, P. Elliott, H. Ueshima, B. Zhou, J. Stamler (London, UK, Shiga, Japan, Beijing, China and Chicago, IL, USA)

382 THE EFFECTS OF WEIGHT LOSS ON LP-PLA2 ACTIVITY AND LOW DENSITY 431LIPOPROTEIN (LDL) PHENOTYPE IN OBESE WOMENT.D. Filippatos, T. Tzotzas, D.N. Kiortsis, A. Triantos, M. Karamouzis, A. Tselepis (Ioannina andThessaloniki, Greece)

383 HIGH CALCIUM DIET WITH WHEY PROTEIN INHIBITS WEIGHT GAIN IN A MODEL OF 431DIET INDUCED OBESITYT.K. Pilvi, R. Korpela, H. Vapaatalo, E. Mervaala (Helsinki, Finland)

384 DEVELOPMENT OF ANTIOBESITY VEGETABLE & FRUIT EXTRACT 431S.H. Bok (Nonsan, South Korea)

385 RESIDENTIAL MULTIDISCIPLINARY REHABILITATION FOR THE TREATMENT OF 431OBESITYM. Mancini, V. Rendina, R. Caporaso, A. Caporaso, M. Lionetti, F.P. Mancini (Naples and Benevento, Italy)

386 DEVELOPMENT OF ANTIOBESITY HAMBURGER INGREDIENT SLIM&SLIM PWH 432S.H. Bok (Nonsan, South Korea)

387 THE DIETARY BREAD, BETTER NUTRITION FOR THE PEOPLE WITH DIABETES 432Z. Savoski, Z. Trpkovski, Z. Servini (Prilep and Negotino, Macedonia)

388 EFFECTS OF FOODS AND DIETS VARYING IN GLYCEMIC INDEX AND GLYCEMIC LOAD 432ON POSTPRANDIAL GLUCOSE AND INSULIN RESPONSE AND MEASURES OFOXIDATIVE STRESSL. Augustin, C.W. Kendall, A. Josse, S. Salvatore, F. Brighenti, D.J. Jenkins (Toronto, ON,Canada and Parma, Italy)

389 THE EFFECT OF PALATINOSE ON ATHEROGENIC INDEX AND VISCERAL FAT IN 432MALE JAPANESE BRAZILIANSE. Moriguchi, M. Mori, H. Mori, P. Ishikawa, T. Sakuma, Y. Moriguchi, Y. Yamori (Porto Alegre, Brazil, Kyoto and Hyogo, Japan)

390 ACTIVATION OF POLYMORPHONUCLEAR LEUKOCYTES BY POTATO CRIPS 432CONSUMPTION IN HEALTY SMOKERSD. Zapolska-Downar, A. Kosmider, G. Nowicka, M. Naruszewicz (Warsaw, Poland)



posterboard no.:

391 CLAS INHIBIT TRANSFORMATION OF ARACHIDONIC AND LINOLEIC ACIDS IN 433MACROPHAGES THROUGH DOWN REGULATION OF CPLA 2/15 LO 1 AND SPLA2/COX 2 PATHWAYSE. Stachowska, D. Chlubek (Szczecin, Poland)

392 CONJUGATED LINOLEIC ACIDS INCREASE NON-OXIDATIVE OXYGENATION OF 433ARACHIDONIC ACID IN MONOCYTES VIA PPAR ALPHA RECEPTOR ACTIVATIOND. Chlubek, E. Stachowska (Szczecin, Poland)

393 THE NATURAL CONCENTRATION OF THE CONJUGATED LINOLEIC ACID, CIS-9, TRANS-11 433IN MILK-FAT CAN MODULATE THE ATHEROGENIC RISK IN HYPERLIPIDEMIC HAMSTERSA. Quignard-Boulange, K. Valeille, J. Ferezou, G. Amsler, D. Gripois, J.C. Martin, M. Parquet (Paris, Castres, Orsay and Marseille, France)

394 INHIBITION OF LDL OXIDATION IN RED YEAST RICE 433E. Yoshioka, H. Uto, C. Yanagisawa, N. Machida, Y. Kishimoto, M. Hasegawa, M. Tani, T. Kido, H. Yoshida, K. Kondo (Bunkyo-ku and Minato-ku, Japan)

395 THE ANTIOXIDANT ACTIVITIES OF ALMONDS AGAINST LDL OXIDATION 434C. Yanagisawa, H. Uto, M. Tani, Y. Kishimoto, N. Machida, M. Hasegawa, E. Yoshioka, T. Kido, K. Kondo (Tokyo, Japan)

396 THE EFFECT OF ALMONDS ON THE SERUM LIPID, LIPOPROTEIN AND 434APOLIPOPROTEIN LEVELS IN JAPANESE MALE SUBJECTSC. Yanagisawa, H. Uto, M. Tani, Y. Kishimoto, N. Machida, M. Hasegawa, E. Yoshioka, T. Kido, K.G. Lapsley, K. Kondo (Tokyo, Japan and Modesto, CA, USA)

397 TESTING VARIOUS VEGETABLES FOR ANTI-THROMBOTIC EFFECT: II. CARROTS 434J. Yamamoto, A. Naemura, Y. Ijiri, K. Ogawa, T. Suzuki, Y. Shimada (Kobe, Kakogawa, Osaka and Shizouka, Japan)

398 ADDITIVE EFFECTS OF STEROLS TO RICE BRAN OIL ON SERUM CHOLESTEROL 434LEVELS IN RATSE. Tsuji, M. Takahashi, S. Kinoshita, M. Tanaka, K. Tsuji (Kakogawa, Funabashi, Tokyo and Himeji, Japan)

399 CAROTID AND BRACHIAL ARTERIAL FUNCTION IN HEALTHY POSTMENOPAUSAL 434WOMEN: A COMPARISON BETWEEN VEGETARIANS AND OMNIVORESP.L. Torng, T.C. Su, J.S. Jeng, M.F. Chen, C.S. Liau (Taipei, Taiwan)

400 OLIVE OIL AND RED WINE POLYPHENOLS INHIBIT REACTIVE OXYGEN SPECIES 435AND EICOSANOID RELEASE INDUCED BY OXIDISED LOW DENSITY LIPOPROTEINSM. Vivancos, J.J. Moreno (Barcelona, Spain)

401 DOES DIETARY INTAKE OF VITAMIN B6 AND FOLATE AFFECT HOMOCYSTEINE 435AND CRP LEVELS IN PATIENTS WITH HEART FAILURE?M. Makarewicz-Wujec, M. Kozlowska-Wojciechowska (Warsaw, Poland)

402 EFFECT OF SEVERAL FATTY ACIDS ON POSTPRANDIAL HYPERLIPEMIA 435Y. Kishimoto, M. Tani, A. Takeuchi, C. Yanagisawa, M. Hasegawa, N. Machida, E. Yoshioka, H. Uto, Y. Masuda, K. Kondo (Tokyo, Japan)

403 DRIP PAPER-FILTERED AND BOILED AND COTTON-FILTERED COFFEE REDUCE 435LIPID PEROXIDATION AND ANTHROPOMETRIC PARAMETERS IN PRIMARYHYPERCHOLESTEROLEMIAR.P. Costa, M.C. Elias, M.C.O. Izar, A.O. Santos, L. Pinto, S.S.M. Ihara, A.A. LasCasas, W.G.M. Relvas, F.A.H. Fonseca (Sao Paulo, Brazil)

404 A MUSHROOM, WHITE BUNASHIMEJI (HYPSIZIGUS MARMOREUS) PREVENTS THE 436DEVELOPMENT OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICEM. Ikeda, K. Mori, C. Kobayashi, Y. Ohmori, T. Tomita (Shizuoka and Nagano, Japan)

405 MECHANISM OF THE ANTI-THROMBOTIC EFFECT OF DIETARY DIACYLGLYCEROL IN 436ATHEROGENIC MICEY. Ijiri, A. Naemura, T. Yamashita, H. Ikarugi, J. Yamamoto (Kobe and Kakogawa, Japan)

406 PALM VITAMIN E INHIBITS THE PROGRESSION OF ATHEROSCLEROSIS IN RABBITS 436FED AN ATHEROGENIC DIETA. Idris, K. Sundram (Kuala Lumpur, Malaysia)

407 EFFECT OF COFFEE ON THE OXIDATIVE SUSCEPTIBILITY OF LOW-DENSITY 436LIPOPROTEINM. Hasegawa, C. Yanagisawa, Y. Kishimoto, N. Machida, E. Yoshioka, M. Tani, T. Kido,H. Uto, K. Kondo (Bunkyo-ku, Japan)

408 THE ANTIOXIDATIVE AND ANTI-ATHEROGENIC EFFECTS OF THE FERMENTATION 436BROTH OF LINGZHI (G. LUCIDUM) CULTIVATED IN THE MEDIUM CONTAININGLEGUMINOUS PLANTSY.L. Chien, Y.L. Yang, L. Sun Hwang (Taipei, Taiwan)

WEDNESDAY

145

WEDNESDAY

146

409 SUPPLEMENTATION OF L-ARGININE IMPROVE ENDOTHELIUM-DEPENDENT 437VASODILATION IN HYPERCHOLESTEROLEMIA WITH IMPAIRED VASODILATIONP.R. Chen, C.M. Lee, T.C. Su, T.L. Liu, B.W. Chuo, C.E. Tsai (Taipei and Taoyan, Taiwan)

410 INTAKES OF PHOSPHORUS, MAGNESIUM AND CALCIUM IN RELATION TO BLOOD 437PRESSURE: THE INTERMAP STUDYP. Elliott, H. Kesteloot, J. Stamler, A.R. Dyer, H. Ueshima, Q. Chan, L. Appel, B. Zhou (London, UK, Leuven, Belgium, Chicago, IL, Baltimore, MD, USA, Otsu, Japan and Beijing, China)

411 MONOSACCHARIDE, DISACCHARIDE INTAKE AND BLOOD PRESSURE IN UK AND 437USA, MEN AND WOMEN AGES 40-59: THE INTERMAP STUDYI.J. Brown, P. Elliott, C.E. Robertson, Q. Chan, A.R. Dyer, J. Stamler (London, UK and Chicago, IL, USA)

412 EFFECTS OF MODERATE CONSUMPTION OF SICILIAN RED WINES ON SOME 437CARDIOVASCULAR RISK FACTORSG. Avellone, V. Di Garbo, D. Campisi, G. Raneli, R. De Simone, A. Indovina, G. Abruzzese, G. Licata (Palermo, Italy)

413 EFFECTS OF SOY PROTEIN ISOFLAVONES ON SERUM LIPID PROFILE AND HORMONES 438OF HYPERCHOLESTEROLEMIC MENR. Amani (Ahvaz, Iran)

414 THE EFFECT OF ZN ON THE PLASMA LEVEL OF CHOLESTEROL AND TRIGLYCERIDE 438A H. Masoudi, B. Mohamadi (Tehran, Iran)

415 PROTECTIVE EFFECT OF TUNISIAN OLIVE OIL PHENOLIC COMPOUNDS AGAINST 438LOW DENSITY LIPOPROTEIN OXIDATIONA. Nakbi, M. Issaoui, N. Koubaa, N. Attia, A. Echbili, S. Debbou, A. Trigui, M. Hammami (Monastir and Sfax, Tunisia)

416 HYPOLIPIDEMIC EFFECTS OF PURSLANE LEAF EXTRACT ON DIET INDUCED 438HYPERCHOLESTEROLEMIC ANIMALSA. Movahedian, A. Ghannadi, M. Vashirnia (Isfahan, Iran)

417 EFFECT OF TRIBESTAN ON LIPID METABOLISM AND HORMONAL STATUS IN MEN 438IN ANDROPAUSEN.I. Doncheva, G. Sheinkova, K. Kalinov, D. Dobreva, M. Protich (Sofia, Bulgaria)

418 EFFECT OF DIETS WITH DIFFERENT FAT CONTENT ON THE AFFINITY OF LOW-DENSITY 439LIPOPROTEIN TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR IN HEPG2 CELLSP. Gómez Luna, J. López-Miranda, C. Marín Hinojosa, B. Cortés, J.A. Moreno Gutierrez, M.J. Gómez Luna, J. Delgado Lista, F. Pérez-Jiménez (Córdoba, Spain)

419 MEDITERRANEAN DIET NEEDS CORRECTIONS TO TREAT HYPERTENSION 439R. Volpe, J. Pille, G. Nantel (Rome, Italy)

420 POLYPHENOLS ENHANCE PLATELET NITRIC OXIDE BY INHIBITING PROTEIN KINASE 439C-DEPENDENT NADPH OXIDASE ACTIVATION. EFFECT ON PLATELET RECRUITMENTP. Pignatelli, S. Di Santo, B. Buchetti, V. Sanguigni, A. Brunelli, F. Violi (Rome, Italy)

421 APOLIPOPROTEIN E4 ALLELE IS A GENETIC FACTOR WHICH CONTRIBUTES TO 439PLASMA CHOLESTEROL RESPONSIVENESS TO DIET THERAPY IN TYPE 2 DIABETICPATIENTSM. Saito, M. Eto (Koriyama, Japan)

422 OLIVE OIL PHENOLS MODULATE TNF-ALPHA-INDUCED MATRIX 439METALLOPROTEINASE-9 IN THP-1 CELLSR. Fagnani, M. Dell'Agli, S. Bellosta, G.V. Galli, R. Parente, M. Crestani, E. De Fabiani, E. Bosisio, D. Caruso (Milan, Italy)

423 DIET AND SUPPLEMENT EFFECTS ON LIPID SUBFRACTIONS AND INFLAMMATORY 440MARKERS IN THE METABOLIC SYNDROME: CHANGE IS POSSIBLE!S.R. Gundry, W.L. Ehrman (Palm Springs, CA, USA)

424 THE EFFECT OF ANTHOCYANINS ON OXIDATIVE-ANTIOXIDATIVE BALANCE 440HYPERCHOLESTEROLAEMIC PATIENTSA. Kopff, E. Kowalczyk, M. Kopff, J. Blaszczyk (Lodz, Poland)

425 THE INFLUENCE OF ANTHOCYANINS ON THE SELECTED PRO- AND 440ANTIANGIOGENIC FACTORS IN HYPERCHOLESTEROLEMIAE. Kowalczyk, A. Kopff, M. Kopff, J. Blaszczyk (Lodz, Poland)

426 SUPPLEMENTATION WITH QUERCETIN AND NON-ALCOHOLIC RED WINE EXTRACT 440INCREASE FIBRINOLYTIC FACTOR t-PA ACTIVITY AND ANTI-INFLAMMATORYCYTOKINE TGF-ß1G. Mielcarz, A.N. Howard, A. Barinow-Wojewódzki (Poznan, Ludwikowo, Poland and Cambridge, UK)

427 LUNCH BOX RICH IN SOY AND FISH REDUCES RISK OF ATHEROSCLEROSIS IN ONE 441MONTH - A DOUBLE BLIND PLACEBO CONTROLLED STUDYM. Mori, H. Mori, Y. Yamori (Kyoto, Hyogo and Hyoto, Japan)

428 FRUIT AND VEGETABLE INTAKE AND THE RISK OF DEVELOPING CORONARY HEART 441DISEASEM. Nikolic, Z. Kostic (Nis, Serbia-Montenegro)

429 DESPITE ITS INSTABILITY, EPIGALLOCATECHIN GALLATE EFFECTIVELY LOWERS 441SERUM CHOLESTEROL IN THE HYPERCHOLESTEROLAEMIC RABBITP.D. Roach, V.H. Le, N. Naumovski, B. Blades (Ourimbah, NSW, Australia)

430 DIETARY INTERVENTION AND BLOOD LIPID PROFILE IN HYPERCHOLESTEROLEMIC 441CHILDRENS. Rossi, C. Pederiva, R. Restelli, G. Banderali, E. Riva, M. Giovannini (Milan, Italy)

431 IS ADHERENCE TO MEDITERRANEAN DIET ENOUGH FOR LOWERING LIPID 441PARAMETERS AMONG A HEALTHY ITALIAN POPULATION?F. Sofi, A.M. Gori, F. Cesari, A.P. Cellai, A. Alessandrello Liotta, A. Abdullahi Said, C. Surrenti, A. Casini, R. Abbate, G.F. Gensini (Florence and Impruneta, Italy)

432 TWO WEEKS SUPPLEMENTATION WITH OLIVE OIL AND EVENING PRIMROSE OIL 442SIMILARLY AFFECT PLASMA LIPIDS LEVEL IN MEN WITH CORONARY ARTERYDISEASEM. Stolyhwo Gofron, J. Bellwon, W. Sobiczewski, D. Ciecwierz, A. Rynkiewicz, A. Stolyhwo (Gdansk, Poland)

433 POSSIBLE IMPORTANCE OF COLONIC FERMENTATION TO POTENTIATE THE 442CHOLESTEROL LOWERING PROPERTIES OF SOY BUT NOT OF OAT B-GLUCANJ.M.W. Wong, R. de Souza, C.W.C. Kendall, D.J.A. Jenkins (Toronto, ON, Canada)

434 LOW CHOLESTEROL DIET INFLUENCE ON BLOOD LIPID PROFILE AND 442ATHEROSCLEROTIC CHANGES IN COMMON CAROTID ARTERIESN.N. Kipshidze, M.G. Beridze, N.G. Kakauridze (Tbilisi, Georgia)

435 NUT CONSUMPTION, CORONARY HEART DISEASE AND RISK FACTORS 442D. Colquhoun, S. Natoli, N. Lapsys, A. Ferreira-Jardim, K. Kostner (Brisbane, QLD and Sydney, NSW, Australia)

436 COMPARISON OF THE EFFECTS OF CHEESE OR BUTTER ON THE SEVERITY OF 443ATHEROGENIC MARKERS IN HAMSTERS FED AN HYPERLIPIDEMIC DIETB. Delplanque, A. Thaminy, G. Agnani, J.C. Martin, K. Bensharif, D. Gripois (Orsay and Marseille, France)

437 EFFECT OF TWO NATURALS PRODUCTS OILS, ARGAN AND OLIVE, IN THE 443NUTRITIONAL PREVENTION ON ATHEROSCLEROSIS IN MANA.F. Derouiche, R. Saile, A. Drissi, M. Cherki, Y. Bamou, A.I. Oudghiri, J.M. Lecef, A. Adlouni (Casablanca, Meknès, Morocco and Lile, France)

438 AD LIBITUM CONSUMPTION OF A HIGH MONOUNSATURATED FATTY ACID DIET AND 443OF A LOW FAT DIET REDUCES PLASMA ADIPONECTIN LEVELSS. Desroches, A. Tchernof, W.R. Archer, P. Couture, N. Bergeron, B. Lamarche (Ste-Foy, QC, Canada and Vallejo, CA, USA)

439 MEDITERRANEAN DIET AND ITS PROTECTIVE EFFECTS ON CARDIOVASCULAR RISK 443FACTORSG. Godàs, R. Solà, J. Girona, J.C. Vallvé, B. Winklhofer-Roob, E. Rock, J. Ribalta, L. Masana (Reus, Spain, Graz, Austria and St. Genes Champanelle, France)

440 MEDITERRANEAN FOOD AND CARDIOVASCULAR HEALTH: IN VIVO STUDIES 443F. Visioli, P. Bogani, C. Galli (Milan, Italy)

441 COFFEE MAY PREVENT THE PROGRESS OF ATHEROSCLEROSIS IN JAPANESE 444C. Iwai, M. Hashimoto, Y. Miyamoto, M. Shimizu, Y. Matsuda, K. Kanazawa, H. Akita,K. Nishimura, D. Sugiyama, K. Ito (Kobe, Japan)

442 BIOFLAVONOID-RICH BOTANICALS REDUCE BLOOD SERUM ATHEROGENICITY IN 444PERIMENOPAUSAL WOMENV. V. Korennaya, V.A. Mysoedova, N.A. Nikitina, I.A. Sobenin, A.N. Orekhov (Moscow, Russia)

443 ENDOTHELIAL CELL DYSFUNCTION: ENVIRONMENTAL CONTAMINANTS AND 444NUTRITIONAL IMPLICATIONSB. Hennig, X. Arzuaga, Z. Majkova, E. Smart, M. Toborek (Lexington, KY, USA)

444 CONSUMPTION OF A POLYPHENOL-RICH GRAPE EXTRACT IMPROVES THE 444CARDIOVASCULAR RISK PROFILE OF HEALTHY MALESR. Draijer, R. Duivenvoorden, Y. De Graaf, E. Haddeman, E. De Groot, C. Kroner (Vlaardingen and Amsterdam, The Netherlands)

WEDNESDAY

147

WEDNESDAY

148

445 DESIGN OF THE MET-ANTIOX STUDY: SYNERGIC BIOACTIVITY OF ANTIOXIDANT 445FUNCTIONAL FOODS IN THE METABOLIC SYNDROMES. Dragan, S. Mancas, D. Cheta, D. Velimirovici, M. Rada, L. Barbu, G. Otiman (Timisoara and Bucharest, Romania)

446 EFFECT OF CRANBERRY JUICE CONSUMPTION ON PLASMA OXIDIZED LDL LEVELS 445IN MEN: RESULTS FROM A 4-WEEK PLACEBO CONTROLLED CROSS-OVER TRIALC. Couillard, G. Ruel, S. Pomerleau, P. Couture, S. Lemieux, B. Lamarche(Québec, QC, Canada)

447 A PROTECTIVE ROLE TOWARDS ATHEROSCLEROSIS BY HYDROGEN SULFIDE AND 445NATURAL ORGANOSULFUR COMPOUNDS DERIVED FROM GARLIC AND ONIONM.A. Eghbal, M.Y. Moridani, P.S. Pennefather, P.J. Obrien (Tabriz, Iran and Toronto, ON, Canada)

448 RESVERATROL SUSTAINS THE INFLAMMATORY RESPONSE IN RAT VASCULAR 445SMOOTH MUSCLE CELLSA. Cignarella, C. Minici, C. Bolego, V. Pelosi, L. Puglisi, R.M. Gaion (Milan and Padua, Italy)

449 THE IMPROVEMENT OF METABOLIC MARKERS WITH NATURAL POLYPHENOLS AND 446ZINC ON DIABETIC RATSM. Ciocoiu, M. Badescu, M. Chicu, C. Bohotin, D. Tutunaru (Iasi and Galati, Romania)

450 AJUGA IVA TREATMENT ATTENUATES HYPERCHOLESTEROLEMIA INDUCED BY A 446CHOLESTEROL SUPPLEMENTED DIET AND IMPROVES LIPID PEROXIDATION ANDANTIOXIDANT ENZYMESA. Chenni, D. Ait-Yahia, F.O. Boukortt, J. Prost, M. Bouchenak (Es Senia Oran, Algeria and Dijon, France)

451 DIETARY IRON OVERLOAD IN RATS STRONGLY AFFECTS LIPID PARAMETERS 446F. Schemeit, D. von Bremen, J. Heeren, P. Nielsen (Hamburg, Germany)

452 EFFECT OF ANTIOXIDANT SUPPLEMENTATION ON GENETIC STABILITY AND LIPID 446PEROXIDATION IN MIDDLE-AGED MENJ. Gasparovic, K. Raslova, M. Barancokova, A. Kazimirova, A. Coll Ins, B. Smolkova, A. Horska, L. Wsolova, M. Dusinska, K. Volkovova (Bratislava, Slovak Republic and Oslo, Norway)

453 ERYTHROCYTE MEMBRANE ELECTRON TRANSFER, DIET AND LIFESTYLE IN 446HEALTHY AND IN TYPE 1 DIABETIC FAMILIESE. Matteucci, S. Manzini, I. Chiti, M. Mariotti, O. Giampietro (Pisa, Italy)

454 THE CHRONIC INTAKE OF A MEDITERRANEAN DIET ENRICHED IN VIRGIN OLIVE OIL, 447DECREASES NUCLEAR TRANSCRIPTION FACTOR KAPPAB ACTIVATION IN HEALTHY MENP. Perez-Martinez, J. Lopez-Miranda, L.M. Blanco-Colio, Y. Jimenez-Gomez, R. Gallego, F. Lopez-Segura, J. Egido, F. Perez-Jimenez (Cordoba and Madrid, Spain)

455 POSTER WITHDRAWN –456 EVALUATION OF POLICOSANOLS AS FUNCTIONAL FOOD INGREDIENTS FOR 447

CHOLESTEROL- LOWERINGA.N. Kassis, P.J.H. Jones (Ste-Anne-de-Bellevue, QC, Canada)

457 OLIVE OIL RICH MEDITERRANEAN AND A LOW FAT ENRICHED IN A-LINOLENIC ACID 447DIETS PREVENT POSTPRANDIAL INCREASE OF FACTOR VII DURING POSTPRANDIALLIPEMIAB. Cortes, J. Lopez-Miranda, C. Marin, A. Lozano, Y. Jimenez, P. Gomez, I. Perez,F. Perez-Jimenez (Cordoba, Spain)

458 POSSIBLE ROLE OF UNSATURATED FATTY ACIDS INTAKE IN INCREASED HUMAN 447SURVIVAL: A 8.5-YEAR FOLLOW-UP OF THE ITALIAN LONGITUDINAL STUDY ON AGINGV. Solfrizzi, C. Capurso, A.M. Colacicco, A. D'Introno, A. Capurso, F. Panza (Bari, Italy)

459 OLIVE OIL AND WALNUT MEALS ELICIT THE INFLAMMATORY RESPONSE IN 448MONONUCLEAR CELLS COMPARED WITH BUTTER MEAL DURING POSTPRANDIALSTATE IN HEALTHY MENY. Jiménez-Gómez, J. López-Miranda, P. Gómez Luna, C. Marín Hinojosa, R. Moreno Luna,I. Romero García, E. Galán, E. Sánchez, F. Pérez-Jiménez (Córdoba, Spain)

460 ORAL ADMINISTRATION OF EICOSAPENTAENOIC ACID REDUCES AND STABILIZES 448ATHEROSCLEROTIC LESIONS IN APOE-DEFICIENT MICEM. Matsumoto, M. Sata, M. Soma, K. Tanaka, D. Fukuda, R. Nagai (Tokyo, Japan)

461 DIETARY FISH OIL ALTERS THE PLASMA LIPID PROFILE AND THE EXPRESSION OF 448HNF4ALPHA IN HYPERCHOLESTEROLEMIC RATSE. Bravo, M. Napolitano, I. Lopez, K.M. Botham, C. Stefanutti (Rome, Italy and London, UK)

462 FISH CONSUMPTION AND SERUM LEVELS OF EICOSAPENTAENOIC AND 448DOCOSAHEXAENOIC ACID ARE NOT RELATED TO FLOW-MEDIATED VASODILATIONL.J. Bjerregaard, I.V. Aardestrup, R. Bülow, O. Frøbert, C. Dethlefsen, J.G. Rasmussen, E.B. Schmidt (Aalborg, Denmark)

463 NO PROTECTION OF A HIGH OMEGA-3 INDEX FOLLOWING AN ACUTE MYOCARDIAL 449INFARCTIONH. Aarsetoey, V. Pônitz, H. Grundt, D. Pritchard, H. Staines, W.S. Harris, D.W.T. Nilsen(Stavanger, Norway, Dundee, UK and Kansas City, MO, USA)

464 PLASMA FATTY ACID COMPOSITION IN OVERWEIGHT PATIENTS WITH 449HYPERTRIGLYCERIDEMIAA. Arsic, D. Ristic-Medic, M. Postic, J. Tepsic, M. Glibetic (Belgrade, Serbia-Montenegro)

465 THE ASSOCIATION OF POLYUNSATURATED FATTY ACIDS AND BLOOD PRESSURE 449IN MEN WITH CORONARY ARTERY DISEASEM. Stolyhwo Gofron, J. Bellwon, W. Sobiczewski, D. Ciecwierz, A. Rynkiewicz, A. Stolyhwo (Gdansk, Poland)

466 PURE OR BLENDED RAPESEED OIL INTAKE TO REACH HUMAN ALPHALINOLENIC 449RECOMMENDATION INCREASE PLASMA AVAILABILITY AND CONVERSION TOEICOSAPENTAENOIC (EPA)B. Delplanque, N. Combe, C. Boue-Vaysse, A. Thaminy, G. Agnani, B. Le Roy, A. Ruelland(Orsay, Talence and Rennes, France)

467 EFFECTS OF THE OMEGA-3 POLYUNSATURATED FATTY ACIDS IN THE TREATMENT OF 450CARDIOVASCULAR AUTONOMIC NEUROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTSV. Serhiyenko, O. Oleksyk, A. Serhiyenko (Lviv, Ukraine)

468 OMEGA-3 SUPPLEMENTATION IS ASSOCIATED WITH AN IMPROVED INFLAMMATION AND 450ENDOTHELIAL FUNCTION IN NORMOGLYCEMIC FIRST-DEGREE RELATIVES OF DIABETESS. Rizza, M. Iantorno, M. Tesauro, M. Federici, G. Donadel, M. Turriziani, G.C. Cocciolillo, P. Sbraccia, R. Lauro, D. Lauro (Rome, Italy)

469 THE EFFECT OF N-3 FATTY ACIDS ON NUTRITIONAL STATUS AND INFLAMMATORY 450MARKERS IN HEMODIALYSIS PATIENTSG. Perunicic-Pekovic, Z. Rasic, S. Pljesa, S. Sobajic, I. Djuricic (Belgrade, Serbia-Montenegro)

470 EFFECT OF SHORT-TERM EXPOSURE TO PHYTOSTANOL - AND STEROL ESTERS 450ON BLOOD LIPIDS IN CHOLESTEROL CHALLENGED WHHL RABBITSM. Schrøder, A. Mortensen, K. Pilegaard, C. Fricke, D. Lütjohann (Copenhagen, Denmark and Bonn, Germany)

471 REDUCTION OF CHOLESTEROL ABSORPTION BY DIETARY PLANT STEROLS AND 450STANOLS IN MICE IS INDEPENDENT FROM THE ABCG5/ABCG8 TRANSPORTERJ.K. Kruit, T. Plösch, V.W. Bloks, N.C.A. Huijkman, R. Havinga, G.S.M.J. Duchateau, Y. Lin, F. Kuipers (Groningen and Vlaardingen, The Netherlands)

472 THE NEW MECHANISM OF THE ACTIVITY OF PLANT STEROLS 451M. Kozlowska-Wojciechowska (Warsaw, Poland)

473 EFFECT OF THE CONSUMPTION OF PECTIN AND PHYTOSTEROLS ON STEROL LEVELS 451 SUPPLEMENTED TO A SATURATED DIET IN GUINEA PIGSG. Brufau, M.A. Canela, J. Quílez, M. Rafecas (Barcelona and Sarral, Spain)

474 FATTY ACID PROFILE AFTER PLANT STEROLS AND PECTIN CONSUMPTION 451ENRICHED INTO A SATURATED DIET IN GUINEA PIGSM. Rafecas, G. Brufau, M.A. Canela, R. Codony (Barcelona, Spain)

475 DETECTION OF UNSAPONIFIABLE COMPONENTS OF OLIVE OIL IN HIV PATIENTS 452I. Kasem, M.C. Pérez-Camino, J.L. Prada, J. Aguilar, J. De la Torre, V. Ruiz-Gutiérrez(Damascus, Syria, Seville and Malaga, Spain)

476 TOCOPHEROLS, POLYPHENOLS AND STEROLS DERIVED FROM ARGAN OIL EXERT 452AN ANTIOXIDANT EFFECT ON HUMAN LDLA. Drissi, J. Girona, M. Cherki, R. Sola, A. Adlouni (Casablanca, Morocco and Reus, Spain)

477 A STANOL YOGURT DRINK ALONE OR COMBINED WITH A LOW-DOSE OTC STATIN 452LOWERS NON-HDLC, BUT ALSO LOWERS TGS & ELEVATES HDLC IN METABOLICSYNDROME PATIENTSJ. Plat, G. Brufau, M. Dasselaar, R.P. Mensink (Maastricht, The Netherlands)

478 REDUCED CALORIE ORANGE JUICE BEVERAGE WITH PLANT STEROLS IN HUMANS 452RESULTS IN CONCOMITANT REDUCTION IN LDL-C AND HSCRP LEVELSS. Devaraj, B. Autret, I. Jialal (Sacramento, CA, USA)

479 ARE WE GOING TOWARDS PLEIOTROPIC EFFECTS WITH PLANT STEROLS? 453C. Nicolle, E. Bruckert, L. Massana, J.M. Cobo Sanz, L. Cohen, L. Lalanne (Palaiseau, Paris, France, Reus, Barcelona, Spain and Leiden, The Netherlands)

480 CHOLESTEROL ESTERASE ACTIVITY AND PLANT STEROLS 453G. Duchateau, J. Ramcharan, J. van Duynhoven (Vlaardingen, The Netherlands)

WEDNESDAY

149

WEDNESDAY

150

481 DEPENDENCE OF THE CHEMICAL NATURE OF THE SOLUBLE FIBERS ON VERY LOW 453DENSITY LIPOPROTEIN PRODUCTION BY HEPATOCYTESP.T. Boban, P.R. Sudhakaran (Kerala, India)

482 EFFICACY OF SOLUBLE FIBER SUPPLEMENTATION IN CV DISEASE RISK MANAGEMENT OF 453 PATIENTS WITH METABOLIC SYNDROME: A 6-MONTHS, RANDOMIZED CLINICAL TRIALA.F.G. Cicero, G. Derosa, M. Bove, L. Laghi, A.V. Gaddi (Bologna and Pavia, Italy)

483 EVALUATION OF NUTRITIONAL AND BIOLOGICAL PROPERTIES OF A LUPIN 453PROTEIN ISOLATE IN SPRAGUE-DAWLEY RATSM. Marchesi, S. Caligari, D. Gilio, L.A. Rubio, S.K. Johnson, G. Chiesa, C.R. Sirtori (Milan, Italy and Granada, Spain)

484 REDUCED MAMMARY TUMOR PROGRESSION IN A TRANSGENIC MOUSE MODEL 454FED AN ISOFLAVONE-POOR SOY PROTEIN CONCENTRATEE. Rigamonti, E. Disconzi, S. Soldati, M.G. Sacco, C. Parolini, A. Arnoldi, C.R. Sirtori, M.R. Lovati, G. Chiesa (Milan, Italy)

485 SESAMIN REDUCED BLOOD GLUCOSE CONCENTRATIONS IN ZUCKER FATTY RAT 454Y. Fujiwara, Y. Okamura, M. Iwamura, S. Ikemoto, Y. Ono, Y. Kiso, Y. Seyama(Tokyo and Osaka, Japan)

486 EPIGALLOCATECHIN GALLATE REDUCES BLOOD PRESSURE, IMPROVES INSULIN 454SENSITIVITY, AND PROTECTS AGAINST MYOCARDIAL ISCHEMIA/REPERFUSIONINJURY IN SHRM.A. Potenza, F.L. Marasciulo, M. Tarquinio, E. Tiravanti, G. Colantuono, A. Federici, M.J. Quon, M. Montagnani (Bari, Italy and Bethesda, MD, USA)

487 THE ROLE OF SOYBEAN PRODUCT PREPARATS IN TREATMENT OF ATHEROSCLEROSIS 454R. Tabukashvili, V. Kapetivadze, K.H. Chaava, G. Grigorashvili (Tbilisi, Georgia)

488 EFFECT OF A WEIGHT REDUCING HIGH PROTEIN VEGAN DIET ON SERUM LIPIDS 455J.M.W. Wong, A. Esfahani, C.W.C. Kendall, D.J.A. Jenkins (Toronto, ON, Canada)

489 INHIBITORY EFFECTS OF TILIANIN ON THE EXPRESSION OF INDUCIBLE NITRIC 455OXIDE SYNTHASE IN LOW DENSITY LIPOPROTEIN RECEPTOR DEFICIENCY MICEK.H. Nam, J.H. Choi, Y.J. Seo, Y.M. Lee, M.R. Lee, M.N. Lee, J.G. Park, G.T. Oh(Seoul and Chung-Nam, South Korea)

We-PL3 Plenary Session 3 NOVEL APPROACHES TO … fileWe-PL3 Plenary Session 3 NOVEL APPROACHES TO...

Documents

Transcript of We-PL3 Plenary Session 3 NOVEL APPROACHES TO … fileWe-PL3 Plenary Session 3 NOVEL APPROACHES TO...